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Background: Alcoholic hepatitis (AH) is a distinct presentation of alcoholic liver disease arising in patients
who have been drinking to excess for prolonged periods, which is characterised by jaundice and liver
failure. Severe disease is associated with high short-term mortality. Prednisolone and pentoxifylline (PTX)
are recommended in guidelines for treatment of severe AH, but trials supporting their use have given
heterogeneous results and controversy persists about their benefit.
Objectives: The aim of the clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for
Alcoholic Hepatitis trial was to resolve the clinical dilemma on the use of prednisolone or PTX.
Design: The trial was a randomised, double-blind, 2 × 2 factorial, multicentre design.
Setting: Sixty-five gastroenterology and hepatology inpatient units across the UK.
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Participants: Patients with a clinical diagnosis of AH who had a Maddrey’s discriminant function value
of ≥ 32 were randomised into four arms: A, placebo/placebo; B, placebo/prednisolone; C, PTX/placebo;
and D, PTX/prednisolone. Of the 5234 patients screened for the trial, 1103 were randomised and after
withdrawals, 1053 were available for primary end-point analysis.
Interventions: Those allocated to prednisolone were given 40mg daily for 28 days and those allocated to
PTX were given 400mg three times per day for 28 days.
Outcomes: The primary outcome measure was mortality at 28 days. Secondary outcome measures
included mortality or liver transplant at 90 days and at 1 year. Rates of recidivism among survivors and the
impact of recidivism on mortality were assessed.
Results: At 28 days, in arm A, 45 of 269 (16.7%) patients died; in arm B, 38 of 266 (14.3%) died; in
arm C, 50 of 258 (19.4%) died; and in arm D, 35 of 260 (13.5%) died. For PTX, the odds ratio for 28-day
mortality was 1.07 [95% confidence interval (CI) 0.77 to 1.40; p= 0.686)] and for prednisolone the odds
ratio was 0.72 (95% CI 0.52 to 1.01; p= 0.056). In the logistic regression analysis, accounting for indices
of disease severity and prognosis, the odds ratio for 28-day mortality in the prednisolone-treated group
was 0.61 (95% CI 0.41 to 0.91; p= 0.015). At 90 days and 1 year there were no significant differences in
mortality rates between the treatment groups. Serious infections occurred in 13% of patients treated with
prednisolone compared with 7% of controls (p= 0.002). At the 90-day follow-up, 45% of patients
reported being completely abstinent, 9% reported drinking within safety limits and 33% had an unknown
level of alcohol consumption. At 1 year, 37% of patients reported being completely abstinent, 10%
reported drinking within safety limits and 39% had an unknown level of alcohol consumption. Only 22%
of patients had attended alcohol rehabilitation treatment at 90 days and 1 year.
Conclusions: We conclude that prednisolone reduces the risk of mortality at 28 days, but this benefit is
not sustained beyond 28 days. PTX had no impact on survival. Future research should focus on
interventions to promote abstinence and on treatments that suppress the hepatic inflammation without
increasing susceptibility to infection.
Trial registration: This trial is registered as EudraCT 2009-013897-42 and Current Controlled
Trials ISRCTN88782125.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 19, No. 102.
See the NIHR Journals Library website for further project information. The NIHR Clinical Research Network
provided research nurse support and the Imperial College Biomedical Research Centre also provided funding.
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Plain English summary
What was the problem?
Alcoholic hepatitis is an inflammatory condition of the liver caused by prolonged excessive alcohol
consumption. Alcoholic hepatitis results in jaundice and liver failure; in the severe form of disease death
may occur in 30% of patients within the first month. Previous clinical trials have failed to conclusively
identify a treatment for this condition.
What did we do?
This trial tested whether or not prednisolone or pentoxifylline (which suppress inflammation) reduced the
number of deaths in patients with severe alcoholic hepatitis. Over 1100 patients in 65 hospitals
were included.
What did we find?
The number of deaths in the first month was reduced among patients taking prednisolone, but the effect
was relatively weak and did not persist. Pentoxifylline did not appear to confer any benefit at any time.
Patients treated with prednisolone had serious infections twice as frequently (13% vs. 7%) as in those who
did not receive this drug. The trial showed that certain laboratory (prothrombin time and levels of bilirubin,
creatinine and urea) and clinical (age and presence of encephalopathy) values helped predict a poor
outcome of alcoholic hepatitis.
After 1 year, half the patients had died, 37% had stopped drinking alcohol and 20% attended an alcohol
rehabilitation programme.
What does this mean?
Prednisolone has a modest effect and could be used to treat alcoholic hepatitis. In the longer term, more
effort needs to be made to get patients into rehabilitation programmes. New treatments are required to
suppress the inflammation in the liver without increasing the risk of infection.
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Scientific summary
Background
Alcoholic hepatitis (AH) is a florid manifestation of alcohol-related liver disease with a 1-month mortality of
20–30% for those with severe disease [Maddrey’s discriminant function (DF) ≥ 32]. It is characterised by
the onset of jaundice in the context of excessive alcohol misuse and is a major cause of acute-on-chronic
liver failure. Despite the serious nature of this illness there is controversy regarding the most effective
medical therapy. Although there are numerous trials on this topic, there is still debate about the role of
corticosteroids, with advocates citing significant improvement in the short- to medium-term mortality,
while detractors raise concerns about the risks of sepsis and gastrointestinal (GI) haemorrhage.
Pentoxifylline (PTX) has also been suggested as a treatment but meta-analyses to date have been
inconclusive. Therefore, optimal medical treatment of AH is unclear and its management inconsistent.
Objectives
We aimed to evaluate whether or not prednisolone or PTX administered for 28 days improved short- and
medium-term mortality in patients admitted with severe AH. We also aimed to assess their relative
cost-effectiveness. The primary outcome measure was mortality at 28 days, with mortality at 90 days and
1 year being secondary outcomes. In addition, we aimed to assess the outcome relative to the Glasgow
Alcoholic Hepatitis Score (GAHS), the model for end-stage liver disease (MELD) score and the Lille score,
all of which have been advocated as methods of assessing disease severity and identifying patients
for treatment.
Methods
Study design
The study design was a multicentre, double-blind, factorial (2 × 2) trial in which patients were randomised
to one of four arms:
1. arm A – placebo/placebo
2. arm B – placebo/prednisolone
3. arm C – PTX/placebo
4. arm D – PTX/prednisolone.
Participants
Patients ≥ 18 years with a clinical diagnosis of AH on admission to hospital were considered for inclusion.
Eligibility criteria were age ≥ 18 years; alcohol consumption > 80 g/day for males and 60 g/day for females
to within 2 months of randomisation; serum bilirubin > 80 µmol/l; and DF ≥ 32. Key exclusion criteria
were: duration of jaundice > 3 months; other causes of liver disease present; aspartate aminotransferase
> 500 IU/ml or alanine aminotransferase > 300 IU/ml; previous entry to the study; previous use of
prednisolone or PTX within 6 weeks of admission; renal failure (creatinine > 500 µmol/l or requiring renal
replacement therapy); active GI bleeding; untreated sepsis; and patients requiring inotropic support. As the
trial was conducted in 65 hospitals across the UK, and many of which do not have access to transjugular
liver biopsy, it was decided not to make liver histology an entry criterion. Patients with GI bleeding,
renal impairment or sepsis during the admission were allowed specific treatment for up to 7 days and
randomised if the condition had been stabilised.
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Main outcome measures
The primary end point was mortality at 28 days; this time point represents the end of the peak period of
mortality for AH and is consistent with other trials in the field. Secondary end points looked at mortality or
liver transplant at 90 days and 1 year, outcome relative to other prognostic scores (GAHS, MELD and Lille
score), rates of recidivism, hospital readmission rates for liver or non-liver-related events, rates of GI
haemorrhage and sepsis, and rates of new or recurrent renal failure (serum creatinine greater than
500 µmol/l or requiring renal support).
Study procedures
Potential patients for the trial were identified on admission to hospital with suspected AH. After clinical
assessment, suitable candidates were given a patient information sheet and were given at least 24 hours
to consider the study and ask questions, after which they (or their legal representatives) were asked to give
written informed consent. Special arrangements were in place to ensure that the interests of patients with
hepatic encephalopathy were protected. After enrolment, patients were registered via Trans European
Network for clinical trials services, a web-based registration and randomisation system. If eligible for the
study, patients were randomised to a study treatment arm, which was blinded to the site staff and
the patient by means of a unique four-digit patient pack number.
Randomisation was performed using the following two stratification factors:
1. geographic region (28 in total)
2. risk group: either high or intermediate risk (high risk was defined as either sepsis or history of GI
bleeding in the previous 7 days, or creatinine > 150 µmol/l, or any combination of the these;
intermediate risk was defined as no sepsis and no history of GI bleeding in the previous 7 days, and
creatinine ≤ 150 µmol/l).
All patients were given one capsule containing 400mg of PTX (or identical placebo) three times per day,
plus one capsule containing 40mg of prednisolone (or identical placebo) once daily. Both medications
were administered for 28 days.
Patients were evaluated on treatment days 7, 14, 21 and 28, and at each time point recordings were
made of vital signs, World Health Organization performance status, concomitant medication and adverse
events. Blood samples were taken for liver function tests, prothrombin time, full blood count, urea and
creatinine. Patients were assessed for the presence of hepatic encephalopathy and the occurrence of GI
bleed or sepsis in the past 7 days. If patients were discharged from hospital before the end of the 28-day
treatment period, assessments were made at 28 days by telephone interview.
After discharge from hospital, patients were similarly evaluated at 90 days and at 1 year.
Statistical methods
A power calculation was performed to estimate sample sizes using the following parameters:
l power= 90%
l significance= 5%
l estimated mortality in placebo-treated group= 35%
l estimated mortality in prednisolone-treated group= 25%
l estimated mortality in PTX-treated group= 25%
l estimated mortality in prednisolone- and PTX- treated group= 17% (estimated assuming no interaction).
Based on a reduction in the 28-day mortality rate from 30% to 21%, a sample size of 513 per group of
single agent versus no single agent was required. Thus, in total, the trial required 1026 patients. We
allowed for a ≈ 10% withdrawal/lost to follow-up rate and therefore aimed to recruit 1200 patients to the
study, with patients being evenly allocated to each treatment arm.
SCIENTIFIC SUMMARY
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Analysis was on the basis of intention to treat. In order to determine the efficacy of prednisolone, the
28-day mortality rate in the prednisolone-treated group (arms B and D) was compared with the mortality
rate in the control group (arms A and C). Similarly, PTX efficacy was assessed by comparing the 28-day
mortality rate in the PTX-treated group (arms C and D) with the mortality rate in the control groups
(arms A and B).
The impact of pre-treatment variables such as GI bleeding, sepsis or renal impairment on admission was
estimated by adding these covariates to the logistic regression analysis. Mortality rates at 90 days and
1 year were compared using the same strategy.
Economic analysis
Within-trial cost-effectiveness and model-based cost–utility analyses were conducted. The economic
evaluation was conducted from the perspective of the UK NHS and all costs were reported in 2014 UK
pounds. The results of the cost-effectiveness analysis are reported as the incremental cost per additional
survivor at 28 days and the results of the cost–utility analysis were reported as the incremental cost per
quality-adjusted life-year (QALY) gained at 1 year and the patient’s lifetime. QALYs were derived from
responses to the European Quality of Life-5 Dimensions administered at baseline, 90 days and 1 year. Costs
were based on the use of primary and secondary care services over the trial follow-up and cost using routine
sources and study-specific estimates.
Results
Main trial results
Between January 2011 and February 2014, 5234 patients were screened for the trial and after applying
eligibility criteria, 1103 patients were randomly allocated to the four treatment arms: 276 to placebo/
placebo; 277 to placebo/prednisolone; 276 to PTX/placebo; and 274 to PTX/prednisolone. Patients were
followed for 1 year or up until the time of their death with the exception of the final 223 patients
recruited, when early cessation of follow-up meant that the trial was completed prior to them reaching this
time point. The four arms were well matched with regard to their baseline characteristics and laboratory
variables. At day 28, 16% of patients had died, 1% had been lost to follow-up and 2% had withdrawn
from the study. At 90 days, 285 of 968 (29%) patients had died, 5% were lost to follow-up and 7% had
withdrawn (including 4% owing to early cessation of follow-up). At 1 year, 421 of 747 (56%) patients
had died or had a liver transplantation (n= 3), 8% were lost to follow-up and 24% of patients had
withdrawn (including 20% owing to early cessation of follow-up).
At 28 days in the placebo/placebo arm, 45 of 269 (16.7%) patients had died, in the placebo/prednisolone
arm 38 of 266 (14.3%) patients had died, in the PTX/placebo arm 50 of 258 (19.4%) patients had died
and in the PTX/prednisolone arm 35 of 260 (13.5%) had died. There was no significant interaction
between prednisolone and PTX. In the logistic regression analysis, the odds ratio for 28-day mortality in the
PTX-treated group versus no-PTX-treated group was 1.07 [95% confidence interval (CI) 0.77 to 1.49;
p= 0.686] and for the prednisolone-treated group versus no-prednisolone-treated group, the odds ratio
was 0.72 (95% CI 0.52 to 1.01; p= 0.056). Although this result is of borderline significance, any effect of
the steroid in the first month is rapidly lost: neither prednisolone nor PTX were found to influence mortality
at 90 days and 1 year. At 90 days, 29.8% of patients treated with prednisolone had died, compared with
29.1% who did not receive this drug (odds ratio 1.02, 95% CI 0.77 to 1.35). At 90 days, 29.1% of
patients treated with PTX had died, compared with 29.8% who did not receive this drug (odds ratio 0.97,
95% CI 0.73 to 1.28). At 1 year, 56.6% of patients treated with prednisolone had died, compared with
56.1% who did not receive this drug (odds ratio 1.01, 95% CI 0.76 to 1.35). At 1 year, 56.2% of patients
treated with PTX had died, compared with 56.5% who did not receive this drug (odds ratio 0.99, 95% CI
0.74 to 1.33).
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Baseline variables were assessed to establish whether or not prednisolone or PTX influenced (i.e. statistical
significant at 5% level) 28-day mortality. In the univariate analysis, DF, GAHS, MELD, Lille score, age,
encephalopathy, white blood cell (WBC) count, prothrombin ratio, serum bilirubin, urea and creatinine
were all significant. In the multivariate analysis, age, encephalopathy, WBC count, urea, creatinine and
prothrombin ratio remained significant. Using the multivariate logistic regression model to take into
account these prognostic variables, we found that the odds ratio for 28-day mortality in the prednisolone-
treated group versus no-prednisolone-treated group was 0.61 (95% CI 0.41 to 0.91; p= 0.015). However,
the odds ratio for mortality in the prednisolone-treated group compared with the group not treated with
prednisolone at 90 days was 1.00 (95% CI 0.73 to 1.36; p= 0.976) and at 1 year was 1.01 (95% CI
0.74 to 1.39; p= 0.942) remained statistically non-significant. This may indicate that minor variation in
baseline factors influenced the result at 28 days. However, even if there is a benefit of steroid use at this
early time point, it does not translate into long-term benefit.
In the univariate analysis, each of the four existing scoring systems provided prognostic information on
patient survival at 28 days, 90 days and 1 year with p-values < 0.001. MELD had a slightly greater area
under the receiver operating characteristic curve compared with the other scoring systems, although the
GAHS had the higher odds ratio on logistic regression analysis at day 28. However, the prognostic value of
each scoring system diminished with increased duration of follow-up. When the Lille score was studied
as an indicator of corticosteroid response using cox proportional hazards regression modelling, Lille
non-responders (≥ 0.45) had a higher overall mortality of 51.9% (70/135) compared with 24.6% (49/199)
for responders (< 0.45) (hazard ratio 2.66, 95% CI 1.95 to 4.05; p< 0.001).
Serious adverse events (SAEs) were reported in 42% of patients with an equal distribution in each
treatment arm and 29% of all SAEs resulted in deaths. Infection occurred in 74 of 547 (13.5%) patients
in the prednisolone-treated group compared with 43 of 545 (7.9%) patients who did not receive
prednisolone (p= 0.003). Acute kidney injury occurred in 9 of 546 (1.65%) patients who received PTX
and 14 of 546 (2.56%) who did not receive this drug (p= 0.4).
Economic analysis
In terms of incremental cost per additional survivor at 28 days, prednisolone was the most likely treatment
to be cost-effective. In the model-based analysis prednisolone was, on average, associated with an
incremental cost per QALY that society may be willing to pay. No other treatment has an incremental cost
per QALY of < £30,000. However, the cautious assumptions made and limited longer-term data available
means that there is considerable imprecision around estimates of cost-effectiveness, so that definitive
conclusions cannot be drawn.
Conclusions
In this study we are able to show a reduction in the 28-day mortality in the prednisolone-treated group on
logistic regression model analysis, but there was not clear evidence of benefit sustained beyond this point.
In contrast there is no evidence of survival benefit for PTX either alone or in combination with steroids,
at any measured time point.
The GAHS, MELD and Lille score performed similarly in assessing overall prognosis, but a high Lille score
did not effectively identify a severe group of patients who may benefit from transplantation, as has been
suggested previously.
Prednisolone use was associated with an increased rate of sepsis, which probably negated some of the
benefits. There was no significant reduction in renal impairment with PTX use; however, there was a low
rate of acute kidney injury in this trial, making a definitive conclusion about renal protection inappropriate.
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Prednisolone was the most likely treatment to be considered cost-effective at 28 days and the results are
suggestive of an incremental cost per QALY of < £30,000 at 1 year and over a lifetime, but remain
tentative owing to limited longer-term data.
Recommendations for future research
1. Development of disease severity scores that allow identification of those most likely to benefit from
corticosteroid use and to identify those for whom other treatment should be considered.
2. To address whether or not additional measures such as the addition of N-acetylcysteine or granulocyte
colony stimulating factor to corticosteroids could reduce the rate of sepsis and improve outcome
beyond 28 days.
3. To investigate methods to improve rates of abstinence after discharge from hospital.
Trial registration
This trial is registered as EudraCT 2009-013897-42 and ISRCTN88782125.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme. The NIHR Clinical Research Network provided research nurse support and the
Imperial College Biomedical Research Centre also provided funding.
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Chapter 1 Aims
The primary objective of this study was to determine whether or not pentoxifylline (PTX) orcorticosteroids reduce the mortality associated with severe alcoholic hepatitis (AH) and thereby to
resolve the ongoing dilemma about the use of these two agents in clinical practice. In order to avoid the
controversies caused by underpowered studies in this field, we aimed to conduct a well-powered,
definitive study.
Gastrointestinal (GI) bleeding, sepsis and renal impairment have previously been exclusion criteria in many
AH treatment studies but patients with these complications have the highest mortality risk and therefore
have potentially most to gain. They were therefore included in the trial.
Early treatment benefits may subsequently be lost owing to an increased incidence of sepsis in the medium
term or recidivism in the longer term. Mortality at 28 days, 90 days and 1 year after treatment was
therefore assessed.
Virtually all trials of therapeutic interventions in AH have used Maddrey’s discriminant function (DF) to
identify a group of patients with severe disease and an appreciable mortality risk. Recent research from the
UK suggests that the Glasgow Alcoholic Hepatitis Score (GAHS) provides a more accurate prognosis.1 In
order to make this trial comparable to previous studies, we elected to keep the DF as an inclusion criterion,
but we have compared the DF, GAHS, model for end-stage liver disease (MELD) and the Lille scores for
their ability to predict mortality and/or response to therapy.
The effect of resumed alcohol abuse is thought to be one of the important predictors of mortality after the
first month and we therefore aimed to collect data on recidivism and abstinence in order to assess
the effect on patient outcomes.
Finally, we aimed to conduct within-trial and longer-term horizon economic evaluations of the
two interventions.
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Chapter 2 Background
Importance of the health problem to the NHS
Alcohol-related illness places an enormous burden on the NHS. It has been estimated by the Royal College of
Physicians that the in-patient costs in 1998–9 arising from the consequences of alcohol misuse were as high as
£2.9B.2 Overall, alcohol-related deaths have more than doubled since 1979,3 and in Scotland, they increased
by 236% between 1980 and 2002.4 Throughout the UK, deaths from cirrhosis rose dramatically between
1987 and 1991.5 Alcohol-related liver disease (ALD) accounts for the majority of alcohol-related deaths in
the UK.6 While many patients presenting with ALD will have cirrhosis, as many as 60% will have evidence of
alcohol-related hepatitis.7 AH is the most florid manifestation of ALD, but is potentially reversible. However,
the short-term mortality of AH is particularly high among those with indicators of severe disease. The 28-day
mortality of patients who have a DF ≥ 32 is 20–30% and historically up to 40%.8–10 The 28-day mortality of
patients who have a GAHS of ≥ 9 is approximately 60%1 (see Appendix 1 for description of DF and GAHS).
AH affects a relatively young population (average age 50 years; patients may present in their twenties to
thirties). Despite the increasing prevalence and the severity of this disease there is no consistency in its
management. Considerable controversy exists, especially regarding the use of corticosteroids.
Summary of current evidence
Corticosteroids
Since 1971 there have been 13 randomised studies and four meta-analyses investigating the role of
corticosteroid therapy for this condition.11,12 Despite this apparent wealth of evidence, controversy persists.
There remains deep division with regard to the use of corticosteroids. Advocates of the treatment cite
significant improvement in the short- to medium-term mortality, while detractors cite the risks of sepsis
and GI haemorrhage with corticosteroid therapy. Many of the published studies have been plagued by
widely varying inclusion and exclusion criteria. The largest placebo-controlled study13 treated 90 patients
and found no benefit with prednisolone compared with a similar placebo-treated group. This study was
hampered by the inclusion of patients with both moderate and severe AH, as well as end-stage ALD.
In the only study to require histological confirmation of AH in all patients, prednisolone was associated
with a short-term improvement in mortality in patients, although this benefit was not apparent after
2 years.14,15 On review of the published studies, none of these reached an adequate statistical power to
make a statement with 80% confidence. The most recent meta-analysis of all of the available trials16
demonstrated that, although there was a trend of benefit with steroids, the results were not statistically
significant (p= 0.2). However, a reanalysis of the three largest studies indicted a significant benefit from
corticosteroids.17 In this meta-analysis, patients with a DF ≥ 32 treated with prednisolone had 28-day
mortality of 15%, compared with mortality of 35% among placebo-treated patients (p= 0.001).
Pentoxifylline
Pentoxifylline has also been studied in the treatment of AH.18–20 It is believed to act, in part, by inhibiting
the synthesis of the proinflammatory cytokine tumour necrosis factor alpha.20 There has been one
randomised controlled trial18 that showed significant benefit. In this study, 100 patients, all with a DF > 32,
were enrolled. PTX was administered for 4 weeks, at a dose of 400mg three times per day. In the PTX
group, 12 of 49 patients (24.5%) died, compared with 24 of 52 (46.1%) in the placebo group during the
index hospitalisation (p= 0.037). The principal benefit for the agent appeared to be a reduction in deaths
attributed to hepatorenal syndrome. However, other studies found contrasting results and meta-analysis
has failed to show any significant benefit of this drug.19–21 Although published evidence for the use of PTX
is inconclusive, the drug is widely used as an alternative to steroids, particularly in the USA, and further
evaluation in a clinical trial is, therefore, clearly warranted.22
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Steroids and/or pentoxifylline
Combinations of steroids and PTX have been evaluated in clinical trials, using steroids alone as the control
arm; however, the combination does not appear to have any benefit over steroids alone.23,24 Three small
studies25–27 have compared steroids directly with PTX but the results were inconsistent. One study28
explored the use of PTX as a rescue therapy once steroids had failed to improve liver function tests (LFTs)
but this strategy did not influence survival.
BACKGROUND
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Chapter 3 Trial design and methods
Study design
The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis
(STOPAH) study was a pragmatic, multicentre, double-blind, factorial (2 × 2) trial to assess prednisolone
and PTX in patients with severe AH. The factorial design meant that the two active treatments could be
concurrently assessed when doubt exists over the efficacy of both medications.
The trial included an economic evaluation to assess which treatment is the most cost-effective, as well as
the quality of life (QoL) and long-term prognosis in patients with AH (see Chapter 5). The main trial was
also supplemented with a number of substudies (see Appendix 2). A description of the trial protocol has
already been published.29
Ethical approval and research governance
Ethical approval for the study was given by Wales Research Ethics Committee (REC) 3 (formerly REC for
Wales) on 27 April 2010 (reference number 09/MRE09/59). The trial was registered with the International
Standard Randomised Controlled Trial Register under the reference number ISRCTN88782125.
Changes to original protocol
A summary of the changes made to the original protocol is given in Table 1.
TABLE 1 Summary of changes to original STOPAH trial protocol approved by the REC
Change to protocol REC approval
‘4 weeks’ changed to ‘28 days’ 19 July 2011
‘Dosing instructions’ section added 19 July 2011
Patient target added – 1200 randomised patients 19 July 2011
Liver transplant added as secondary end point at 90 days 19 July 2011
Past medication substudy text clarified 19 July 2011
Informed consent process clarified. Time for consideration of study changed to < 24 hours if appropriate 19 July 2011
Clarification that consent should be sought from ‘incapacitated’ patient, once able 19 July 2011
‘TENALEA account creation and registration’ sections added 19 July 2011
History of excess alcohol timeline added to ensure that patients have been drinking sufficiently heavily
recently (to within 2 months of randomisation)
19 July 2011
Period of abstinence changed from ‘6 weeks’ to ‘> 2 months’ 19 July 2011
‘Clinically apparent’ jaundice added 19 July 2011
‘6-month’ timeline for previous use of study drugs changed to ‘6 weeks’ 19 July 2011
Treatment of patients with renal impairment, sepsis or GI bleed clarified 19 July 2011
Prohibited drugs clarified, i.e. N-acetylcysteine and ketorolac, plus prescription of study drugs during the
treatment phase
19 July 2011
continued
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TABLE 1 Summary of changes to original STOPAH trial protocol approved by the REC (continued )
Change to protocol REC approval
‘Start of treatment and treatment breaks’ section added 19 July 2011
‘Renal impairment dose reduction’ section added 19 July 2011
IMP manufacture, labelling and storage procedures clarified, and IMP shipment process expanded 19 July 2011
IMP ‘temperature monitoring’ section added, to explain storage requirements and use of WarmMark
Temp Tags (Tela Temp Inc., Anaheim, CA, USA) for transit
19 July 2011
IMP ‘documentation’, ‘dispensing procedures’ and ‘drug returns’ sections updated 19 July 2011
‘Patient adherence’ section added 19 July 2011
Screening assessments updated/corrected 19 July 2011
‘EDTA sample for DNA analysis’ moved to baseline 19 July 2011
‘Central pathology review’ analysis section added 19 July 2011
Baseline assessments and timelines updated, including permitted 14-day window between screening and
baseline visits
19 July 2011
‘Inflammatory markers in serum analysis’ section added 19 July 2011
‘Analysis of genetic causes of AH’ section added 19 July 2011
‘Monocyte study’ section added 19 July 2011
Treatment and follow-up assessments updated, including the permitted window around visits. Height
removed from all assessments except screening
19 July 2011
WHO performance status added to all on treatment assessments 19 July 2011
Prior 48-hour window for blood samples at discharge added 19 July 2011
Details of day 28 telephone call added 19 July 2011
Only existing AEs to be followed up at day 90 and 1 year. No new AEs to be recorded after 4 weeks
post IMP last dose
19 July 2011
Clarification of expected AEs and recording requirements for 4 weeks post IMP 19 July 2011
‘Exclusions to AE recording requirements’ section added 19 July 2011
Reporting of SAEs and SUSARs corrected, post-treatment SAE reporting and follow-up clarified, SUSAR
causality assessment clarified, expedited SUSAR reporting clarified
19 July 2011
‘Patient loss from study’, ‘patients lost’, ‘patients not lost’ sections added 19 July 2011
‘National registries’ section added 19 July 2011
Other reasons for trial termination added 19 July 2011
‘Quality of life in cirrhosis study’ section clarified 19 July 2011
CRF completion and return to SCTU procedures clarified 19 July 2011
Change from ‘minimum of 24 hours’ to ‘< 24 hours for study consideration’ for some patients 19 July 2011
Updated WHO performance status definitions added 19 July 2011
Parameters for standard gamble analysis added 19 July 2011
AE, adverse events; CRF, case report form; DNA, deoxyribonucleic acid; EDTA, ethylenediaminetetraacetic acid;
IMP, investigational medicinal product; SAE, serious adverse event; SUSARS, suspected unexpected serious adverse event;
TENALEA, Trans European Network for clinical trials services; SCTU, Southampton Clinical Trials Unit; WHO, World
Health Organization.
TRIAL DESIGN AND METHODS
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Study setting and sample
Patients were identified, screened and recruited in the secondary care setting after admission with acute
AH. A total of 66 hospitals across England, Wales and Scotland took part, although only 65 of these
recruited patients to the study.
Inclusion criteria
l Aged ≥ 18 years.
l Clinical AH:
¢ serum bilirubin level of > 80 µmol/l
¢ history of excess alcohol (> 80 g/day for males and > 60 g/day for females) to within 2 months
of randomisation.
l Less than 4 weeks since admission to hospital.
l DF of ≥ 32.
l Informed consent.
Exclusion criteria
l Abstinence of > 2 months prior to randomisation.
l Duration of clinically apparent jaundice > 3 months.
l Other causes of liver disease including:
¢ evidence of chronic viral hepatitis (hepatitis B or C)
¢ biliary obstruction
¢ hepatocellular carcinoma.
l Evidence of current malignancy (except non-melanotic skin cancer).
l Previous entry into the study, or use of either prednisolone or PTX within 6 weeks of admission.
l aspartate aminotransferase (AST) level of > 500 IU or alanine aminotransferase (ALT) level of > 300 IU
(not compatible with AH).
l Patients with a serum creatinine level of > 500 µmol/l or requiring renal support.
l Patients dependent on inotropic support (adrenaline or noradrenaline). Terlipressin is allowed.
l Active GI bleeding.
l Untreated sepsis.
l Patients with known hypersensitivity to PTX, other methylxanthines or any of the excipients.
l Patients with cerebral haemorrhage, extensive retinal haemorrhage, acute myocardial infarction (within
the last 6 weeks) or severe cardiac arrhythmias (not including atrial fibrillation).
l Note that patients with evidence of sepsis, GI bleeding or renal failure may be treated for these
conditions for up to 7 days and, if stable, the patients can then be rescreened for eligibility. Treatment
can continue for > 7 days if they are stable. Patients who are not stable after 7 days of treatment will
not be eligible for the study.
Study interventions
Patients were randomised to one of four arms:
l arm A – placebo/placebo
l arm B – placebo/prednisolone
l arm C – PTX/placebo
l arm D – PTX/prednisolone.
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The Pharmacy Manufacturing Unit at the Royal Free Hospital in London manufactured the investigational
medicinal product (IMP) by overencapsulating the active medication in gelatin capsules. Placebo preparations,
which precisely matched the active medication in appearance, contained only microcrystalline cellulose. The
IMP was provided in capsule form in two bottles (bottle A and bottle B). Bottle A contained PTX 400mg or
matched placebo and bottle B contained prednisolone 40mg or matched placebo. Ideally, patients started
their IMP within 48 hours of randomisation. It was administered for 28 days (bottle A one capsule daily and
bottle B three times daily) and treatment breaks of up to 7 days were acceptable if required.
Concomitant medications may have been administered as medically indicated, including alcohol withdrawal
therapy as required. All patients received supportive nutritional therapy. Nutritional supplements were
offered but if the patient was unable to take these, enteral nutrition via a nasogastric tube was offered.
The aim was to provide 35–40 kcal/kg/day non-protein energy with 1.5 g/kg/day of protein.
Study procedures
Recruitment
Site staff assessed patients admitted into secondary care with an acute episode of AH for potential
eligibility for the trial.
Informed consent
Potentially eligible patients (or their legal representatives) were informed about the trial by one of the study
team, and then given a patient information sheet to review. Patients were given a minimum of 24 hours in
which to consider the study and ask questions, after which they (or their legal representatives) were asked
to give written informed consent to participate, on the trial informed consent form.
For relevant patients, consent given by a legal representative was in place until the patient recovered
capacity, at which point the patient was informed about the trial and asked to decide whether or not they
wanted to continue in the trial. Consent to continue was then sought from the patients themselves.
Randomisation and concealment
Site staff registered patients onto the trial via Trans European Network for clinical trials services (TENALEA),
a web-based registration and randomisation system, after written informed consent was obtained from
the patient (or their legal representative). Subsequently, screening assessments took place to ascertain
eligibility. Non-eligible patients were deemed screening failures, while eligible patients were then
randomised by site staff, via the TENALEA, to one of four trial treatment arms. Treatment allocation was
blinded to site staff and the patient by providing each patient with a unique four-digit patient pack
number. The treatment arm was also concealed to investigators and researchers. Only the study
statisticians were unblinded and this was for analysis purposes only.
Randomisation was stratified and performed using the following two stratification factors:
1. geographic region (28 in total)
2. risk group – either ‘high’ or ‘intermediate’ risk (‘high’ risk was defined as either sepsis or history of
GI bleeding in the previous 7 days or creatinine level of > 150 µmol/l, or any combination of the these;
‘intermediate’ risk was defined as no sepsis and no history of GI bleeding in the previous 7 days and
creatinine ≤ 150 µmol/l).
Unblinding service
The Emergency Scientific and Medical Services at Guy’s and St Thomas’ NHS Foundation Trust provided a
24-hour unblinding service for the trial. The Emergency Scientific and Medical Services held a copy of the
study randomisation list and were able to perform emergency unblinding if the enquirer considered
the medical management of the patient to be dependent on knowing their treatment allocation.
TRIAL DESIGN AND METHODS
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Data collection and management
Sites entered trial-specific data, as specified in the protocol, onto paper case report forms (CRFs).
Completed paper CRFs were sent to the Southampton Clinical Trials Unit (SCTU) that was responsible for
the data management of the trial. Data were transcribed from paper CRFs into an InForm database
(InForm version 5.0, ORACLE, Redwood Shoves, CA, USA) at the SCTU. A range of data validation checks
was carried out within both InForm and SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) to minimise
incorrect or missing data.
Source data verification was undertaken during site monitoring visits, in accordance with the SCTU’s trial
monitoring plan. For sites that recruited ≥ 15 patients a planned monitoring visit was scheduled.
In total, 29 planned monitoring visits and two triggered monitoring visits took place.
Baseline
At baseline, a number of characteristics were collected to determine the patient’s prognosis at the
beginning of the trial. The outcomes collected at this time point included the following: vital signs, World
Health Organization performance status, concomitant medication, LFTs, prothrombin time (PT), full blood
count (FBC), urea, creatinine, GI bleed or sepsis since screening and time since admission to hospital.
Prognostic scores at baseline (DF, MELD score, GAHS and Lille score) were derived using baseline data with
the exception of the Lille score, which also uses data from day 7. Demographic data were captured
at screening.
Follow-up
Patients who were being treated as in-patients were followed-up every 7 days from the start of treatment
until the end of treatment (day 28). If the patient was discharged from hospital during the treatment
phase, then the 28-day follow-up visit was conducted by phone, when possible, in order to gather
treatment information. All patients were scheduled for a follow-up hospital visit at 90 days and 1 year
from start of treatment, at which time details of the patients’ alcohol consumption and attendance at
alcohol counselling were collected. There were also repeated measurements of outcomes recorded
at baseline (see Baseline) as well as if patients had experienced an occurrence of GI bleed or sepsis since
their last visit. Finally, for the 1-year follow-up visit only, demographic data were collected on the patients’
marital status, employment status and housing status.
All patients were asked to consent to information about their health status being held and maintained
by the Health and Social Care Information Centre and the NHS Central Register to enable long-term
follow-up. In January 2013, the National Institute for Health Research Health Technology Assessment
(funding body) awarded a no-cost extension to recruitment (from the end of December 2012 to the end
of February 2014), but with follow-up reduced to a minimum of 28 days (to the end of March 2014),
so that primary outcome data could be collected for all randomised patients.
Outcome measures
Primary outcome
The primary outcome was 28-day mortality. This was chosen as this time point represents the end of the
peak period of mortality for AH. Also, this is consistent with other AH trials, which allows a comparison to
be made. Patient mortality at day 28 was treated as a binary outcome (1= dead, 0= alive).
Secondary outcomes
Secondary outcomes at day 90 and 1 year
Mortality or liver transplant at day 90 and 1 year were considered as secondary outcome measures. These
were calculated in a similar fashion to the primary outcome; the main difference being that these also
included the incidence of liver transplantation.
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Overall survival (OS) was also evaluated, for which an event was defined as any death occurring during
1-year post-treatment start. The OS time was defined as the following:
l if the date of death was < 1-year post-treatment start, then the OS time was the difference between
the treatment start date and death date
l if the date of death was > 1-year follow-up, then patients were censored with an OS time of 365 days
l if no date of death was received, then patients were censored with an OS time of 365 days, if they
were known to be alive at 1 year, or the difference between treatment start and date last known alive.
Outcomes of recidivism in patient’s alcohol intake were collected at day 90 and 1 year. This included
whether or not patients had attended any alcohol counselling sessions. Development of renal failure,
sepsis and GI bleed at day 90 and 1 year were also assessed.
Prognostic scores and predictors of mortality
The outcomes of 28-day, 90-day and 1-year mortality were considered in relation to the GAHS at baseline.
Other scores considered were DF, MELD score and the Lille score (see Appendix 1).
Other baseline measures were evaluated to see whether or not they were predictors of mortality,
including: pyrexia (temperature > 37.2 °C), hypotension (systolic blood pressure < 100mmHg), tachycardia
(pulse > 100 beats per minute), alcohol intake (units/week), albumin (g/l), alkaline phosphatase (ALP) (U/l),
bilirubin (µmol/l), hepatic encephalopathy (presence vs. absence), PT ratio or international normalised ratio
(INR), age (years), white blood cell (WBC) count (109 WBC/l), urea (mmol/l) and creatinine (µg/dl).
Safety
Serious adverse events (SAEs) were measured during the treatment period using the National Cancer
Institute Common Toxicity Criteria for Adverse Events version 4.0.
Health-related quality of life
Hospital readmission rates for liver- or non-liver related events (including access to other health services)
and incremental NHS costs and QoL data [using the European Quality of Life-5 Dimensions (EQ-5D) score],
were collected at day 90 and 1-year follow-up visits.
Duration of hospitalisation, type of hospital, time of initial presentation and time of admission to treating
hospital (if a tertiary referral) were evaluated.
Sample size
The sample size was performed in nQuery Advisor version 2.0 (Statistical Solutions, Boston, MA, USA) using
a two-group continuity-corrected chi-squared test and the following parameters:
l power= 90% (to allow for secondary outcomes)
l two-sided significance level of 5%.
Estimated 28-day mortality rate in each treatment arm is given in Table 2.
Based on a reduction in the 28-day mortality rate at the margins from 30% to 21%, a sample size of
513 per group of single agent versus no single agent was required. Thus, in total, the trial required
1026 patients. We allowed for an approximate 10% dropout rate up to day 28 and therefore aimed to
randomise 1200 patients to the study, with an equal treatment group allocation.
TRIAL DESIGN AND METHODS
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The sample size for this trial was not powered to assess for any observed treatment interaction and, in fact,
assumed that there was no interaction between the two treatments (i.e. that receiving prednisolone in
addition to PTX does not change the effect of PTX and vice versa). Assessing the size of any interaction
was not of primary interest, as it was assumed to be small or non-existent and would require a fourfold
increase in the sample size, so it was deemed appropriate not to power for assessing an interaction.
Stopping guidelines
Prior to this trial, the benefits and harms of PTX in this patient population were unknown, as only limited
data were available, and prednisolone had a significant, although uncertain, evidence base. In addition,
there was huge uncertainty about whether or not the combination of PTX and prednisolone would be
harmful or beneficial, and whether or not there would be a treatment interaction. It was therefore
important to conduct interim analyses with predefined criteria to assess both for harm and benefit.
Prespecified stopping guidelines were developed based on the Peto–Haybittle rule, as recommended by
Pocock.30 The guidelines recommended that certain treatment arms were stopped if a two-sided (i.e. for
harm or benefit) p-value of < 0.001 was found in group comparisons of day-28 mortality using logistic
regression analysis. Pocock30 states this p-value ties in well with the concept of proof beyond reasonable
doubt. This p-value was used for both stopping guidelines of harm and benefit, as the treatments were
not new and were already in use in practice. Also, should evidence of harm or benefit arise, evidence
needed to be sufficiently convincing to ensure that others would believe it and change their practice
accordingly. No adjustment in the significance of the p-value for the final analysis was made, owing to the
p-value of 0.001 being considered sufficiently small.
The Data Monitoring and Ethics Committee met to review cumulative safety and efficacy data at three
time points during the trial. The following interim stopping guideline assessments were made:
l Primary end-point data from 200 patients: only stopping guidelines for harm were assessed.
No treatment arms were stopped for harm at this interim assessment.
l Primary end-point data from 400 patients: stopping guidelines for harm and benefit were assessed.
No treatment arms were stopped for harm or benefit at this interim assessment.
l Primary end-point data from 800 patients: stopping guidelines for harm and benefit were assessed.
No treatment arms were stopped for harm or benefit at this interim assessment.
TABLE 2 Estimated 28-day mortality rates for sample size
PTX
TotalNo Yes
Prednisolone
No 35% (placebo/placebo) 25% (PTX/placebo) 30%
Yes 25% (placebo/prednisolone) 17%a (prednisolone/PTX) 21%
Total 30% 21% –
a Estimated assuming no interaction, that is multiplicative independent effects.
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Statistical analysis
All trial analyses and reporting were carried out following the Consolidated Standards of Reporting Trials
(CONSORT) guidelines. Statistical analysis was carried out in SAS version 9.2 and/or 9.3 following a
predefined statistical analysis plan, which was approved by the Data Monitoring and Ethic Committee.
Some subsequent analyses were carried out that were not predefined; these will be highlighted in the
relevant sections of this report (see Chapter 3, Secondary Outcomes).
Analyses were carried out with respect to the factorial design for which:
l the prednisolone-treated group (arms B and D) was compared with the prednisolone control group
(arms A and C)
l the PTX-treated group (arms C and D) was compared with the PTX control group (arms B and D).
If a significant interaction (at the 5% significance level) was found then the comparison of interest was
individual treatment arm. All descriptive tables were presented by treatment arm.
All analyses were adjusted for risk group and factorial design unless otherwise stated, and were assessed
at the two-sided 5% significance level.
Analysis populations
All summaries and analyses were carried out on the intention-to-treat (ITT) population unless otherwise
specified. The ITT population included all patients who were randomised regardless of treatment
adherence. For analyses at a certain time point, the ITT population was modified to include only patients
who were known to be alive at the specified time point or had died prior to the time point, that is, for
primary analysis, this included all randomised patients for whom we knew that they were alive at day 28
or who died prior to or on day 28.
A per-protocol population was defined as:
l treatment adherence ≥ 75%
¢ patients who reached day 28 needed to have had taken at least 75% of treatment (> 21 days) to
be included in the per-protocol population
¢ patients who withdrew or died before day 28 needed to have had a minimum of 7 days of
treatment and taken at least 75% of treatment up until they withdrew/died
l patients who had no major protocol violations.
The primary end-point analysis was repeated for the per-protocol population.
Preliminary analyses
Summary statistics were produced for a selection of key clinical and demographic characteristics at baseline
to assess baseline comparability between the four treatment arms. Any significant differences
were reported.
Primary analyses
The primary outcome of 28-day mortality was analysed using logistic regression. Although the trial was not
powered to detect a treatment interaction, this was tested using a secondary logistic regression model in
order to test the underlying model assumptions surrounding factorial design.
TRIAL DESIGN AND METHODS
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Secondary analyses
The primary outcome analysis method was repeated for the 90-day and 1-year mortality or liver transplant
outcomes. For OS, comparisons were made using Cox proportional hazards regression and Kaplan–Meier curves.
A number of analyses were carried out on the DF, GAHS, MELD and Lille prognostic scores. First, to assess the
predictive power of the scores on 28-day, 90-day and 1-year mortality, a receiver operating characteristic
(ROC) curve analysis was carried out. Graphical representation of the ROC curves was produced along with
area under the curve statistics. Further ROC curve analysis was carried out on the Lille score comparing the
two prednisolone-treated groups (not predefined). Univariate logistic regression analysis was also carried out
to look at the relationship between the scores and outcome.
Univariate logistic regression analysis was carried out to assess the relationship between baseline prognostic
factors and 28-day, 90-day and 1-year mortality. The prognostic factors included in this analysis were as
follows: pyrexia, hypotension, tachycardia, alcohol intake, albumin, ALP, bilirubin, encephalopathy, PT ratio/INR,
age, WBCs, urea and creatinine. Odds ratios with a 95% confidence interval (CI) and corresponding p-value
were produced for each model fitted. Any factors that were significant in the univariate analysis were added to
a multivariate model, which also included the treatment indicators for prednisolone and PTX. Backward
elimination was then applied to produce adjusted odds ratios for the effects of prednisolone and PTX. Please
note that the use of backward elimination was not predefined in the statistical analysis plan.
Descriptive summaries of the following were produced: causes of death, SAEs, alcohol behaviour and
alcohol counselling attendance.
Finally, the effect of drinking habits on 1-year mortality was explored by fitting a logistic regression model
with abstinence as the reference event. This was compared with the other three alcohol consumption
statuses (reduced drinking to below government defined safety limits, reduced drinking but still above
safety limits and not reduced). Please note that this analysis was not predefined.
For all regression models applied, the assumptions underlying these models were checked using
appropriate methods; the Hosmer–Lemeshow goodness-of-fit test for assessing logistic regression
modelling and the proportional hazards assumption for Cox proportional hazards modelling. Covariates
used in logistic regression modelling were assessed for outliers. Subsequently, outliers were excluded
during a sensitivity analysis to allow for any differences in results to be examined.
Sensitivity analyses
A sensitivity analysis of the primary end-point outcome was produced by excluding any patients who were
randomised and followed-up but were later found to be ineligible through central monitoring of baseline
characteristics. Patients were excluded if they had any of the following characteristics at baseline:
l < 18 years old
l bilirubin level of < 80 µmol/l
l maximum alcohol consumption in past 2 months < 70 units/week for a male
l maximum alcohol consumption in past 2 months < 52.5 units/week for a female
l time between initial admission and screening date > 4 weeks
l DF of < 32
l AST level of > 500 IU/l
l ALT level of > 300 U/l
l creatinine level of > 500 µmol/l
l unresolved sepsis
l unresolved GI bleed.
Please note that this sensitivity analysis was not predefined.
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Subgroup analyses
Subgroup analyses were performed to further explore whether or not particular subsets of the patient
population were at more benefit to treatment and prolongation of survival. The subgroups considered
were the prognostic scores (DF, GAHS, MELD and Lille score) and risk at baseline. These analyses looked at
28-day, 90-day and 1-year mortality using logistic regression analysis methods as described in Statistical
analysis. Please note that these subgroup analyses were not predefined.
Patient and public involvement
The Trial Management Group (TMG) was delighted to recruit Mr Colin Stanfield as a patient representative.
He attended the majority of TMG meetings during the set up and running of the STOPAH trial. His input
from a patient perspective was valuable in terms of the design of the patient information sheet and consent
form. He also provided guidance on a number of occasions about patient behaviour and acceptability of
interventions, and data collection.
TRIAL DESIGN AND METHODS
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Chapter 4 Trial results
Recruitment and randomisation
The SCTU site staff performed initiation visits between October 2010 and August 2012. In total, 66 trial
sites were opened but subsequently one site was closed after failing to recruit any patients. The details of
recruitment by site are given in Figure 1.
A total of 5234 patients were screened for the trial, and after applying inclusion and exclusion criteria,
1103 were randomised and evenly allocated to the four treatment arms. Analysis of screening logs
indicates that the trial recruited 85% of eligible patients; disease severity being too mild was the most
common reason for patients not being recruited. There were a total of 50 dropouts prior to the primary
end-point time point at 28 days. A total of 168 patients died between 28 days and the next time point at
90 days, and 221 patients dropped out of the study between 90 days and 1 year. We were unable to
follow-up 228 patients recruited during the last 9 months of the trial as the study was closed. Details of
the patient flow are provided in the CONSORT diagram (Figure 2).
As detailed in the sample size and power calculation in Chapter 3, Sample size, the trial aimed to recruit
1200 patients in order to be confident of having primary end-point data on 1026 patients. Although the
final number of patients recruited fell short of the target number, the trial exceeded the number needed
for the trial power to be maintained in the primary end-point analysis.
Flow of participants through the trial
See Figure 2 for CONSORT flow diagram.
Unblinding of patients
Requests for unblinding were received for a small number of patients. In all cases there were reasonable
clinical justifications for the unblinding (detailed in Table 3), which were judged to be acceptable by the
trial chief investigator (ChI). In view of the hard trial end points and the small number of unblinding events
these are not thought to have any impact on the trial result.
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Southampton (37 months)
Imperial (36 months)
Bristol (36 months)
Sheffield (36 months)
Exeter (35 months)
Royal Infirmary, GG&C (35 months)
Liverpool (35 months)
Torbay (34 months)
Nottingham (34 months)
Blackpool (34 months)
Derby (33 months)
Gartnavel General, GG&C (33 months)
Kings (33 months)
Gloucester (33 months)
Truro (33 months)
Bournemouth (33 months)
Newcastle upon Tyne (32 months)
Inverness (32 months)
Hull (32 months)
Bradford (32 months)
Weston (31 months)
Doncaster (31 months)
Bassetlaw (30 months)
Royal Free Hospital (30 months)
St Georges (30 months)
Portsmouth (29 months)
Royal London (29 months)
Royal Alexandra, GG&C (29 months)
Poole (29 months)
Chelsea and Westminster (29 months)
Bath (29 months)
Addenbrookes (29 months)
Luton (28 months)
Chesterfield (28 months)
Durham (28 months)
Dundee (27 months)
Swansea (27 months)
South Tyneside (27 months)
Newport (27 months)
Birmingham (27 months)
Sunderland (27 months)
Southern General, GG&C (27 months)
Aintree (26 months)
Chester (26 months)
Leicester (26 months)
Northumbria (25 months)
Dumfries (25 months)
West Middlesex (24 months)
Edinburgh (24 months)
South Tees (24 months)
Taunton (24 months)
Barnstaple (24 months)
Frimley Park (24 months)
Sandwell (23 months)
Sherwood (23 months)
North Staffordshire (22 months)
Warrington (21 months)
Leeds (21 months)
Basildon (21 months)
Forth Valley (19 months)
Lincoln (19 months)
Aberdeen (Grampian) (18 months)
Worthing (16 months)
Boston (16 months)
Rotherhama (16 months)
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FIGURE 1 Number of patients randomised by site, ordered by number of months open to recruitment. a, All sites
closed to recruitment on 28 February 2014 with the exception of Rotherham, which closed on 19 October 2012,
after 16 months open, owing to poor recruitment activity. GG&C, Greater Glasgow and Clyde.
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Allocated to 
placebo/placebo
(n = 276)
• Alive, n = 224
• Deceased, n = 45
Drop-out before day 28
(N = 7)
• Incorrect 
   randomisation, n = 4
• No use of data,a n = 0
• Lost to follow-up, n = 1
• Withdrawn,b n = 2
• Died before 
   randomisation, n = 0
Analysed at day 28 
(N = 269)
• Alive, n = 86
• Deceased/
   transplant, n = 106
Analysed at 1 year 
(N = 192)
• Alive, n = 183
• Deceased/
   transplant, n = 66
Analysed at day 90 
(N = 249)
Drop out before 1 year
but after day 90
(N = 57)
• Lost to follow-up, n = 14
• Withdrawn,b n = 4
• Early cessation of 
   follow-up,c n = 39
Allocated to 
prednisolone/
placebo
(n = 277)
• Alive, n = 228
• Deceased, n = 38
Drop-out before day 28
(N = 11)
• Incorrect 
   randomisation, n = 1
• No use of data,a n = 2
• Lost to follow-up, n = 3
• Withdrawn,b n = 5
• Died before 
   randomisation, n = 0
Analysed at day 28 
(N = 266)
• Alive, n = 80
• Deceased/
   transplant, n = 110
Analysed at 1 year 
(N = 190)
• Alive, n = 161
• Deceased/
   transplant, n = 80
Analysed at day 90 
(N = 241)
Drop out before 1 year
but after day 90
(N = 51)
• Lost to follow-up, n = 12
• Withdrawn,b n = 2
• Early cessation of 
   follow-up,c n = 37
Allocated to 
placebo/PTX
(n = 276)
• Alive, n = 208
• Deceased, n = 50
Drop-out before day 28
(N = 18)
• Incorrect 
   randomisation, n = 1
• No use of data, n = 2
• Lost to follow-up, n = 3
• Withdrawn,b n = 12
• Died before 
   randomisation, n = 0
Analysed at day 28 
(N = 258)
• Alive, n = 79
• Deceased/
   transplant, n = 105
Analysed at 1 year 
(N = 184)
• Alive, n = 160
• Deceased/
   transplant, n = 75
Analysed at day 90 
(N = 235)
Drop out before 1 year
but after day 90
(N = 51)
• Lost to follow-up, n = 8
• Withdrawn,b n = 0
• Early cessation of 
   follow-up,c n = 43
Allocated to 
prednisolone/PTX
(n = 274)
• Alive, n = 225
• Deceased, n = 35
Drop-out before day 28
(N = 14)
• Incorrect 
   randomisation, n = 1
• No use of data,a n = 0
• Lost to follow-up, n = 4
• Withdrawn,b n = 8
• Died before 
   randomisation, n = 1
Analysed at day 28 
(N = 260)
• Alive, n = 81
• Deceased/
   transplant, n = 100
Analysed at 1 year 
(N = 181)
Drop-out before 
day 90 but after day 28
(N = 20)
• Lost to follow-up, n = 9
• Withdrawn,b n = 2
• Early cessation of 
   follow-up,c n = 9
Drop-out before
 day 90 but after day 28
(N = 25)
• Lost to follow-up, n = 17
• Withdrawn,b n = 1
• Early cessation of 
   follow-up,c n = 7
Drop-out before 
day 90 but after day 28
(N = 23)
• Lost to follow-up, n = 10
• Withdrawn,b n = 0
• Early cessation of 
   follow-up,c n = 13
Drop-out before 
day 90 but after day 28
(N = 17)
• Lost to follow-up, n = 11
• Withdrawn,b n = 2
• Early cessation of 
   follow-up,c n = 4
• Alive, n = 179
• Deceased/
   transplant, n = 64
Analysed at day 90 
(N = 243)
Drop out before 1 year
but after day 90
(N = 62)
• Lost to follow-up, n = 20
• Withdrawn,b n = 2
• Early cessation of 
   follow-up,c n = 40
Assessed for potential enrolment
(n = 5234)
Randomised
(n = 1103)
Excluded (N = 4131)
• Patient/relative declined, n = 426
• Alcohol consumption < limit for trial, n = 198
  • Persistent sepsis/rental failure/GI bleed, n = 161
  • Recent steroids/PTX, n = 160
  • Too mild (DF of < 32), n = 518
  • Bilirubin level of < 80 µmol/l, n = 1488
  • Prolonged jaundice/suspected decompensated 
    cirrhosis, n = 190
  • HBV/HCV, n = 199
  • Other infection, n = 128
  • Patient unable to swallow, n = 59
  • Clinician decision, n = 188
  • Other, n = 416
FIGURE 2 Consolidated Standards of Reporting Trials flow chart. HBV, hepatitis B virus; HCV, hepatitis C virus.
a, No usage of data allowed – patient withdrew consent and would not allow any data collection to be used;
b, withdrew – patient withdrew consent but allowed use of data collection up to point of withdrawal; and c, early
cessation of follow-up – recruitment extended to end of February 2014, but follow-up for all patients ceased end
March 2013, so that primary end-point data could be collected for all patients.
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TABLE 3 Summary of patients unblinded during the STOPAH trial
Treatment allocation Reason for unblinding
Placebo/prednisolone Research nurse requested unblinding of patient who had had surgery following bowel
perforation previous night. Treating medical/surgical team wanted to know if patient had
received steroids
PTX/placebo Patient’s clinical condition had deteriorated. Responsible clinician has discussed this with ChI
who has authorised unblinding
PTX/placebo Due to forthcoming inquest into patient’s death, ChI requested unblinding via Hull RI
research nurse
Placebo/placebo Patient has been in ICU for 5–6 days following complications during an investigative
procedure. Admitted to ICU 6 days after starting trial drug(s) and these ceased on
admission. Patients condition ‘stable but critical’. Patient put on hydrocortisone when
admitted to ICU and needs to stop [prednisolone]. Caller insists decision to stop
hydrocortisone dependent on knowledge of study treatment so they can decide to stop
immediately or taper drug off
PTX/prednisolone Patient admitted to West Middlesex Hospital with sepsis and pneumonia. Condition
developing and worsening over last 2 days
Placebo/prednisolone Patient is very poorly on ITU and the his/her medical management is dependent on
knowing if he/she is receiving active or placebo drug
PTX/placebo Unblinding request from ChI (no further details available)
Placebo/prednisolone The patient died and the treatment allocation information would be useful for the
post-mortem
PTX/placebo ChI agreed to unblinding as patient developed severe psychosis
Placebo/prednisolone Patient had persistent jaundice since November – caller would like to know what treatment
the patient was receiving when taking trial medication. The patient finished treatment on
20/12/2012
PTX/placebo Patient due to stop trial tomorrow (15/06/2013) but has been deteriorating. Consultant
treating patient would like to start steroids, but only if patient hasn’t already been on
steroids in the study
Placebo/prednisolone First call at 23.50 – patient on GI ward with suspected perforation. Dr wants to administer
IV hydrocortisone and would like to know treatment that the patient is on. Second call
at 00.12 – confirming that the Dr would like to unblind as the patient has an actual
perforation and sepsis. No further details on patient’s condition as caller is the on-call
pharmacist
Placebo/prednisolone Caller has been asked by the PI to find out what arm the patient was on. They finished the
trial over 3 weeks ago and have been hospitalised with deranged LFTs. The caller has
spoken to the ChI and they have confirmed that this subject can be unblinded
Placebo/placebo Caller has a patient with severe VT and torsade and requires tertiary cardiac HDU care. The
patient was enrolled on to the trial on 31/07/2013 and completed a month’s supply of IMP.
The patient was transported from their local hospital for tertiary cardiac HDU care from the
cardiologist. Local PI has received confirmation to unblind from ChI
PTX/prednisolone Caller requested unblinding of a patient that has died, stating that they needed to know
the treatment allocation for the coroner’s report. They think the patient died of necrotising
pancreatitis and peritonitis
ChI, chief investigator; ICU, intensive care unit; ITU, intensive therapy unit; IV, intravenous; HDU, high-dependency unit;
RI, Royal Infirmary; PI, principal investigator; VT, ventricular tachycardia.
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Characteristics of the study sample
The baseline characteristics of the patients are typical of those seen in other studies in this population of
patients. In particular, disease severity scores (DF, MELD, GAHS and Lille) were consistent with those seen
in other publications.23,31 Details of the clinical and laboratory values are provided in Table 4. There were
no significant differences in laboratory values or prognostic scores between the four treatment arms except
for ALP and Lille score, which were significant at the 1% level, and PT, which was significant at the
5% level.
TABLE 4 Baseline characteristics
Baseline characteristics
Placebo/placebo
(N= 272)
Prednisolone/placebo
(N= 274)
Placebo/PTX
(N= 273)
Prednisolone/PTX
(N= 273)
n (%)
Male 162 (60) 177 (65) 164 (60) 182 (67)
White 259 (95) 262 (96) 264 (97) 261 (96)
WHO performance status
0 – asymptomatic 14 (5) 24 (9) 21 (8) 26 (10)
1 – symptomatic but
completely ambulatory
75 (28) 84 (31) 90 (33) 77 (28)
2 – symptomatic < 50%
in bed
91 (33) 77 (28) 69 (25) 77 (28)
3 – symptomatic > 50%
in bed
66 (24) 69 (25) 74 (27) 67 (25)
4 – bedbound 22 (8) 17 (6) 15 (5) 17 (6)
Encephalopathy
None 191 (70) 205 (75) 211 (77) 190 (70)
Grade I 46 (17) 38 (14) 33 (12) 48 (18)
Grade II 19 (7) 19 (7) 16 (6) 12 (4)
Grade III 5 (2) 1 (< 0.5) 5 (2) 7 (3)
Grade IV 0 0 0 0
Sepsis on admission 31 (11) 27 (10) 23 (8) 29 (11)
Renal failure on admission 1 (< 0.5) 0 1 (< 0.5) 0
GI bleeding on admission 16 (6) 21 (8) 15 (5) 15 (5)
Pyrexia 42 (15) 28 (10) 32 (12) 34 (12)
Hypotension 49 (18) 46 (17) 45 (16) 52 (19)
Tachycardia 47 (17) 46 (17) 56 (21) 52 (19)
continued
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Allocation of treatments
Allocation to treatment arms is detailed in Table 5. Overall, 22% of patients were categorised in the
high-risk classification at randomisation, although a small number of these were inappropriately classified
and were correctly defined for the primary end-point analysis.
TABLE 4 Baseline characteristics (continued )
Baseline characteristics
Placebo/placebo
(N= 272)
Prednisolone/placebo
(N= 274)
Placebo/PTX
(N= 273)
Prednisolone/PTX
(N= 273)
Mean (SD)
Age (years) 48.8 (10.28) 49.3 (10.57) 47.9 (10.23) 48.6 (9.81)
Alcohol consumption (g/day)
Female 153.7 (98.54) 141.7 (75.42) 145.7 (93.11) 157.0 (143.77)
Male 195.4 (126.53) 209.9 (117.67) 192.4 (129.81) 201.7 (127.28)
Time from admission to
treatment (days)
6.1 (3.82) 6.5 (3.85) 6.7 (4.16) 6.5 (4.40)
Laboratory values
Bilirubin (µmol/l) 305.9 (157.94) 297.5 (155.19) 292.6 (144.62) 306.1 (163.09)
Albumin (g/l) 25.6 (6.26) 25.2 (6.22) 25.1 (5.37) 25.3 (6.01)
AST (IU/l) 143.7 (69.53) 133.6 (64.78) 134.3 (73.24) 143.4 (77.19)
ALP (U/l)a 184.7 (86.36) 207.7 (113.06) 182.4 (85.09) 196.1 (98.52)
Creatinine (µmol/l) 73.4 (38.33) 79.8 (46.31) 78.5 (49.08) 81.5 (51.65)
WBC (× 109/l) 10.1 (5.56) 10.6 (8.13) 9.9 (5.42) 9.8 (4.94)
Neutrophils (× 109/l) 7.6 (5.20) 7.7 (5.24) 7.4 (4.92) 7.3 (4.51)
PT (seconds)a 21.1 (5.27) 20.8 (5.26) 22.1 (6.79) 21.1 (5.17)
Prognostic scores
DF 61.9 (25.66) 60.7 (25.34) 65.6 (31.64) 62.4 (25.62)
GAHS 8.2 (1.18) 8.3 (1.27) 8.3 (1.19) 8.3 (1.32)
MELD 20.7 (5.54) 21.2 (6.19) 21.4 (6.32) 21.5 (6.84)
Lille scorea,b 0.5 (0.32) 0.4 (0.33) 0.5 (0.34) 0.4 (0.34)
SD, standard deviation; WHO, World Health Organization.
a There were no significant differences between treatment arms for the baseline characteristics except for ALP and Lille
score, which were significant at the 1% level, and PT, which was significant at the 5% level (looking at non-missing
data only).
b The Lille score uses data at baseline and day 7.
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TABLE 5 Allocation of treatment arms by stratification factors
Stratification factors
Placebo/placebo
(N= 272)
Prednisolone/placebo
(N= 274)
Placebo/PTX
(N= 273)
Prednisolone/PTX
(N= 273)
Risk used in randomisation,a n (%)
Intermediate 212 (78) 214 (78) 216 (79) 214 (78)
Highb 60 (22) 60 (22) 57 (21) 59 (22)
Actual risk at baseline,c n (%)
Intermediate 216 (79) 219 (80) 222 (81) 213 (78)
Highb 56 (21) 55 (20) 51 (19) 60 (22)
IMP centre, n (%)
Aberdeen 3 (1) 3 (1) 3 (1) 2 (1)
Addenbrookes 6 (2) 6 (2) 7 (3) 6 (2)
Basildon 0 0 1 (< 0.5) 0
Blackpool 4 (1) 4 (1) 4 (1) 4 (1)
Bradford 4 (1) 5 (2) 5 (2) 4 (1)
Bristol 18 (7) 18 (7) 18 (7) 18 (7)
Derby 17 (6) 18 (7) 17 (6) 18 (7)
Dumfries 1 (< 0.5) 0 1 (< 0.5) 0
Dundee 3 (1) 5 (2) 4 (1) 4 (1)
Edinburgh 6 (2) 6 (2) 6 (2) 6 (2)
Forth Valley 2 (1) 1 (< 0.5) 1 (< 0.5) 0
Frimley Park 4 (1) 4 (1) 3 (1) 3 (1)
Hull 4 (1) 3 (1) 3 (1) 4 (1)
Imperial 23 (8) 23 (8) 22 (8) 23 (8)
Inverness 2 (1) 1 (< 0.5) 3 (1) 2 (1)
King’s 9 (3) 8 (3) 8 (3) 8 (3)
Leeds 0 1 (< 0.5) 0 0
Liverpool 30 (11) 29 (11) 30 (11) 29 (11)
Luton 1 (< 0.5) 1 (< 0.5) 1 (< 0.5) 2 (1)
Newcastle upon Tyne 26 (10) 25 (9) 24 (9) 26 (10)
Nottingham 23 (8) 23 (8) 25 (9) 25 (9)
Plymouth 20 (7) 21 (8) 21 (8) 21 (8)
Glasgow Royal Infirmary 34 (13) 36 (13) 34 (12) 35 (13)
Sheffield 9 (3) 10 (4) 11 (4) 10 (4)
Southampton 16 (6) 16 (6) 16 (6) 15 (5)
St Georges 2 (1) 2 (1) 1 (< 0.5) 2 (1)
Swansea 4 (1) 4 (1) 3 (1) 4 (1)
Worthing 1 (< 0.5) 1 (< 0.5) 1 (< 0.5) 2 (1)
a Risk classification as used in randomisation system.
b High risk is defined as either sepsis or history of GI bleeding in the previous 7 days or creatinine level of > 150 µmol/l,
or any combination of the these; intermediate risk is defined as no sepsis and no history of GI bleeding in the previous
7 days and creatinine level of ≤ 150 µmol/l.
c Risk classification at baseline.
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Treatment adherence
The predefined per-protocol analysis depended on measurement of treatment adherence as defined in
Chapter 3, Analysis population. Per-protocol analysis required patients to have taken at least 75% of
prescribed medication and that they had no protocol violations. Data on treatment adherence were poorly
documented, so it was difficult to define a sufficiently sized ‘per-protocol’ population for analysis.
Primary outcome
Table 6 documents the primary outcome at 28 days. At day 28, 45 of 269 (16.7%) patients in the
placebo/placebo arm had died, 50 of 258 (19.4%) patients in the PTX/placebo arm had died, 38 of 266
(14.3%) patients in the prednisolone/placebo arm had died and 35 of 260 (13.5%) patients in the
PTX/prednisolone arm had died. Therefore, in the prednisolone-treated group, 13.9% of patients died
compared with 18.0% in the group who did not receive prednisolone (odds ratio 0.72, 95% CI 0.52 to
1.01; p= 0.056). In the PTX-treated group, 16.5% of patients died compared with 15.5% in the group
who did not receive PTX (odds ratio 1.07, 95% CI 0.77 to 1.49; p= 0.686). There was no interaction
between the effects of prednisolone and PTX (p= 0.407) (Table 7).
TABLE 6 Observed 28-day mortalitya
PTX
TotalNo Yes
Prednisolone
No 16.7% (45/269) (placebo/placebo) 19.4% (50/258) (placebo/PTX) 18.0% (95/527)
Yes 14.3% (38/266) (prednisolone/placebo) 13.5% (35/260) (prednisolone/PTX) 13.9% (73/526)
Total 15.5% (83/535) 16.5% (85/518) 16.0% (168/1053)
a Includes all randomised patients who have at least 28 days of data or died prior to or on day 28.
TABLE 7 Primary analysis results: logistic regression analysis for 28-day mortalitya
Prednisolone No prednisolone PTX No PTX
28-day mortality (n/N) 13.9% (73/526) 18.0% (95/527) 16.4% (85/518) 15.5% (83/535)
Adjusted odds ratiob (95% CI) 0.72 (0.52 to 1.01) 1.07 (0.77 to 1.49)
p-value 0.056 0.686
a Includes all randomised patients who have at least 28 days of data or died prior to or on day 28.
b Adjusted for risk (high or intermediate) at baseline and factorial design (all comparisons are for the intervention
compared with its respective control).
Notes
Odds ratios < 1 represent a favourable outcome for the corresponding intervention.
The interaction between the interventions was investigated as a secondary analysis and was found to be non-significant
[interaction coefficient= –0.284, 95% CI –0.956 to 0.387; p-value= 0.407)].
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Secondary outcomes
Day 90, year 1 and overall survival
Table 8 documents the secondary outcomes at day 90. At day 90, there had been 139 deaths out of
478 participants (29.1%) deaths in the PTX group compared with 146 deaths out of 490 participants
(29.8%) deaths in the group not treated with PTX (odds ratio 0.97, 95% CI 0.73 to 1.28; p= 0.807). There
had been 144 of 484 (29.8%) deaths in the prednisolone group compared with 141 of 484 (29.1%) deaths
in the group not treated with prednisolone (odds ratio 1.02, 95% CI 0.77 to 1.35; p= 0.875) (Table 9).
At 1 year there had been 205 of 365 (56.2%) deaths in the PTX group, compared with 216 of 382
(56.5%) deaths in the group not treated with PTX (odds ratio 0.99, 95% CI 0.74 to 1.33; p= 0.972).
There had been 210 of 371 (29.8%) deaths in the prednisolone group, compared with 211 of 376
(56.1%) deaths in the group not treated with prednisolone (odds ratio 1.01, 95% CI 0.76 to 1.35;
p= 0.937) (Tables 10 and 11).
Neither prednisolone nor PTX appear to influence all-cause survival after 28 days (Figures 3–5). Analysis of
the causes of mortality as recorded by the investigators indicate that most patients died from liver-related
causes, and in many cases this included a contribution from sepsis. The 28-day mortality in this trial was
appreciably less than that seen in other studies in this patient group. However, the overall mortality at
1 year is 56%, illustrating the extent to which ALD contributes to the alarming rise in liver disease
mortality in the UK.
TABLE 8 Observed 90-day mortality or liver transplanta
PTX
TotalNo Yes
Prednisolone
No 26.5% (66/249) (placebo/placebo) 31.9% (75/235) (placebo/PTX) 29.1% (141/484)
Yes 33.2% (80/241) (prednisolone/placebo) 26.3% (64/243) (prednisolone/PTX) 29.8% (144/484)
Total 29.8% (146/490) 29.1% (139/478) 29.4% (285/968)
a Includes all randomised patients who have at least 28 days of data or died prior to or on day 28.
TABLE 9 Logistic regression analysis for 90-day mortalitya
Prednisolone No prednisolone PTX No PTX
90-day mortality/liver transplant 29.8% (144/484) 29.1% (141/484) 29.1% (139/478) 29.8% (146/490)
Odds ratio (95% CI)b 1.02 (0.77 to 1.35) 0.97 (0.73 to 1.28)
p-value 0.875 0.807
a Includes all randomised patients who have at least 90 days of data or died prior to or on day 90.
b Adjusted for true risk at baseline and factorial design.
Notes
Odds ratios < 1 represent a favourable outcome for the corresponding intervention.
The interaction between the interventions was investigated as a secondary analysis and was found to be significant at the
5% significance level (interaction coefficient –0.622, 95% CI –1.181 to –0.064; p= 0.029).
Logistic regression model: 90-day mortality= intercept+ prednisolone indicator+ PTX indicator+ risk.
No patients had a liver transplant by day 90.
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TABLE 10 Observed 1-year mortality or liver transplanta
PTX
TotalNo Yes
Prednisolone
No 55.2% (106/192) (placebo/placebo) 57.1% (105/184) (placebo/PTX) 56.1% (211/376)
Yes 57.9% (110/190) (prednisolone/placebo) 55.2% (100/181) (prednisolone/PTX) 56.6% (210/371)
Total 56.5% (216/382) 56.2% (205/365) 56.4% (421/747)
a Includes all randomised patients who have 1 year of data, died prior to or at 1 year or had a liver transplant prior to or at
1 year.
Notes
Three patients had a liver transplant by 1 year: one in the prednisolone/PTX arm at day 216 and two in placebo/PTX arm at
days 270 and 360 (patients situated at the following sites: Southampton, Nottingham and Glasgow Southern General).
TABLE 11 Logistic regression analysis for 1-year mortality or liver transplanta
Prednisolone No prednisolone PTX No PTX
1-year mortality/liver transplant, % (n/N) 56.6% (210/371) 56.1% (211/376) 56.2% (205/365) 56.5% (216/382)
Adjusted odds ratiob (95% CI) 1.01 (0.76 to 1.35) 0.99 (0.74 to 1.33)
p-value 0.937 0.972
a Includes all randomised patients who have 1 year of data, died prior to or at 1 year or had a liver transplant prior to or at
1 year.
b Adjusted for risk (high or intermediate) at baseline and factorial design (all comparisons are for the intervention
compared with its respective control).
Notes
Odds ratios < 1 represent a favourable outcome for the corresponding intervention.
The interaction between the interventions was investigated as a secondary analysis and was found to be non-significant at
the 5% significance level (interaction coefficient= –0.205, 95% CI –0.787 to 0.377; p= 0.490).
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Prognostic scores
Four scoring systems have been described for use in providing prognostic information in patients with AH.
DF, GAHS and MELD are derived from clinical and laboratory parameters at baseline whereas the Lille
score also incorporated the response to 1 week of prednisolone therapy, determined by the change in
bilirubin level at 7 days. Although each of the scores were highly significantly associated with mortality
(Table 12) at each time point, the diagnostic performance was not considered to be adequate at a
threshold for the area under the ROC curve of 0.75 (Table 13 and Figure 6). Inevitably the prognostic value
of the scores diminished with increasing duration of follow-up.
TABLE 12 Univariate logistic regression analysis for prognostic scores
Prognostic
score
28-day mortalitya 90-day mortalityb 1-year mortalityc
n
Odds
ratio 95% CI p-value n
Odds
ratio 95% CI p-value n
Odds
ratio 95% CI p-value
DF 1049 1.021 1.016 to
1.027
< 0.001 965 1.022 1.017 to
1.028
< 0.001 744 1.022 1.015 to
1.028
< 0.001
GAHS 930 2.128 1.789 to
2.532
< 0.001 855 1.956 1.698 to
2.253
< 0.001 650 1.406 1.239 to
1.595
< 0.001
MELD 1008 1.147 1.116 to
1.179
< 0.001 925 1.138 1.109 to
1.168
< 0.001 715 1.105 1.076 to
1.136
< 0.001
Lilled 697 1.027 1.019 to
1.034
< 0.001 637 1.024 1.019 to
1.030
< 0.001 498 1.017 1.012 to
1.023
< 0.001
a Includes all randomised patients who have at least 28 days of data or died prior to or on day 28 and have data for the
relevant prognostic score.
b Includes all randomised patients who have at least 90 days of data or died prior to or on day 90 and have data for the
relevant prognostic score.
c Includes all randomised patients who have 1 year of data or died prior to or on 1 year and have data for the relevant
prognostic score.
d Lille fitted as a continuous variable using a simple transformation.
TABLE 13 Receiver operating characteristics curve analysis
Prognostic
score
28-day mortalitya 90-day mortalityb 1-year mortalityc
n AUC 95% CI n AUC 95% CI n AUC 95% CI
DF 1049 0.688 0.646 to 0.730 965 0.683 0.647 to 0.720 744 0.653 0.614 to 0.693
GAHS 930 0.733 0.689 to 0.778 855 0.711 0.673 to 0.748 650 0.619 0.577 to 0.660
MELD 1008 0.741 0.699 to 0.783 925 0.712 0.676 to 0.749 715 0.664 0.624 to 0.704
Lille 697 0.735 0.682 to 0.789 637 0.718 0.675 to 0.761 498 0.663 0.616 to 0.711
AUC, area under the curve.
a Includes all randomised patients who have at least 28 days of data or died prior to or on day 28 and have data for the
relevant prognostic score.
b Includes all randomised patients who have at least 90 days of data or died prior to or on day 90 and have data for the
relevant prognostic score.
c Includes all randomised patients who have 1 year of data or died prior to or on 1 year and have data for the relevant
prognostic score.
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FIGURE 6 Receiver operating characteristics curves for prognostic scores. (a) 28-day mortality; (b) 90-day mortality;
and (c) 1-year mortality. AUC, area under the curve. (continued )
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The impact of prognostic scores on the response to prednisolone was explored by stratifying patients
by the magnitude of the prognostic score value or by their risk category (Table 14). These data suggest
that the risk group (high vs. intermediate) has no impact on the effect of prednisolone on mortality. Based
on the odds ratios, patients with a low DF and low GAHS appear to derive more benefit from prednisolone.
However, in contrast, patients may benefit from prednisolone when they have a higher MELD score. These
results appear contradictory and will need to be explored in further studies.
The Lille score was originally derived to predict mortality based on the response to prednisolone. When the
analysis of Lille performance was restricted to only those patients who received prednisolone, the diagnostic
performance improved (Table 15 and Figure 7). However, in the original description of the Lille score, a
score ≥ 0.45 identified a population of patients who had an expected mortality of 75% by 6 months,
whereas in our study a Lille score ≥ 0.45 was associated with around 50% survival at 6 months
DF (AUC = 0.653)
GAHS (AUC = 0.619)
MELD (AUC = 0.664)
Lille (AUC = 0.663)
Reference (AUC = 0.500)
1.00
(c)
0.75
0.50
0.25
0.00
0.00 0.25 0.50
1 – specificity
Se
n
si
ti
vi
ty
0.75 1.00
FIGURE 6 Receiver operating characteristics curves for prognostic scores. (a) 28-day mortality; (b) 90-day mortality;
and (c) 1-year mortality. AUC, area under the curve.
TABLE 14 Prednisolone vs. no prednisolone logistic regression model results for 28-day, 90-day and 1-year
mortality by factorial design and risk group (ITT population at day 28, day 90 and 1 year)
Risk
Day 28 Day 90 1 year
n
Odds ratio
(95% CI) p-value n
Odds ratio
(95% CI) p-value n
Odds ratio
(95% CI) p-value
High 218 0.72
(0.39 to 1.33)
0.291 203 0.86
(0.49 to 1.52)
0.603 151 0.82
(0.42 to 1.61)
0.561
Intermediate 835 0.72
(0.48 to 1.07)
0.105 765 1.08
(0.79 to 1.49)
0.631 596 1.07
(0.78 to 1.48)
0.665
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FIGURE 7 Receiver operating characteristics curves to compare the Lille score (prednisolone-treated group only).
(a) 28-day mortality; (b) 90-day mortality; and (c) 1-year mortality. AUC, area under the curve. (continued )
TABLE 15 Receiver operating characteristics analysis for Lille score (prednisolone-treated group only)
Lille score by
treatment group
28-day mortalitya 90-day mortalityb 1-year mortalityc
n AUC 95% CI n AUC 95% CI n AUC 95% CI
Prednisolone/
placebo
168 0.765 0.661 to 0.870 152 0.726 0.640 to 0.812 116 0.650 0.549 to 0.751
Prednisolone/PTX 158 0.735 0.596 to 0.873 145 0.740 0.643 to 0.837 107 0.656 0.552 to 0.761
AUC, area under the curve.
a Includes all randomised patients in the prednisolone/placebo or prednisolone/PTX groups who have at least 28 days of
data or died prior to or on day 28 and have data for the Lille score.
b Includes all randomised patients in the prednisolone/placebo or prednisolone/PTX groups who have at least 90 days of
data or died prior to or on day 90 and have data for the Lille score.
c Includes all randomised patients in the prednisolone/placebo or prednisolone/PTX groups who have at least 1 year of
data or died prior to or on 1 year and have data for the Lille score.
Notes
Four patients (prednisolone/placebo= 2, prednisolone/PTX= 2) have negative values of DF derived from PT and bilirubin at
baseline. The PT values were queried but were not resolved prior to database lock; therefore, they are excluded from the
table as all of the prognostic factors use PT in their derivation.
Interpretation: perfect tests yield an AUC of 1.0. As a rule of thumb, a test with an AUC of > 0.9 has high accuracy,
whereas a score of 0.7–0.9 indicates moderate accuracy, a score of 0.5–0.7 indicates low accuracy and a score of 0.5
indicates a chance result.
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placebo (AUC = 0.650)
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FIGURE 7 Receiver operating characteristics curves to compare the Lille score (prednisolone-treated group only).
(a) 28-day mortality; (b) 90-day mortality; and (c) 1-year mortality. AUC, area under the curve.
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(Table 16 and Figure 8). At this survival rate the Lille score cannot be used to identify a population who may
be suitable for liver transplantation as envisaged in the French pilot scheme.
Other predictive factors of mortality
Factors that influenced mortality at 28 days, 90 days and 1 year were analysed in univariate and
multivariate analyses using baseline clinical and laboratory characteristics. Table 17 summarises the findings
from the univariate analysis. As expected, the variables significantly associated with mortality were
encephalopathy, bilirubin, PT ratio, age, WBC count, creatinine and urea.
1.0
0.9
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Days from start of treatment to death/last follow-up
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33
Lille < 0.45
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FIGURE 8 Kaplan–Meier graph for over survival by Lille score (< 0.45 and > 0.45) (prednisolone-treated group only).
TABLE 16 Cox proportional hazards model for mortality up to 1 year by Lille categories (< 0.45 and ≥ 0.45)
(prednisolone-treated group only)a
Prednisolone group,
Lille category ≥ 0.45
Prednisolone group,
Lille category < 0.45
1-year mortality, (n/N) 51.9% (70/135) 24.6% (49/199)
Adjusted hazard ratiob (95% CI) 2.80 (1.94 to 4.03)
p-value < 0.001
a Includes all randomised prednisolone-treated patients who have 1 year of data or died prior to or at 1 year and have
data on the Lille score.
b Adjusted for risk (high or intermediate) at baseline.
DOI: 10.3310/hta191020 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 102
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Thursz et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
TA
B
LE
17
U
n
iv
ar
ia
te
lo
g
is
ti
c
re
g
re
ss
io
n
an
al
ys
is
a
V
ar
ia
b
le
(b
as
el
in
e
va
lu
e)
28
-d
ay
m
o
rt
al
it
yb
90
-d
ay
m
o
rt
al
it
yc
1-
ye
ar
m
o
rt
al
it
yd
n
O
d
d
s
ra
ti
o
95
%
C
I
p
-v
al
u
e
n
O
d
d
s
ra
ti
o
95
%
C
I
p
-v
al
u
e
n
O
d
d
s
ra
ti
o
95
%
C
I
p
-v
al
u
e
Py
re
xi
a
(t
em
pe
ra
tu
re
>
37
.2
°C
)
10
49
0.
65
8
0.
37
4
to
1.
15
9
0.
14
7
96
5
0.
66
4
0.
42
2
to
1.
04
5
0.
07
7
74
5
0.
78
0
0.
50
3
to
1.
21
0
0.
26
7
H
yp
ot
en
si
on
(S
BP
<
10
0m
m
/H
g)
10
48
1.
20
0
0.
78
9
to
1.
82
6
0.
39
4
96
5
0.
98
1
0.
68
0
to
1.
41
4
0.
91
7
74
5
1.
13
4
0.
76
8
to
1.
67
3
0.
52
7
Ta
ch
yc
ar
di
a
(p
ul
se
>
10
0
be
at
s
pe
r
m
in
ut
e)
10
48
1.
08
5
0.
71
5
to
1.
64
6
0.
70
2
96
5
1.
02
4
0.
71
9
to
1.
45
9
0.
89
4
74
5
0.
94
1
0.
64
8
to
1.
36
6
0.
74
8
A
lc
oh
ol
in
ta
ke
(g
/d
ay
)
10
32
0.
99
9
0.
99
8
to
1.
00
1
0.
37
1
94
9
0.
99
9
0.
99
8
to
1.
00
0
0.
05
5
73
3
0.
99
9
0.
99
8
to
1.
00
0
0.
06
6
A
lb
um
in
(g
/l)
10
44
0.
98
8
0.
96
1
to
1.
01
6
0.
40
5
96
0
0.
98
6
0.
96
3
to
1.
00
9
0.
23
5
74
3
0.
99
3
0.
96
9
to
1.
01
7
0.
55
7
A
LP
(U
/l)
10
31
0.
99
8
0.
99
6
to
1.
00
0
0.
07
4
94
8
0.
99
9
0.
99
7
to
1.
00
0
0.
11
9
73
3
0.
99
9
0.
99
7
to
1.
00
0
0.
17
8
Bi
lir
ub
in
(µ
m
ol
/l)
10
53
1.
00
4
1.
00
3
to
1.
00
5
<
0.
00
1
96
8
1.
00
3
1.
00
2
to
1.
00
4
<
0.
00
1
74
7
1.
00
2e
1.
00
1
to
1.
00
3
0.
00
1
H
ep
at
ic
en
ce
ph
al
op
at
hy
(p
re
se
nc
e
vs
.
ab
se
nc
e)
10
09
3.
70
0
2.
58
7
to
5.
29
2
<
0.
00
1
92
9
2.
35
2
1.
72
0
to
3.
21
7
<
0.
00
1
71
7
2.
19
1
1.
53
9
to
3.
11
8
<
0.
00
1
PT
ra
tio
or
IN
Re
10
46
1.
37
9e
1.
10
1
to
1.
72
7
0.
00
5
96
2
1.
90
9e
1.
45
6
to
2.
50
4
<
0.
00
1
74
1
1.
79
7
1.
31
7
to
2.
45
3
<
0.
00
1
A
ge
(y
ea
rs
)
10
53
1.
04
9
1.
03
2
to
1.
06
7
<
0.
00
1
96
8
1.
05
0
1.
03
5
to
1.
06
5
<
0.
00
1
74
7
1.
03
6
1.
02
1
to
1.
05
1
<
0.
00
1
W
BC
s
(1
09
/l)
10
50
1.
05
5
1.
02
7
to
1.
08
4
<
0.
00
1
96
5
1.
04
5
1.
01
9
to
1.
07
1
0.
00
1
74
4
1.
01
7
0.
99
1
to
1.
04
3
0.
20
0
U
re
a
(m
m
ol
/l)
10
41
1.
14
0e
1.
09
9
to
1.
18
2
<
0.
00
1
95
8
1.
14
2e
1.
09
9
to
1.
18
6
<
0.
00
1
74
0
1.
12
4
1.
07
2
to
1.
17
8
<
0.
00
1
C
re
at
in
in
e
(m
g/
dl
)
10
14
3.
07
4e
2.
31
5
to
4.
08
2
<
0.
00
1
93
0
3.
07
0
2.
26
6
to
4.
16
1
<
0.
00
1
72
0
2.
69
5e
1.
84
3
to
3.
94
1
<
0.
00
1
SB
P,
sy
st
ol
ic
bl
oo
d
pr
es
su
re
.
a
Lo
gi
st
ic
re
gr
es
si
on
m
od
el
:
28
-d
ay
(o
r
90
-d
ay
/1
-y
ea
r)
m
or
ta
lit
y
=
in
te
rc
ep
t
pl
us
pr
og
no
st
ic
fa
ct
or
.
b
In
cl
ud
es
al
lr
an
do
m
is
ed
pa
tie
nt
s
w
ho
ha
ve
at
le
as
t
28
da
ys
of
da
ta
or
di
ed
pr
io
r
to
or
on
da
y
28
an
d
ha
ve
da
ta
fo
r
th
e
co
rr
es
po
nd
in
g
va
ria
bl
e.
c
In
cl
ud
es
al
lr
an
do
m
is
ed
pa
tie
nt
s
w
ho
ha
ve
at
le
as
t
90
da
ys
of
da
ta
or
di
ed
pr
io
r
to
or
on
da
y
90
an
d
ha
ve
da
ta
fo
r
th
e
co
rr
es
po
nd
in
g
va
ria
bl
e.
d
In
cl
ud
es
al
lr
an
do
m
is
ed
pa
tie
nt
s
w
ho
ha
ve
at
le
as
t
1
ye
ar
of
da
ta
or
di
ed
pr
io
r
to
or
on
1
ye
ar
an
d
ha
ve
da
ta
fo
r
th
e
co
rr
es
po
nd
in
g
va
ria
bl
e.
e
M
od
el
pr
od
uc
ed
a
si
gn
ifi
ca
nt
re
su
lt
fo
r
pr
es
en
ce
of
la
ck
of
fit
at
th
e
5%
si
gn
ifi
ca
nc
e
le
ve
l.
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
32
Multivariate analysis was conducted by first including variables from the univariate analysis that were
significant at the 5% level (Table 18). Variable selection was performed using backward elimination at the
5% significance level. The logistic regression analysis now demonstrated a clearly significant influence of
prednisolone on 28-day mortality with an odds ratio of 0.609 (95% CI 0.409 to 0.909; p= 0.015). The
odds ratio for 28-day mortality is adjusted for the following baseline factors: PT ratio or INR, bilirubin, age,
WBC count, urea, creatinine and encephalopathy.
Further multivariate analysis was performed after the removal of patients who had outlying observations.
A patient was classed as an outlier if they had a standardised residual with an absolute value of > 2 for the
fitted variables. The results of this analysis (Table 19) show an important increase in the treatment effect of
prednisolone (odds ratio 0.427, 95% CI 0.253 to 0.721); however, the treatment effect is confined to
28-day mortality with no impact on later time points.
Serious adverse events and deaths
As expected in this patient population, there were numerous adverse events and fatalities. As shown in
Table 20 the vast majority of deaths were liver related and include all the common complications of
acute-on-chronic liver failure.
Serious adverse events are summarised in Table 21. Over 75% of SAEs were at Common Toxicity Criteria
For Adverse Events grade 3 or above. SAEs resulted in mortality in 31% of cases. Details of the SAEs are
given in Table 22 and the incidence of infection is shown in Table 23.
Infections were frequent causes of SAEs and were reported more frequently in the prednisolone-treated
group (see Table 21). Although infections led to mortality in approximately 35% of cases, the risk of
mortality owing to an infection-related SAE was no greater in the prednisolone-treated group than in the
controls, suggesting that corticosteroids increase the risk of infection but do not necessarily make the
consequences of infection any worse (see Table 22). The most common site of infection was the lung and
it is interesting to note that prednisolone had a more significant impact on pulmonary infections than any
other site.
Alcohol behaviour
It is well recognised that return to heavy alcohol use is one of the most important determinants of
medium- to long-term prognosis in patients admitted with AH or decompensated alcoholic cirrhosis.32 We
therefore sought to document the rates of recidivism in the STOPAH cohort. Accurate measures of alcohol
consumption are difficult to ascertain, so we asked patients to report on if their alcohol consumption was:
1. completely abstinent
2. reduced to within government-defined safety limits
3. reduced but above safety limits (14 units/week for females, 21 units/week for males)
4. not reduced.
The alcohol use questions were asked at day 90 and 1-year follow-up.
Overall 45% of patients reported abstinence at 90 days and 36% reported abstinence at 1 year (Table 24).
It is disappointing to record that only 22% of patients had attended one or more alcohol counselling
sessions by the 90-day follow-up, which appears to have influenced alcohol recidivist behaviour. Inevitably
there is a high proportion of missing data from these CRFs, reflecting a loss to follow-up, which in many
cases is probably associated with recidivism.
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TABLE 20 Causes of death
Cause of death
Placebo/placebo
(n= 272), n (%)
Prednisolone/placebo
(n= 274), n (%)
Placebo/PTX
(n=273), n (%)
Prednisolone/PTX
(n= 273), n (%)
Total number of deaths (during
follow-up period)a
106 (39) 110 (40) 103 (38) 99 (36)
Liver related 92 (87) 99 (90) 93 (90) 81 (82)
Cardiac arrest (in addition to
liver-related causes)
0 0 0 1 (1)
Encephalopathy 3 (3) 3 (3) 3 (3) 1 (1)
Gastric haemorrhage 1 (1) 0 1 (1) 0
Hepatic failure 39 (37) 36 (33) 40 (39) 38 (38)
Hepatobiliary disorders
(other, alcohol abuse)
1 (1) 0 0 0
Infection-related causes 26 (25) 26 (24) 24 (23) 20 (20)
Multiorgan failure 10 (10) 16 (15) 9 (9) 5 (5)
Oesophageal varices
haemorrhage
6 (6) 2 (2) 8 (8) 4 (4)
Pulmonary oedema 0 0 0 1 (1)
Renal failure-related causes 3 (3) 9 (8) 2 (2) 6 (6)
Upper GI haemorrhage 3 (3) 7 (6) 6 (6) 5 (5)
Non-liver related 2 (2) 1 (1) 0 4 (4)
Cardiac arrest (with no
liver-related causes)
0 0 0 1 (1)
Infection-related causes 0 1 (1) 0 2 (2)
Intracranial haemorrhage 1 (1) 0 0 0
Nervous system disorders
(other, hypoxic brain injury)
1 (1) 0 0 0
Respiratory failure 0 0 0 1 (1)
Both liver and non-liver related 7 (7) 10 (9) 8 (8) 6 (6)
Cardiac arrest (both
liver-related and
non-liver-related causes)
0 1 (1) 0 0
Duodenal haemorrhage 0 0 1 (1) 0
GI disorders (other, ruptured
umbilical hernia)
0 0 0 1 (1)
Hepatic failure 1 (1) 5 (5) 3 (3) 1 (1)
Infection-related causes 1 (1) 1 (1) 1 (1) 1 (1)
Injury, poisoning and
procedural complications
(other, intoxicated)
0 1 (1) 0 0
Intracranial haemorrhage 0 1 (1) 0 1 (1)
Multiorgan failure 0 0 0 1 (1)
Nervous system disorders
(other, traumatic brain injury)
2 (2) 0 1 (1) 0
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TABLE 21 Summary of the SAEs reported
SAEs reported
Placebo/placebo
(n= 272), n (%)
Prednisolone/placebo
(n= 274), n (%)
Placebo/PTX
(n=273), n (%)
Prednisolone/PTX
(n= 273), n (%)
Number of patients experiencing
at least one SAEa
106 (39) 128 (47) 111 (41) 116 (42)
Total number of SAEs 136 184 145 159
Number of SAEs/SARs/SUSARs per patienta
1 83 (31) 90 (33) 84 (31) 87 (32)
2 17 (6) 25 (9) 22 (8) 19 (7)
3 5 (2) 11 (4) 3 (1) 6 (2)
4 1 (< 0.5) 0 2 (1) 4 (1)
≥ 5 0 2 (1) 0 0
Principal investigator assessment (with reference to prednisolone/PTX)b
SUSAR/SAE 0 3 (2) 0 1 (1)
SAE/SAR 1 (1) 2 (1) 5 (3) 0
SAR/SAE 5 (4) 24 (13) 13 (9) 19 (12)
SAR/SAR 4 (3) 11 (6) 4 (3) 3 (2)
SAE (no IMP taken) 3 (2) 6 (3) 3 (2) 13 (8)
SAE/SAE 123 (90) 138 (75) 120 (83) 123 (77)
continued
TABLE 20 Causes of death (continued )
Cause of death
Placebo/placebo
(n= 272), n (%)
Prednisolone/placebo
(n= 274), n (%)
Placebo/PTX
(n=273), n (%)
Prednisolone/PTX
(n= 273), n (%)
Pulmonary oedema 0 0 1 (1) 0
Renal failure-related causes 0 0 1 (1) 1 (1)
Respiratory failure 1 (1) 0 0 0
Stroke 2 (2) 0 0 0
Thromboembolic event 0 1 (1) 0 0
Unknown 4 (4) 0 2 (2) 7 (7)
General disorders and
administration site conditions
(other, bleeding)
1 (1) 0 0 0
Natural causes 0 0 0 1 (1)
Not available 3 (3) 0 2 (2) 5 (5)
Upper GI haemorrhage 0 0 0 1 (1)
Missing 1 (1) 0 0 1 (1)
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TABLE 21 Summary of the SAEs reported (continued )
SAEs reported
Placebo/placebo
(n= 272), n (%)
Prednisolone/placebo
(n= 274), n (%)
Placebo/PTX
(n=273), n (%)
Prednisolone/PTX
(n= 273), n (%)
CTCAE gradeb
1 – mild 4 (3) 9 (5) 7 (5) 4 (3)
2 – moderate 28 (21) 41 (22) 30 (21) 42 (26)
3 – severe 37 (27) 49 (27) 36 (25) 41 (26)
4 – life-threatening 25 (18) 28 (15) 25 (17) 31 (19)
5 – death-related to SAE 42 (31) 57 (31) 47 (32) 41 (26)
Why the event was serious
1 – resulted in death 45 (33) 54 (29) 47 (32) 37 (23)
2 – life-threatening 21 (15) 20 (11) 19 (13) 31 (19)
3 – required hospitalisation
or prolongation of existing
hospitalisation
68 (50) 110 (60) 75 (52) 91 (57)
4 – persistent or significant
disability/incapacity
2 (1) 0 2 (1) 0
5 – congenital anomaly/birth
defect
0 0 1 (1) 0
6 – medically significant event 0 0 1 (1) 0
Action taken following prednisoloneb
0 – none – 131 (71) – 107 (67)
1 – dose reduction – 0 – 0
2 – treatment delayed – 14 (8) – 13 (8)
3 – treatment reduced and
delayed
N/A 0 N/A 0
4 – treatment stopped – 33 (18) – 26 (16)
No IMP given – 6 (3) – 13 (8)
Action taken following PXTb
0 – none – – 77 (53) 107 (67)
1 – dose reduction – – 2 (1) 1 (1)
2 – treatment delayed – – 10 (7) 12 (8)
3 – treatment reduced and
delayed
N/A N/A 1 (1) 0
4 – treatment stopped – – 52 (36) 26 (16)
No IMP given – – 3 (2) 13 (8)
CTCAE, Common Toxicity Criteria For Adverse Events; N/A, not applicable; SAR, serious adverse reaction; SUSAR, suspected
unexpected serious adverse reaction.
a Percentages are based on the number of patients in the ITT population.
b Percentages are based on the number of SAEs.
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TABLE 22 Summary of the events reported on the SAE form (sorted by % of total events)
System organ class and
CTCAE event
Placebo/placebo
(n= 272), n (%)
Prednisolone/placebo
(n= 274), n (%)
Placebo/PTX
(n=273), n (%)
Prednisolone/PTX
(n= 273), n (%)
Total number of SAEs 136 184 145 159
GI disorders 31 (23) 49 (27) 56 (39) 48 (30)
Ascites 7 (5) 13 (7) 14 (10) 13 (8)
Upper GI haemorrhage 5 (4) 12 (7) 10 (7) 18 (11)
Oesophageal varices
haemorrhage
7 (5) 5 (3) 7 (5) 5 (3)
Abdominal pain 6 (4) 5 (3) 4 (3) 1 (1)
Pancreatitis 1 (1) 1 (1) 2 (1) 3 (2)
Vomiting 1 (1) 1 (1) 3 (2) 2 (1)
Abdominal distension 0 3 (2) 3 (2) 0
Diarrhoea 0 0 5 (3) 1 (1)
GI disorders: other 0 1 (1) 3 (2) 0
Oesophageal haemorrhage 1 (1) 2 (1) 0 0
Lower GI haemorrhage 2 (1) 1 (1) 0 0
Colonic perforation 0 2 (1) 0 0
Gastric haemorrhage 0 1 (1) 1 (1) 0
GI pain 0 0 1 (1) 1 (1)
Nausea 1 (1) 0 0 1 (1)
Rectal haemorrhage 0 1 (1) 0 1 (1)
Colitis 0 0 1 (1) 0
Colonic obstruction 0 0 0 1 (1)
Constipation 0 0 1 (1) 0
Duodenal perforation 0 1 (1) 0 0
Enterocolitis 0 0 0 1 (1)
Ileus 0 0 1 (1) 0
Infections and infestations 27 (20) 44 (24) 16 (11) 30 (19)
Lung infectiona 11 (8) 20 (11) 6 (4) 18 (11)
Sepsis 8 (6) 11 (6) 6 (4) 3 (2)
Infections and infestations:
other
6 (4) 9 (5) 3 (2) 3 (2)
Skin infection 1 (1) 1 (1) 1 (1) 2 (1)
Hepatic infection 0 2 (1) 0 1 (1)
Urinary tract infection 0 1 (1) 0 1 (1)
Abdominal infection 0 0 0 1 (1)
Endocarditis infective 1 (1) 0 0 0
Joint infection 0 0 0 1 (1)
continued
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TABLE 22 Summary of the events reported on the SAE form (sorted by % of total events) (continued )
System organ class and
CTCAE event
Placebo/placebo
(n= 272), n (%)
Prednisolone/placebo
(n= 274), n (%)
Placebo/PTX
(n=273), n (%)
Prednisolone/PTX
(n= 273), n (%)
Hepatobiliary disorders 27 (20) 27 (15) 24 (17) 23 (14)
Hepatic failure 26 (19) 27 (15) 23 (16) 22 (14)
Hepatobiliary disorders:
other
1 (1) 0 1 (1) 1 (1)
Renal and urinary disorders 10 (7) 10 (5) 13 (9) 8 (5)
Acute kidney injury 9 (7) 5 (3) 4 (3) 5 (3)
Renal and urinary disorders:
other
1 (1) 5 (3) 9 (6) 3 (2)
Nervous system disorders 12 (9) 12 (7) 6 (4) 9 (6)
Encephalopathy 8 (6) 4 (2) 4 (3) 4 (3)
Seizure 1 (1) 3 (2) 2 (1) 2 (1)
Syncope 0 4 (2) 0 1 (1)
Stroke 2 (1) 0 0 1 (1)
Depressed level of
consciousness
1 (1) 0 0 0
Intracranial haemorrhage 0 0 0 1 (1)
Nervous system disorders:
other
0 1 (1) 0 0
Respiratory, thoracic and
mediastinal disorders
7 (5) 12 (7) 9 (6) 11 (7)
Respiratory failure 1 (1) 5 (3) 1 (1) 5 (3)
Dyspnoea 2 (1) 4 (2) 2 (1) 1 (1)
Adult respiratory distress
syndrome
0 0 5 (3) 1 (1)
Pulmonary oedema 1 (1) 1 (1) 0 2 (1)
Pleural effusion 0 1 (1) 0 1 (1)
Respiratory, thoracic and
mediastinal disorders: other
0 1 (1) 0 1 (1)
Aspiration 1 (1) 0 0 0
Bronchospasm 1 (1) 0 0 0
Epistaxis 1 (1) 0 0 0
Hypoxia 0 0 1 (1) 0
General disorders and
administration site conditions
8 (6) 6 (3) 7 (5) 9 (6)
Multiorgan failure 6 (4) 3 (2) 6 (4) 7 (4)
Malaise 1 (1) 2 (1) 0 1 (1)
General disorders and
administration site
conditions: other
1 (1) 0 1 (1) 0
Non-cardiac chest pain 0 1 (1) 0 0
Oedema limbs 0 0 0 1 (1)
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
TABLE 22 Summary of the events reported on the SAE form (sorted by % of total events) (continued )
System organ class and
CTCAE event
Placebo/placebo
(n= 272), n (%)
Prednisolone/placebo
(n= 274), n (%)
Placebo/PTX
(n=273), n (%)
Prednisolone/PTX
(n= 273), n (%)
Injury, poisoning and
procedural complications
5 (4) 7 (4) 3 (2) 8 (5)
Fall 2 (1) 1 (1) 2 (1) 4 (3)
Injury, poisoning and
procedural complications:
other
0 4 (2) 1 (1) 2 (1)
Fracture 1 (1) 2 (1) 0 1 (1)
Arterial injury 1 (1) 0 0 0
Hip fracture 1 (1) 0 0 0
Seroma 0 0 0 1 (1)
Psychiatric disorders 4 (3) 2 (1) 1 (1) 4 (3)
Confusion 1 (1) 1 (1) 0 3 (2)
Hallucinations 2 (1) 0 0 0
Psychosis 0 0 1 (1) 1 (1)
Psychiatric disorders: other 0 1 (1) 0 0
Suicide attempt 1 (1) 0 0 0
Cardiac disorders 3 (2) 3 (2) 1 (1) 3 (2)
Cardiac arrest 1 (1) 1 (1) 1 (1) 2 (1)
Chest pain – cardiac 1 (1) 1 (1) 0 0
Atrial fibrillation 0 0 0 1 (1)
Myocardial infarction 0 1 (1) 0 0
Ventricular tachycardia 1 (1) 0 0 0
Metabolism and nutrition
disorders
0 5 (3) 1 (1) 1 (1)
Hyperglycaemia 0 4 (2) 0 1 (1)
Dehydration 0 0 1 (1) 0
Hypoglycaemia 0 1 (1) 0 0
Investigations 0 3 (2) 1 (1) 2 (1)
Blood bilirubin increased 0 1 (1) 1 (1) 1 (1)
Investigations: other 0 2 (1) 0 1 (1)
Vascular disorders 1 (1) 1 (1) 2 (1) 2 (1)
Hematoma 1 (1) 1 (1) 2 (1) 1 (1)
Thromboembolic event 0 0 0 1 (1)
Blood and lymphatic system
disorders
0 1 (1) 3 (2) 0
Anaemia 0 0 2 (1) 0
Haemolysis 0 0 1 (1) 0
Leucocytosis 0 1 (1) 0 0
continued
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TABLE 23 Incidence of infection
Type of SAE and time point
Prednisolone
(n= 551), n (%)
No prednisolone
(n= 552), n (%)
Number of patients with an infection-related SAE 71 (13) 38 (7)
Before start of treatment 3 (1) 2 (< 0.5)
Day 1–28 50 (9) 31 (6)
Day 29–56 16 (3) 3 (1)
Multiple time points 2 (< 0.5) 2 (< 0.5)
Number of patients who died from an infection-related SAEa 25 (35) 12 (32)
Before start of treatment 1 (1) 2 (5)
Day 1–28 16 (23) 10 (26)
Day 29–56 8 (11) 0
a Denominator is the number of patients who had an infection-related SAE.
An infection-related SAE was any SAE with a system organ class of ‘infections and infestations’, which could happen from
the date of informed consent up to 4 weeks after treatment completion (i.e. day 56).
TABLE 22 Summary of the events reported on the SAE form (sorted by % of total events) (continued )
System organ class and
CTCAE event
Placebo/placebo
(n= 272), n (%)
Prednisolone/placebo
(n= 274), n (%)
Placebo/PTX
(n=273), n (%)
Prednisolone/PTX
(n= 273), n (%)
Musculoskeletal and connective
tissue disorders
1 (1) 1 (1) 0 1 (1)
Back pain 0 1 (1) 0 0
Muscle weakness lower
limb
0 0 0 1 (1)
Myositis 1 (1) 0 0 0
Skin and subcutaneous tissue
disorders
0 1 (1) 1 (1) 0
Skin ulceration 0 1 (1) 0 0
Toxic epidermal necrosis 0 0 1 (1) 0
Social circumstances 0 0 1 (1) 0
Social circumstances: other 0 0 1 (1) 0
CTCAE, Common Toxicity Criteria For Adverse Events.
a A test for significance to compare the proportion of lung infection SAEs experienced between prednisolone and no
prednisolone was computed [38 (69%) vs. 17 (31%) events]. The difference was found to be significant at the 5%
significance level (p= 0.005), for which the null hypothesis is that the two proportions are equal.
Percentages are out of the total number of SAEs.
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TABLE 24 Alcohol consumption and counselling at day 90 and 1 year
Alcohol consumption and
counselling at day 90a
Placebo/placebo
(n= 183), n (%)
Prednisolone/placebo
(n= 161), n (%)
Placebo/PTX
(n=160), n (%)
Prednisolone/PTX
(n= 179), n (%)
Alcohol consumption at day 90 compared with last assessment
Abstinent 88 (48) 74 (46) 65 (41) 80 (45)
Reduced drinking to below
safety limits
18 (10) 19 (12) 12 (8) 10 (6)
Reduced drinking but above
safety limits
9 (5) 10 (6) 17 (11) 12 (7)
Not reduced (i.e. still drinking
as much as or more than
when presented)
11 (6) 16 (10) 10 (6) 10 (6)
Missing 57 (31) 42 (26) 56 (35) 67 (37)
Has the patient attended one or more alcohol counselling session?
No 76 (42) 80 (50) 69 (43) 70 (39)
Yes 45 (25) 36 (23) 29 (18) 38 (21)
Not still attendingb 19 (42) 10 (28) 6 (21) 7 (18)
Still attendingb 26 (58) 26 (72) 23 (79) 31 (82)
Missing 62 (34) 45 (28) 62 (39) 71 (40)
Alcohol consumption and
counselling at 1 yearc
Placebo/placebo
(n= 86), n (%)
Prednisolone/placebo
(n= 80), n (%)
Placebo/PTX
(n=79), n (%)
Prednisolone/PTX
(n= 81), n (%)
Alcohol consumption at 1 year compared with last assessment
Abstinent 43 (50) 29 (36) 24 (30) 23 (28)
Reduced drinking to below
safety limits
5 (6) 12 (15) 9 (11) 8 (10)
Reduced drinking but above
safety limits
4 (5) 8 (10) 5 (6) 4 (5)
Not reduced (i.e. still drinking
as much as or more than
when presented)
4 (5) 5 (6) 8 (10) 7 (9)
Missing 30 (35) 26 (33) 33 (42) 39 (48)
Has the patient attended one or more alcohol counselling session?
No 28 (33) 31 (39) 35 (44) 26 (32)
Yes 22 (26) 21 (26) 11 (14) 13 (16)
Not still attendingd 13 (59) 13 (62) 5 (45) 9 (69)
Still attendingd 9 (41) 8 (38) 5 (45) 4 (31)
Missing on CRF (still
attending question)
0 0 1 (9) 0
Missing 36 (42) 28 (35) 33 (42) 42 (52)
a Includes all randomised patients who have at least 90 days of data.
b Percentages are based on the number of patients who have attended one or more alcohol counselling session at day 90.
c Includes all randomised patients who have at least 1 year of data.
d Percentages are based on the number of patients who have attended one or more alcohol counselling session at 1 year.
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The impact of abstinence (compared with other drinking patterns) at 90 days or mortality at 1 year was
explored (see Table 25). These data indicate that even modest drinking, within government guidelines, is
associated with increased mortality (odds ratio 2.17, 95% CI 1.07 to 4.39; p= 0.03) whereas resumption
of previous levels of alcohol use results in approximately a threefold increased mortality compared with
abstinence. These findings reinforce the need to promote and support abstinence in this patient group.
Sensitivity analyses
A sensitivity analysis of the primary end-point outcome was produced on 939 patients, excluding any
patients who were randomised and followed up but were later found to be ineligible through central
monitoring of baseline characteristics (n= 114). This was not substantially different from the primary
analysis results. Detailed tables for the sensitivity analysis can be found in Appendix 3.
Subgroup analyses
We used the disease-specific scoring systems to subclassify patients into higher or lower severity categories
to explore whether or not disease severity had an impact on response to treatment (Tables 25 and 26).
We also analysed whether or not the risk classification used to stratify the trial randomisation influenced
response to prednisolone.
Risk classification made no impact on the response to therapy, indicating that in the future patients
admitted with complications of AH such as renal failure, GI bleeding and sepsis should be included in
clinical trials without stratification once the complication has been stabilised.
Based on the odds ratio, it would appear that patients classified as having more severe disease by DF or
MELD were more likely to benefit from steroids than patients with milder disease. However, these analyses
did not reach statistical significance. In contrast, patients with a higher GAHS appear to derive less benefit
from steroids than those with a lower score. This contrasts with the original report on GAHS that found
a higher response in patients with a GAHS of > 9.1,33
TABLE 25 Univariate logistic regression analysis to assess the effect of alcohol consumption status at day 90 on
1-year mortality
Alcohol consumption at day 90
1-year mortality
na Odds ratio 95% CI p-value
Not reduced (i.e. still drinking as much as or more than
when presented) vs. abstinent
478 2.99 1.47 to 6.05 < 0.001
Reduced drinking but above safety limits vs. abstinent 478 2.28 1.07 to 4.86 0.032
Reduced drinking to below safety limits vs. abstinent 478 2.17 1.07 to 4.39 0.031
a Includes all randomised patients who have at least 1 year of data, or died prior to or on 1 year and have data for alcohol
consumption status at day 90.
Logistic regression model: 1 year mortality= intercept+ alcohol consumption status at day 90.
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
TA
B
LE
26
Su
b
g
ro
u
p
an
al
ys
es
fo
r
28
-d
ay
,9
0-
d
ay
an
d
1-
ye
ar
m
o
rt
al
it
y
b
y
fa
ct
o
ri
al
d
es
ig
n
D
is
ea
se
se
ve
ri
ty
cl
as
si
fi
ca
ti
o
n
Pr
ed
n
is
o
lo
n
e
vs
.n
o
p
re
d
n
is
o
lo
n
e
PT
X
vs
.
n
o
PT
X
D
ay
28
D
ay
90
1
ye
ar
D
ay
28
D
ay
90
1
ye
ar
n
O
d
d
s
ra
ti
o
(9
5%
C
I)
p
-v
al
u
e
n
O
d
d
s
ra
ti
o
(9
5%
C
I)
p
-v
al
u
e
n
O
d
d
s
ra
ti
o
(9
5%
C
I)
p
-v
al
u
e
n
O
d
d
s
ra
ti
o
(9
5%
C
I)
p
-v
al
u
e
n
O
d
d
s
ra
ti
o
(9
5%
C
I)
p
-v
al
u
e
n
O
d
d
s
ra
ti
o
(9
5%
C
I)
p
-v
al
u
e
Ri
sk
H
ig
h
21
8
0.
72
(0
.3
9
to
1.
33
)
0.
29
1
20
3
0.
86
(0
.4
9
to
1.
52
)
0.
60
3
15
1
0.
82
(0
.4
2
to
1.
61
)
0.
56
1
21
8
1.
33
(0
.7
2
to
2.
46
)
0.
36
4
20
3
0.
94
(0
.5
3
to
1.
65
)
0.
81
8
15
1
1.
09
(0
.5
5
to
2.
15
)
0.
80
3
In
te
rm
ed
ia
te
83
5
0.
72
(0
.4
8
to
1.
07
)
0.
10
5
76
5
1.
08
(0
.7
9
to
1.
49
)
0.
63
1
59
6
1.
07
(0
.7
8
to
1.
48
)
0.
66
5
83
5
0.
98
(0
.6
6
to
1.
46
)
0.
91
4
76
5
0.
98
(0
.7
1
to
1.
35
)
0.
89
6
59
6
0.
94
(0
.6
8
to
1.
29
)
0.
69
8
D
Fa
,b <
55
51
5
0.
56
(0
.3
1
to
1.
04
)
0.
06
6
47
3
1.
04
(0
.6
5
to
1.
67
)
0.
87
5
33
5
1.
20
(0
.7
8
to
1.
85
)
0.
41
4
51
5
0.
93
(0
.5
1
to
1.
70
)
0.
82
5
47
3
0.
75
(0
.4
6
to
1.
20
)
0.
23
2
33
5
0.
71
(0
.4
6
to
1.
10
)
0.
12
5
≥
55
53
4
0.
82
(0
.5
4
to
1.
23
)
0.
33
7
49
2
1.
06
(0
.7
4
to
1.
51
)
0.
76
7
40
9
0.
91
(0
.6
0
to
1.
37
)
0.
64
7
53
4
1.
06
(0
.7
1
to
1.
60
)
0.
76
7
49
2
1.
02
(0
.7
1
to
1.
46
)
0.
92
2
40
9
1.
13
(0
.7
5
to
1.
71
)
0.
55
1
M
EL
D <
18
35
1
1.
16
(0
.4
4
to
3.
01
)
0.
76
5
32
0
1.
34
(0
.7
1
to
2.
52
)
0.
37
1
23
2
1.
47
(0
.8
6
to
2.
49
)
0.
15
5
35
1
1.
83
(0
.6
9
to
4.
83
)
0.
22
4
32
0
0.
65
(0
.3
4
to
1.
25
)
0.
19
7
23
2
0.
78
(0
.4
6
to
1.
33
)
0.
36
3
≥
18
66
0
0.
69
(0
.4
7
to
1.
00
)
0.
05
2
60
7
1.
04
(0
.7
5
to
1.
45
)
0.
81
6
48
5
0.
89
(0
.6
2
to
1.
29
)
0.
54
1
66
0
0.
98
(0
.6
8
to
1.
42
)
0.
92
7
60
7
1.
02
(0
.7
3
to
1.
41
)
0.
92
2
48
5
1.
00
(0
.6
9
to
1.
44
)
0.
98
6
G
A
H
S <
9
53
5
0.
47
(0
.2
3
to
0.
97
)
0.
04
0
49
5
0.
93
(0
.5
8
to
1.
51
)
0.
78
3
36
7
1.
07
(0
.7
1
to
1.
62
)
0.
74
3
53
5
1.
61
(1
.2
1
to
2.
39
)
0.
58
3
49
5
0.
81
(0
.5
0
to
1.
31
)
0.
38
0
36
7
0.
91
(0
.6
1
to
1.
38
)
0.
66
8
≥
9
39
8
0.
79
(0
.5
0
to
1.
26
)
0.
32
4
36
2
1.
15
(0
.7
6
to
1.
75
)
0.
50
7
28
5
1.
02
(0
.6
3
to
1.
65
)
0.
94
2
39
8
0.
99
(0
.6
3
to
1.
58
)
0.
98
2
36
5
1.
05
(0
.6
9
to
1.
60
)
0.
81
7
38
5
1.
01
(0
.6
3
to
1.
64
)
0.
95
9
a
Lo
gi
st
ic
re
gr
es
si
on
m
od
el
:
28
-d
ay
(o
r
90
-d
ay
/1
-y
ea
r)
m
or
ta
lit
y
=
in
te
rc
ep
t+
pr
ed
ni
so
lo
ne
in
di
ca
to
r+
PT
X
in
di
ca
to
r,
by
su
bg
ro
up
.
b
C
ut
-o
ff
of
55
us
ed
fo
r
D
F
as
th
is
w
as
cl
os
e
to
th
e
m
ed
ia
n
va
lu
e
at
ba
se
lin
e.
N
um
be
r
in
cl
ud
ed
in
ea
ch
m
od
el
is
th
e
nu
m
be
r
of
pa
tie
nt
s
in
th
e
IT
T
po
pu
la
tio
ns
at
ea
ch
of
th
e
th
re
e
tim
e
po
in
ts
th
at
ha
ve
no
n-
m
is
si
ng
da
ta
fo
r
th
e
su
bg
ro
up
va
ria
bl
es
at
ba
se
lin
e.
DOI: 10.3310/hta191020 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 102
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Thursz et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45

Chapter 5 Health economic evaluation
Introduction
This chapter reports the two elements of the health economics work conducted as part of this study:
a standard gamble (SG) preference elicitation exercise and an economic evaluation conducted as part of
the STOPAH trial.
Part 1: eliciting health state utility values for cirrhosis owing to
alcohol abuse and cirrhosis owing to viral hepatitis – a standard
gamble exercise
A necessary part of any resource allocation decision is to measure the outcomes that arise from treatment,
which in the case of many treatments for liver disease, are improvements in QoL in addition to
improvements in life expectancy. One way of presenting the outcomes of a treatment is in the form of
quality-adjusted life-years (QALYs).
There are a number of methods available to measure health-related QoL. Generic questionnaire-based
tools such as the EQ-5D34 or Short Form questionnaire-36 items (or 12-item version),35 and disease-specific
questionnaires, such as the chronic liver disease questionnaire and liver disease QoL questionnaire,36,37
can be used. The limitation of some of these is that their methods of ‘scoring’ changes in patients QoL are
ill-suited to informing decisions about how best to allocate our scarce health-care resources, that is they
do not produce utility values.
There are a number of direct valuation techniques that can be used to assign values or utilities to different
health states. These include the rating scale, SG and time trade-off methods.38 Of these, the SG is
considered to be the gold standard as it is based on expected utility theory, which is the dominant
paradigm in economics on how the preferences of an individual behave.39
A systematic review of health-state utility values in liver disease found that few estimates exist for liver
disease in the literature.40 This systematic review spanned 1966–2006 and found only 30 studies that
measured utility values in liver disease, none of which related to alcoholic liver disease. An updated review
conducted in September 2014 found no significant further relevant research.
Given this paucity of existing evidence, the objectives of this study were to directly elicit QoL in patients
with cirrhosis owing to alcohol abuse and cirrhosis owing viral hepatitis. A further objective was to relate
direct measures of health-state valuations (using SG), to indirect measures of patients’ health valuations as
measured by the European Quality of Life-5 Dimensions-3 Levels (EQ-5D-3L).
Methods
Quality of life was measured in a sample of patients with liver cirrhosis caused by alcohol abuse or viral
hepatitis, using the SG technique. Utility values were obtained for patients in three health states that
correspond to different stages of cirrhosis. All utility values are measured on a scale from 0 to 1, for which
0 represents death and 1 represents full health. Each participant was also asked to value their own health
that day using both the SG and EQ-5D-3L. Standard clinical and laboratory variables were also collected
from patient medical records and were used to calculate the Child–Pugh and MELD scores for
each participant.
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Standard gamble methodology
The SG is the gold standard technique for eliciting preferences for both chronic and temporary health
states.38 Figure 9 provides an example of a SG when respondents are presented with two alternatives.
In Figure 9, alternative A is a health state with certainty, and alternative B is a health state with
uncertainty, that is, there is a gamble associated with this choice. Alternative B comprises two possible
health states: the patient returns immediately to full health or dies immediately. Each of these states has
probabilities attached to them. The respondent makes the choice between remaining in the chronic health
state or taking the gamble with a probability that they will return to full health (p) and a probability that
they would die (1 – p). The probabilities within alternative B continue to change in an iterative fashion until
the participant becomes indifferent to alternatives A and B.
Development of health-state descriptions
Three health states were developed reflecting the Child–Pugh classification system for cirrhosis.41,42 The
Child–Pugh classification system is based on three categories A, B and C. A is the mildest form of cirrhosis
and C is the most severe and is commonly used in studies of liver cirrhosis.
The health-state descriptions were based on previous research.43 Mason et al.43 based the health state
descriptions on expert opinion, the domains of chronic liver disease questionnaire36 and reviews of
the literature (liver disease and cirrhosis of the liver). The health state descriptions for Child–Pugh
classifications A, B and C can be seen in Box 1.
Sample
We aimed to recruit 100 participants with alcoholic cirrhosis and 100 participants with cirrhosis owing to
viral hepatitis to be able to represent of all levels of disease severity. Five centres took part in the study
(St Mary’s Hospital, London; King’s College Hospital, London; Queens Medical Centre, Nottingham; Freeman
Hospital, Newcastle upon Tyne; Glasgow Royal Infirmary, Glasgow). Participants aged ≥ 18 years who were
able to give informed consent were recruited to hepatology wards and outpatient clinics by a research nurse.
Those individuals who had difficulty in understanding written or verbal information in English, or had
deterioration in liver function (change in Child–Pugh score of > 2) in the last 2 weeks were excluded from
the study. Patients were given a minimum of 24 hours to consider the study and ask questions, after which
they (or their legal representatives) were asked to give written informed consent to participate, on the trial
informed consent form. Full ethical approval for the study was granted (REC reference: 09/MRE09/59).
Alternative A
Alternative B
p
1 – p
Full
health
Chronic health
state i
Death
FIGURE 9 Example of a SG. p, probability.
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BOX 1 Description of health state used in SG exercise
State X=Child–Pugh classification A
l You will not develop jaundice.
l You will feel tired some of the time.
l You will not develop a swollen stomach.
l You will not be troubled by itching.
l A little bit of the time you will be worried about your condition getting worse.
State Y=Child–Pugh classification B
l Occasionally you will have jaundice.
l You will feel tired a lot of the time.
l Occasionally you will have swollen stomach.
l Some of the time you will feel depressed about your condition.
l You may become confused.
l You may occasionally be admitted to hospital.
State Z=Child–Pugh classification C
l You will often have jaundice.
l You will feel tired all of the time.
l It is likely you will develop a swollen stomach.
l You may be troubled by itching.
l Some of the time you will be depressed about your condition.
l You may become confused.
l You are likely to spend several weeks a year in hospital.
l You may vomit blood.
l You may develop liver cancer.
State O
l Your own health today.
Interview process
Research nurses (n= 10) were fully trained in the use of the SG methodology. The interviews were
conducted using a visual aid know as a chance board.44 In an interview lasting approximately
30–45 minutes, each participant was asked to complete the SG exercise and value the three Child–Pugh
health states and a fourth health state ‘their own health today’. In addition, participants completed an
EQ-5D-3L questionnaire and a set of questions on demographic and socioeconomic characteristics
(see Data analysis). Standard clinical and laboratory variables from patient’s medical records were used to
calculate the Child–Pugh and MELD scores for each patient.
Data analysis
Data were collected on the utility scores of four health states, estimated using SG methodology, when the
value of a health state is:
U(state i) = p U(full health) + (1 p) U(death), (1)
or
U(state i) = p. (2)
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Results
A sample of 142 people with liver cirrhosis was recruited, 91 with alcoholic liver disease and 51 with
viral hepatitis (see Table 27). The majority of participants had the mildest form of liver cirrhosis (58%).
Also in Table 27 are the demographic and socioeconomic characteristics of the sample. The majority of
respondents were male (75%), 39% were married, 44% were unable to work and 82% were white
British. Thirty-one per cent of the sample stated that they had no formal qualifications. The average age
was 57 years.
The mean values for each of the health states can be seen in Table 28. When health state X represents
Child–Pugh A, health state Y represents Child–Pugh B and health state Z represents Child–Pugh C. Mean
values follow the expected patterns, for which the most severe health states have the lowest health-state
values. Paired sample t-tests were used to assess if valuations for state Child–Pugh A (X) were significantly
different from Child–Pugh B (Y) and valuations for Child–Pugh B (Y) significantly different from Child–Pugh
C (Z). It was expected that these differences would be statistically significant, reflecting the differences in
severity between states and the different severities of the disease. These tests were performed for the full
sample and for both subsamples. All were found to be statistically significant at the 5% level. Further
t-tests were conducted to test whether or not there was concordance between own health, as valued by
the SG, and own health as valued by the EQ-5D. As expected, no significant differences were found.
Discussion
This study measured QoL directly using the SG and indirectly via the EQ-5D-3L. The aim was to explore
health-state values for various stages of disease, represented by different Child–Pugh classifications (A, B
and C). However, the collection of SG data from participants with Child–Pugh C was complicated by the
presence of encephalopathy in many of these participants, which interfered with the ability of participants
to give informed consent and also to understand the concept. This problem accounts for the relatively
small sample size in this category.
TABLE 27 Study sample characteristics
Sample characteristics All (%) Alcoholic cirrhosis (%) Viral (%)
Study site
Mary’s London 29 (20) 16 (18) 13 (25)
King’s London 33 (23) 20 (22) 13 (25)
Nottingham 7 (5) 3 (3) 4 (8)
Glasgow 34 (24) 27 (30) 7 (14)
Newcastle upon Tyne 39 (27) 25 (27) 14 (27)
Total 142 91 51
Respondents classified in each Child–Pugh classification (missing n = 6)
A 79 (58) 48 (55) 31 (63)
B 46 (34) 30 (35) 16 (33)
C 11 (8) 9 (10) 2 (4)
Demographic data
Gender (missing= 2)
Male 105 (75) 65 (72) 40 (78)
Female 36 (25) 25 (28) 11 (22)
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TABLE 27 Study sample characteristics (continued )
Sample characteristics All (%) Alcoholic cirrhosis (%) Viral (%)
Marital status (missing= 2)
Married 54 (39) 39 (44) 15 (29)
Single 35 (25) 17 (19) 18 (35)
Divorced/separated 46 (33) 29 (33) 17 (33)
Widowed 5 (4) 4 (5) 1 (2)
Employment status (missing= 3)
Employed 30 (22) 17 (19) 13 (26)
Retired 38 (27) 28 (32) 10 (20)
At home/not looking for work 3 (2) 3 (3) 0 (0)
Unable to work 61 (44) 35 (40) 26 (51)
Unemployed 5 (4) 3 (3) 2 (4)
Other 2 (1) 2 (2) 0 (0)
Qualifications (missing= 4)
None 42 (31) 27 (31) 15 (30)
GCSEs (1–5) 23 (17) 17 (20) 6 (12)
GCSEs (> 5) 14 (10) 10 (12) 4 (8)
A-levels (1–2) 2 (1) 2 (2) 0 (0)
A-levels (> 2) 4 (3) 1 (1) 3 (6)
Degree 10 (7) 8 (9) 2 (4)
Higher degree 10 (7) 7 (8) 3 (6)
NVQ1 4 (3) 3 (3) 1 (2)
NVQ2 5 (4) 1 (1) 4 (8)
NVQ3 2 (1) 2 (2) 0 (0)
NVQ4 3 (2) 0 (0) 3 (6)
Other 19 (14) 9 (10) 10 (20)
Ethnicity (missing= 2)
White British 115 (82) 79 (89) 36 (71)
White Irish 6 (4) 4 (5) 2 (4)
White other 8 (6) 2 (2) 6 (12)
Mixed white Asian 2 (1) 0 (0) 2 (4)
Asian Indian 2 (1) 0 (0) 2 (4)
Black Caribbean 2 (1) 2 (2) 0 (0)
Black African 2 (1) 1 (1) 1 (2)
Black other 1 (1) 1 (1) 0 (0)
Other 2 (1) 0 (0) 2 (4)
A-level, Advanced level; GCSE, General Certificate of Secondary Education; NVQ, National Vocational Qualification.
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At the aggregate level, results of health-state valuations were in line with a priori expectations, when
Child–Pugh A was preferred to Child–Pugh B and Child–Pugh B preferred to Child–Pugh C. As expected,
at the aggregate level, statistically significant differences between the values of health states Child–Pugh
A, B and C were found, adding credibility to the results. As disease severity increases, health-state
valuations significantly decrease. Convergent validity was tested by examining valuations of an individual’s
own health today, as measured by the SG and EQ-5D. These values were not significantly different,
suggesting high levels of convergent validity between the two measures values. These results hold for
the full sample analysis and subsample analyses.
At the individual level there were some inconsistencies in both the ranking of health states and the
valuation exercise. Such results are not uncommon at the individual level.45 Importantly, valuations at
the aggregate level are consistent with a priori expectations.
Conclusion
As seen in the systematic review40 and a search of literature since 2008 there is little empirical research into
health-state valuations in liver disease generally, and in alcoholic liver disease specifically, that can be used to
derive QALYs for use in economic evaluations and decision-making. This study has measured QoL using the
SG method to obtain utility values for three different classifications of disease: Child–Pugh A, B and C, and
in two separate populations: those suffering from cirrhosis owing to alcoholic liver disease and those with
cirrhosis owing to viral hepatitis. This research offers a unique opportunity to estimate QALYs on future trials
for liver cirrhosis when QoL can be mapped to Child–Pugh classification of the trial participant.
TABLE 28 Health state valuations
Mean
Standard
deviation
p-value
(X>Y and Y> Z)
p-value (EQ-5D
SG and EQ-5D)
Full sample
State X (n= 141) 0.645 0.305 – –
State Y (n= 142) 0.566 0.567 < 10.000** –
State Z (n= 142) 0.429 0.279 < 0.0001** –
Own health (n= 139) (SG) 0.578 0.311 – –
Own health (n= 139) (EQ-5D) 0.602 0.381 – 0.570
ALD sample
State X (n= 91) 0.632 0.314 – –
State Y (n= 91) 0.537 0.319 < 0.0001** –
State Z (n= 91) 0.417 0.282 < 0.0001** –
Own health (n= 89) (SG) 0.572 0.317 – –
Own health (n= 89) (EQ-5D) 0.6187 0.376 – 0.372
Viral sample
State X (n= 50) 0.669 0.289 – –
State Y (n= 51) 0.616 0.283 0.003* –
State Z (n= 51) 0.451 0.272 < 0.0001** –
Own health (n= 50) (SG) 0.582 0.297 – –
Own health (n= 50) (EQ-5D) 0.572 0.389 – 0.729
*, significantly different at 5% level, X compared with Y and Y compared with Z.
**, significantly different at 1% level, X compared with Y and Y compared with Z.
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Part 2: economic evaluation
The aim of the economic evaluation was to determine which single treatment (PTX or prednisolone), dual
treatment (PTX and prednisolone) or standard care (placebo) is the most cost-effective option when
treating AH. The following comparisons have been made:
i. PTX vs. no PTX
ii. prednisolone vs. no prednisolone
iii. PTX vs. prednisolone vs. PTX and prednisolone vs. placebo.
Table 29 provides an illustrative example of the 2 × 2 factorial trial design adopted for the STOPAH study.
It is important to note that the assumption made with this form of trial design is that there is no
interaction between PTX and prednisone.
The perspective (i.e. whose costs and benefit are considered relevant) of the trial is of the health service
provider (NHS), hence only costs borne by the NHS were considered. Patient time and travel costs were not
collected for this trial as it was anticipated that the response rate would be low and information of poor
quality. For the economic evaluation both within-trial and a model-based evaluations were conducted.
The role of the latter was to extrapolate from the short trial follow-up over the estimated lifetime of the trial
participants. For both the within-trial and model-based analyses, the following outcomes were reported:
l costs to the NHS at 28 days and 1 year
l mortality at 28 days and 1 year
l QALYs over 1 year based on responses to the EQ-5D-3L questionnaire administered at discharge,
90 days and 1 year.
For all outcomes there were missing data after 28 days (the treatment phase) for those participants who
were recruited towards the end of study, owing to an extension in the recruitment phase.
Methods overview
This economic evaluation includes a within-trial analysis and a model-based analysis.
First, a cost-effectiveness analysis was conducted that allowed us to calculate the incremental cost per
additional survivor at 28 days. Second, we planned to repeat the analysis for a 1-year time horizon;
however, as estimates of the incremental cost per additional survivor may be difficult to interpret according
to standard decision-making criteria within the NHS,46 a cost–utility analysis was also performed.
When we came to analyse the data there were few responses (n= 192) to the use of medical services
questionnaire administered at 1 year across the four treatment arms. If we used these responses, even with
imputations for the missing responses, there would be significant concerns that there would have selection
biases given the nature and extent of the missing data. However, to extrapolate to 1 year and longer
follow-up we used a Markov model. In a Markov model people move between discrete states of health
over time. Within a Markov model, movement between states can take place only once every period of
time, called a cycle length. In this model we have adopted a cycle length of 1 day, as this will allow us to
TABLE 29 A 2×2 factorial design for the STOPAH study
Placebo for A Treatment for A
Placebo for B OO (placebo for A and placebo for B) AO (treatment for A and placebo for B)
Treatment for B OB (placebo for A and treatment for B) AB (treatment for A and treatment for B)
A, prednisolone; B, PTX; O, placebo.
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cross-validate estimates with the within-trial analysis data and be sufficiently sensitive to changes over time.
In this model the costs and utility values were collected over the treatment phase and 90 days to estimate
the total average cost per day and average QoL utility per day for each treatment arm.
Incremental cost-effectiveness
In both the within-trial analysis and the model-based analysis, data on costs and effects of the
interventions were combined to obtain an incremental cost-effectiveness ratio (ICER). For the within-trial
analysis, this was performed by calculating the mean difference in costs between the interventions and
control group over the difference in effect between the interventions and control group. This gives us the
cost per additional unit of effectiveness (e.g. survivors or QALYs) gained – a more effective but more costly
intervention relative to a less costly but less effective intervention. A similar approach was used to estimate
the ICER for the model-based analysis.
Cost data collection
NHS costs and frequency of use of health-care services
The costs to the NHS depended on the use of NHS resources during the initial treatment phase and during
the 1-year follow-up. The frequency of resource use was calculated for each participant to generate the
average cost per patient in each arm of the trial. Any potential differences in costs and outcomes between
patient groups were identified from this analysis. All unit costs were collected from routine sources, for
example NHS Reference Costs.47
During the initial admission, the discharge visit form captured information on the length of admission and
the procedures that were performed during this time. After participants were discharged, their resource
use was captured using the use of medical services self-reported questionnaires completed at 90 days and
1 year, and the day-90 and 1-year visit forms. The use of the medical services questionnaire allowed us to
divide resource use into secondary care, primary care and social care. Secondary care resources included
inpatient stays, day-case visits, accident and emergency visits, and outpatient visits. Primary care resources
included general practitioner (GP) practice and home visits, nurse practice and home visits, and home and
office visits with a social worker or care worker. If a participant was prescribed a medication, the number
of prescriptions they received was recorded. To summarise, data collection and costs can be split into
thee areas:
1. initial treatment costs
2. secondary care costs
3. primary and other community care costs.
Initial treatment costs
The treatments being examined during the STOPAH trial were relatively low-cost medications. The cost of
each treatment is based on the dosage and length of treatment (28 days), specified in the trial protocol.
The cost for PTX and prednisolone came from the British National Formulary (BNF).48
Other costs incurred prior to discharge were collected via the discharge form and incorporated into the
total cost of initial treatment. This form contained information on length of initial admission (based on trial
recruitment and discharge dates), medical procedures and medical events that could occur during the
treatment phase. A number of participants had a trial start date after their date of discharge, so we
assumed the length of their initial admission was 0 days. If a participant was missing their discharge date
then assumptions on the date of discharge were informed by data in their records. The length of initial
admission for participants without a discharge date but whose date of death was relatively close to the
end of their treatment phase was taken as 28 days. Participants who withdrew from the trial or had a date
of death at a later stage of the trial were given a length of admission that was the average of their patient
group. This simple form of imputation was used because there were relatively few people (9.5% of the
trial population) in this category.
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The discharge form also contained information on whether or not a participant was admitted to an
intensive care unit (ICU) during the initial treatment phase and the length of time that they spent there.
The initial length of admission was multiplied by the NHS cost per night for an inpatient stay on a general
ward. A higher cost was used for an ICU stay and the initial length of admission was reduced by the
number of nights in ICU to prevent any double counting. In terms of procedures, the discharge form
included information on imaging, including use of computerised tomography and magnetic resonance
imaging, as well as a wide range of procedures. All these events were costed using the NHS Reference
Costs.47 These reference costs were, however, amended by removing any element of hospitalisation, as
these costs were already included. This was done by estimating the average cost per day from the cost of
the relevant non-elective long-stay reference cost, then multiplying this cost per day by the average length
of stay for the national tariff. This hospitalisation cost was then subtracted from the procedure cost to give
a cost of the procedure without any length-of-stay component. An example of this calculation is the
procedure cost for banding varices. This is captured in the NHS tariff ‘GI with single intervention’. The
non-elective cost of a long stay is £1582 and the average length of stay for this procedure is 4.0 days.
The average length of stay is multiplied by £265, the cost of a non-elective bed stay. This results in a
procedure cost of £522. This is a rough estimate of the procedure cost including staff costs. The same
calculation was used to estimate the cost adverse events procedures.
A participant may receive some procedures more than once. If this happened then the number of
procedures that a participant had was multiplied by the cost per procedure. Unfortunately, no information
was captured on the number of standard procedures performed on the discharge form, which may have
caused an underestimation of the cost of discharge procedures. In some cases, additional information on
the number of procedures performed was available in the ‘Comments’ data set and when this was the
case, these data were included in the costs for that participant and used to estimate the total cost of
discharge procedures per randomised arm (note: the comments data set contained participant information
that was provided by participants and clinicians). For participants for whom the discharge information was
completely missing, the median costs of discharge procedures were imputed on the data available for the
randomised arm. The median estimate was used instead of the mean, as this was felt more representative
as the mean value was skewed because a number of participants in each arm had extremely high
discharge procedure costs caused by an extended admission to ICU.
Nutritional supplements were provided for participants who were admitted into hospital. Assumptions
about the nature and type of these supplements were informed by clinical advice from a dietitian. It was
assumed that participants with this illness would need 1.5 kcal/ml sip feed and a suitable nutritional
substitute would have 300 kcal and 12 g of protein in a 200-ml bottle. It was assumed that participants
took the nutritional supplement five times per day every day for the length of their initial admission; we
have made the assumption that participants would take this nutritional drink during only their initial
admission as their sole source of nutrition. Sensitivity analysis was used to test this assumption. The unit
cost of this nutritional supplement was taken from the BNF.48
We planned to cost GI bleed, sepsis and renal failure as common adverse events. The data to estimate the
cost for the treatments for sepsis and GI bleed were captured in the concomitant medication form and
procedures to diagnose sepsis, and to diagnose and treat GI bleeds, were captured in the discharge and
adverse events forms. Renal failure was based on the NHS tariff for ‘hospital haemofiltration’. Using clinical
advice it was assumed that the haemofiltration would be performed continuously. This information was
collected during the treatment phase at 7-day intervals and as a result we assumed that the participant
had the treatment for a period of 7 days continuously. Using the treatment day forms at days 7, 14, 21
and 28 we could determine if the renal failure was resolved or if the participant needed further treatment.
If the patient had renal failure at day 28 and it was not resolved, we assumed that he/she continued the
treatment for another 7 days. Sensitivity analysis was conducted around this assumption in our
model-based analysis.
DOI: 10.3310/hta191020 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 102
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Thursz et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
Laboratory tests were routinely performed on participants during the treatment phase and follow-up
period to monitor their disease progression and the effects of the initial medical treatments being
examined in the trial. The laboratory tests include, but are not limited to, FBC, glucose, urea and PT. Every
participant was due to have these laboratory tests during their initial admission and at each follow-up visit.
There could be a discrepancy between randomised arms if one group had a shorter/longer initial admission
on average than the other arms. The unit costs for these laboratory tests were collected from the Royal
Victoria Infirmary’s Newcastle University Hospitals costing tool.49 Within the discharge visit laboratory
test data, there were additional data for some participants who had ‘subsequent visit’ laboratory test
information. The information collected on laboratory tests at this visit was excluded from our analysis
because it was not consistently recorded across sites.
Adverse events
Participants’ adverse event information was collected via the adverse event form. Within this form, adverse
events that occurred were categorised as: no action taken; change in concomitant medication;
investigations and hospitalisation. Only investigations and hospitalisations were costed, as medications
were captured in the concomitant medication form. Some of the investigations recorded included being
‘observed’ and ‘getting vital signs checked’, and we made the assumption that these costs would form
part of standard care when in hospital. All other investigations were costed using national tariffs. The
calculation that was used for generating procedure costs was used here, unless it was explicitly stated in
the adverse event form or ‘comments’ data set that the participant was treated in a different health-care
setting (e.g. outpatient). One participant was referred to their GP but it was assumed this cost would be
captured in the use of medical services questionnaire. We divided the adverse events into the three time
periods: 28 days, 90 days and 1 year. We presented the average resource use of the adverse event
investigations performed during the 28-day treatment phase. This time period was used because there was
limited information about who was missing data at 90 days and 1 year. Information on adverse events that
required hospitalisation was collected via the SAE form. This form recorded the length of admission if a
participant was hospitalised and the severity of their admission. If a person died while in hospital we used
the participant’s date of death to estimate their length of admission. For some participants, data on
hospitalisation were duplicated and, when this could be verified, the duplicate data were removed from
our analysis. We assumed, based on clinical advice, that unless stated otherwise in the adverse event or
‘comments’ data set, a participant was treated on a general ward rather than in ICU. Sensitivity analysis
was conducted around this assumption to determine what effect an ICU admission would have on total
average costs; this was conducted in the model-based analysis.
Appendix 4 provides a detailed description of all the unit costs used, where they were sourced from and
what CRF they relate to. Appendix 5 provides a detailed description on the average number of adverse
event investigations performed at 28 days.
Concomitant medications
During the treatment phase and 1-year follow-up, additional medications prescribed to the participant
were collected via the concomitant medication form. Many participants used a large number of additional
medications for a wide variety of indications, including, for example, fungal nail infection treatments,
paracetamol for headaches, vitamin supplements and medications for alcohol withdrawal. There were over
22,000 additional medications reported by participants. These were broken down into categories so the
results could be presented in an interpretable manner. We used a dummy variable for final indication, for
which final indication was based on the 15 BNF categories, with a further three additional categories
added for medications that did not fall under these BNF categories: emergency treatment of poisoning,
wound dressing and procedure medication. This allowed us to segregate our medications based on
established indications. All costs of concomitant medications were sourced from the BNF when possible.
Imputations for participants with a reduced follow-up period were based on the final indication of
concomitant medications instead of the frequency of use of individual medications.
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Secondary care costs
The secondary care resources that were used by participants were accident and emergency visits, inpatient
admissions, day admissions and outpatient visits (Table 30). Each hospital visit/admission incured a different
tariff depending on the length of stay and type of admission. When possible, tariffs directly related to the
condition were used (e.g. hepatology outpatient visit), as it is a more accurate indication of costs. The
frequency of use of these health-care resources were multiplied by the national tariff to get the total
follow-up cost per patient. In the ‘comments’ data set it was reported that some participants were too ill
to complete their use of medical services questionnaire but patient records were used when possible to
provide this information. As a result, many participants have information on only secondary care resource
use and imputations were made for the use of primary care services. If participants were admitted during
the follow-up period, the ward that they were admitted to was not collected in the use of medical services
questionnaire. We decided to remove participant-reported inpatient admissions from our primary analysis,
as this information duplicated that collected in the CRFs and that the CRF data would be a more accurate
representation of length of admissions, as it was not subject to recall bias. Sensitivity analysis was
conducted around the different wards participants could potentially be admitted to: general ward and ICU.
Primary care and social care costs
The health-care resources available to participants at a primary care setting included GPs, practice and
district nurses, social workers and care workers (see Table 30). All visits with these practitioners could occur
at the health-care practice or at the participant’s house. We distinguished between the different locations
of each consultation to account for the different costs associated with each consultation.
If a participant attended a health-care practitioner during the follow-up period they could be given a
prescription. Information on the type of medication prescribed was not recorded in the use of medical
services questionnaire but the number of prescriptions each participant received was recorded. We applied
a generic cost for prescriptions from the Personal Social Services Research Unit.50 This is calculated as the
average cost of prescriptions prescribed by GPs over the previous year. We have not incorporated
TABLE 30 Unit costs: follow-up
Costs Unit Unit cost (£) Source
Follow-up costs: hospital
A&E visit Per visit 115 Resource-use questionnaire/NHS tariffs
Day case Per day 693 Resource-use questionnaire/NHS tariffs
Inpatient: general ward Per night 265 Resource-use questionnaire/NHS tariffs
Outpatient Per visit 213 (hepatology department) Resource-use questionnaire/NHS tariffs
Primary care
GP: at practice Per visit 45 Resource-use questionnaire/PSSRU50
GP: at home Per visit 114 Resource-use questionnaire/PSSRU50
GP nurse: at practice Per visit 11.37 Resource-use questionnaire/PSSRU50
GP nurse: at home Per visit 39 Resource-use questionnaire/PSSRU50
Prescription cost Per script 7.73 Resource-use questionnaire/PSSRU50
Social services
Social worker: at home
(including travel costs)
Per visit 190.80 Resource-use questionnaire/PSSRU50
Social worker: at office Per visit 159 Resource-use questionnaire/PSSRU50
A&E, accident and emergency; PSSRU, Personal Social Services Research Unit.
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participants’ costs if they had to pay for a prescription but we have accounted for the cost associated with
administering prescriptions. The number of prescriptions was multiplied by this cost for each participant.
A care worker collected information on visits but owing to misinterpretations about care workers this cost
was excluded from our analysis. A number of patients interpreted a care worker visit to their home as
home help and they had reported daily visits. Using the ‘comments’ data set we could identify the
different interpretations to the care worker question (e.g. alcohol counselling, daily support from a
sponsor) and as a result we could not accurately assign a unit cost for this resource use and it was hence
omitted from our analysis. The average resource use for this service will be presented but take caution in
its interpretation, as some people classed it as home care. Social workers tend to work on an individual
level with clients, so to estimate the length of appointments was difficult. Using expert opinion we
assumed a visit with a social worker, regardless of location, would have a duration of 1 hour. If a visit was
a home visit we included an extra 12 minutes to incorporate travelling time, using the Personal Social
Services Research Unit GP average travelling time as a guide.50
We used a simple imputation of including the upper interquartile range for participants’ use of medical
services information. We used this range, as the mean value was very skewed because of a small number
of participants who used very high quantities of medical services and the majority of participants who
responded to the questionnaires had little resource use. This assumption was tested in the sensitivity
analysis in our model-based analysis.
Information on alcohol counselling was collected at the 90-day and 1-year visits. There was no information on
the frequency of counselling attendances, just whether or not the participant had attended and, if they had
attended, whether or not they attended more than once. Information reported in the ‘comments’ data set was
used when many participants reported the number of times they attended counselling sessions. These data
were used to estimate an average number of visits, which was then assigned to every participant who reported
that they had seen an alcohol counsellor. A sensitivity analysis was conducted around this assumption. For
participants with missing counselling information we assumed a proportion of each treatment arm had at least
one counselling session, dependent on the number of people in each arm who reported having at least one
counselling session. This was explored in our sensitivity analysis by assuming that everyone had at least
one counselling session and assuming that no one had a counselling session, unless it was reported.
All health-care resource use was captured via the use of a medical services questionnaire at 90 days and
1 year. We initially planned on presenting the combined average health-care resource use over the complete
follow-up period of 1 year; however, owing to the extent of missing data (caused by the reduction in
the trial follow-up period because of the recruitment extension) this resulted in participants having a length
of follow-up considerably shorter than 1 year. As a result of this we presented the average 90-day
health-care resource use and average 1-year health-care resource use separately.
Effectiveness measures
The economic evaluation was conducted with different outcome measures at 28 days (mortality only) and
1 year (mortality and QALYs).
Mortality rates
The initial economic evaluation considered the incremental cost per additional survivor, with mortality rates
assessed at 28 days and 1 year. For participants recruited later in the trial, we have information only on
their mortality status until the end of the trial follow-up period, which was 31 March 2014.
Quality-adjusted life-years based on responses to the European Quality of
Life-5 Dimensions-3 Levels
Quality-adjusted life-years were generated from the utility values derived from responses to the EQ-5D-3L
during the follow-up period. For participants without a 1-year follow-up, their probability of mortality was
estimated with a survival function. QALYs were based on the utility estimates from the EQ-5D-3L at
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discharge, 90 days and 1 year during the follow-up period using the areas under the curve approach. The
EQ-5D-3L is commonly used to assess the QoL for participants with different medical conditions. It allows
us to generate a QoL profile for participants and make comparisons between different groups of patients.
The EQ-5D-3L questionnaire describes health status in five dimensions. These dimensions are mobility,
self-care, usual activities, pain/discomfort and anxiety/depression. Each of these dimensions has three
levels, regressing from the best possible situation in the dimension to the worse possible situation in the
dimension. The number of dimensions and levels within each dimension provide 243 possible health states
for participants to choose from.
The responses to the EQ-5D-3L questionnaire were transformed using a standard algorithm51 to produce a
health-state utility score at scheduled intervals during the follow-up for each participant in the four
treatment groups. Utility values for perfect health and death are 1 and 0, respectively. The area under the
curve approach puts a time weight onto each utility score. The time-weighted average of the scores based
on the responses to the EQ-5D-3L measured at discharge, 90 days and at the end of measurement period
(1 year) allows us to generate QALY values for each participant.52 Missing baseline EQ-5D-3L scores
occurred as some participants were unable to complete the questionnaires at their time of admission.
Missing utility values at 90 days and 1 year were estimated based on additional information provided by
the participant’s status from the ‘comments’ data set, with imputations based on utility values reported
by participants in similar health states.
Baseline utility values were estimated based on how this patient group is usually admitted to hospital
(typically as emergency cases, and unconscious and needing urgent medical treatment). Some participants
have their discharge extremely close to their start date, so the assumed baseline utility values can be tested
in a sensitivity analysis using these utility values. However, an issue may arise with the utility scores
generated from the EQ-5D-3L because it allows participants to have negative utility values, that is, a health
state worse than death. If this appeared to be the case a small positive utility value (0.01) was imputed for
baseline utility values to prevent participants experiencing a utility gain if they die.
The average utility scores for each treatment arm were presented for the three data collection points:
discharge, 90 days and 1 year. The results presented are only for survivors who had completed the
EQ-5D-3L questionnaire. It is important to note that for the initial presentation of results, no utility value
was imputed for participants who died or did not complete the EQ-5D-3L questionnaire. Fewer than 2%
of participants at each data collection point partially completed the questionnaire. The missing values for
some participants could be estimated using information in the ‘comments’ data set, for example one
participant was missing information on ‘usual activities’ but in the ‘comments’ data set it was written that
they were ‘in a care home’, hence it was assumed that they were unable to perform their usual activities
as a result of this. An extreme imputation method was used for participants with missing information and
no additional information in the ‘comments’ data set; a ‘worst case scenario’ was assumed for these
missing values. This imputation method was explored in the sensitivity analysis.
In the economic analysis it was assumed that if a participant died during the trial, their utility value was
assumed to be 0 for every utility data collection point after their date of death. To estimate the utility
values of the remaining participants we used the interquartile range of the utility values provided by
participants still alive at each data collection point. A number of participants were ‘too ill’ to complete the
EQ-5D-3L questionnaire at the different visits and hence we imputed their utility value as the lower
interquartile range estimate of their treatment arm. If a participant ‘did not attend’ a scheduled visit we
assumed that these participants were too ill to attend the visit and hence could not complete the
questionnaire. We assumed that these participants would have a slightly greater utility value than
participants who were ‘too ill’ to complete the questionnaire, as they would be able to complete the
questionnaire if they had attended their scheduled visit. As a result we estimated their utility value to be
the higher value of the interquartile range of their treatment arm. For all other missing utility values a
multiple imputation technique was applied. These assumptions were explored in our sensitivity analysis in
our model-based analysis.
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The methods, results and sensitivity analyses will be presented separately into two sections: within-trial
analysis and model-based analysis.
Within-trial analysis
Our main analysis was the relative cost-effectiveness of the study treatments at 28 days.
Methods
The cost-effectiveness analysis at 28 days will be replicated for three analyses using the methods below.
Four-arm comparison: within-the-table analysis
A four-arm comparison was undertaken as the primary analysis. This comparison considers each treatment
arm of the 2 × 2 factorial trial design and compares it as if they were mutually exclusive individual
strategies; PTX or prednisolone, PTX and prednisolone or standard care (placebo). This allows us to identify
the effects of PTX and prednisolone when there is no interaction between the two treatments. The
within-the-table analysis looked at the costs, outcomes and net benefits for the four treatment arms.
The results were presented on the cost-effectiveness plane from which a cost-effectiveness frontier was
generated. The cost-effectiveness frontier allows us to determine the treatment option that maximises net
benefits at our chosen ceiling ratio. For example, in a cost–utility analysis, the National Institute for Health
and Care Excellence typically adopted a threshold value for society’s willingness to pay of £30,000 per
QALY;46 however, it is unclear what the ceiling ratio is for the cost per additional survivor.
As noted in the previous paragraph, the proposed primary is unbiased but is not efficient; the trial was not
powered to detect differences between the four separate arms. A four-arm comparison is arguably more
useful for the economic analysis but lacks statistical power so conclusions are based on the balance
of probabilities.
At-the-margins analysis
An at-the-margins approach was used to present a two-arm comparison between PTX and no PTX, and
prednisolone and no prednisolone. It is essentially analysing the data as if it were two overlapping, but
independent, two-arm randomised controlled trials. Costs and outcomes were presented for all those
participants who received PTX versus those not receiving PTX (prednisolone and placebo plus prednisolone
plus PTX vs. placebo and placebo plus placebo and PTX) and all those participants who received prednisolone
versus those not receiving prednisolone (placebo and PTX plus prednisolone and PTX vs. placebo and placebo
plus prednisolone and placebo) (see Table 29). The simple effect of each treatment is the mean difference in
outcomes across all participants who have received the treatment compared with all the participants who
have not received the treatment. This analysis assumes there is no interaction between treatments. This
analysis is efficient but the results will be biased if the interaction of the two treatments does not equal 0.
Sensitivity analysis
For the within-trial analysis, stochastic sensitivity analyses were performed. A stochastic sensitivity analysis
was undertaken to allow presentation of the level of variance around outcome measures included in
the cost–utility analysis. Uncertainty surrounding the cost-effectiveness ratio was addressed using
the bootstrapping technique. The results of the bootstrapping simulation were presented on the
‘cost-effectiveness plane’, which highlights the preferred treatment option. If the results lie in the
north-west or south-east quadrants the preferred treatment is clear, as one option dominates the other
(i.e. is less costly and more effective). If the results lie in the north-east or south-west quadrants, the
decision as to which is the preferred treatment is less clear (i.e. one option may be less costly but also less
effective, or more effective but at greater cost); the ICER may aid this decision. The bootstrapping was
also used to estimate CIs for both costs and effects from the four-arm and at-the-margins analyses.
A cost-effectiveness acceptability curve was also used to present the probability of a treatment being
cost-effective based on a range of values for society’s willingness to pay. In the four-arm comparison we
compared the bootstrapped results of the mean costs and mean outcomes for each treatment option
against every other treatment option.
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An extreme sensitivity analysis was conducted on our base-case analysis removing the most costly 10% of
the participants from each treatment arm. There was a number of participants across the treatment arms
that had an extended period of admission and this appears to be a key cost driver in our analysis.
Results
There were 1103 participants recruited into the STOPAH trial. Four participants who withdrew from the
trial and withdrew consent for their information to be used were excluded from the analysis, seven
participants who were randomised incorrectly were also excluded; this was consistent with the statistical
analysis. One participant was randomised after they died so they were also excluded from the health
economics analysis. Of the 1091 participants left in our analysis, 223 were affected by the trial extension
for recruitment and we have information only on their 28-day status. Nearly 400 participants died during
the trial period and only 223 participants were alive and completed the 1-year trial follow-up.
The 1091 participants that were used in the health economic analyses were evenly dispersed across the
four treatment arms; 272 receiving standard care (placebo), 274 receiving prednisolone and placebo,
273 receiving PTX and placebo and 272 receiving the dual treatment (prednisolone and PTX).
Costs were estimated during the initial admission and during the follow-up period. We initially planned on
presenting the combined total average cost of follow-up for each treatment arm, however, owing to the
reduction in the follow-up period because of the extended recruitment period we decided to present
follow-up costs individually.
Tables 31 and 32 describe the average health-care resource use by the randomised arms at 90 days for
both liver-related and non-liver-related use of services. There were 415 use of medical services
questionnaires returned at day 90, and of these, five were completely blank. For our analysis we assumed
TABLE 31 Follow-up resource use at 90 days: liver related
Follow-up resource
use – day 90
OO AO OB AB
na Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
A&E 106 1.05 (5.65)b 104 1.55 (9.01) 94 0.52 (1.12) 107 0.62 (1.01)
Inpatient 106 12.17 (23.17) 104 12.11 (24.73) 94 10.36 (17.76) 107 11.38 (21.52)
Day case 106 0.10 (0.39) 104 1.08 (8.83) 94 0.31 (1.25) 107 0.53 (3.54)
Outpatient 106 1.91 (3.58) 104 2.87 (9.66) 94 1.72 (3.41) 107 1.22 (1.57)
GP practice 106 2.38 (8.92) 104 1.31 (1.78) 94 3.45 (13.02) 107 1.51 (1.96)
GP home 106 0.23 (1.10) 104 0.09 (0.28) 94 0.12 (0.67) 107 0.15 (0.55)
Practice nurse 106 1.75 (9.62) 104 0.62 (1.73) 94 0.33 (1.14) 107 0.77 (2.41)
District nurse 106 0.17 (1.04) 104 0.13 (0.71) 94 0.79 (5.08) 107 0.03 (0.22)
Social worker: home 106 0.23 (1.96) 104 0.05 (0.29) 94 0.00 (0.00) 107 0.21 (1.10)
Social worker: office 106 0.05 (0.40) 104 0.01 (0.98) 94 0.07 (0.55) 107 0.11 (0.59)
Care worker: home 106 0.23 (1.12) 104 0.66 (2.93) 94 0.74 (3.54) 107 0.79 (5.12)
Care worker: office 106 0.89 (5.90) 104 0.07 (0.53) 94 0.57 (2.61) 107 0.25 (1.30)
Prescription 106 5.43 (18.56) 104 2.10 (4.46) 94 2.54 (9.34) 107 2.06 (5.07)
A, prednisolone; A&E, accident and emergency; B, PTX; O, placebo; SD, standard deviation.
a n is the number of participants in each arm who responded to the questionnaire.
b How to interpret the table: the average A&E attendances from those in the placebo group who responded to the
questionnaire was 1.05 visits.
DOI: 10.3310/hta191020 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 102
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Thursz et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
61
that any participant who partially completed the questionnaire left their other responses blank, as they
were not applicable to them. This assumption was explored in the sensitivity analysis. For participants
who had died during the 90-day follow-up period, their resource use was automatically imputed as 0.
This could cause an underestimation in our costs as they may have used some services within the data
collection period but before they died. In our preliminary analysis of the health-care resource use data we
discovered some unintuitive results reported by participants; an example is reporting 215 inpatient nights
in the last 90 days. For our analysis we decided to cap these unintuitive responses at 90.
Tables 33 and 34 present similar data to Tables 31 and 32, but for the 1-year follow-up period.
Table 31 highlights that the prednisolone only treatment arm has a higher, on average, liver-related
secondary care resource use. The number of inpatient nights for non-liver-related conditions for the
prednisolone-only treatment arm is also the highest out of all treatment arms (see Table 32). The primary
care resource use for the PTX/placebo treatment arm is relatively low compared with the other treatment
arms, especially in relation to GP visits and office visits with a social worker or care advisor. The standard
care treatment arm has the highest prescription use reported for both liver- and non-liver-related causes.
For all other health-care resource use the pattern of resource use is similar for all treatment arms. A similar
pattern of resource use is observed in Tables 33 and 34.
Utility data were collected at discharge, day 90 and 1 year but were used only in our 1-year analysis.
Preliminary utility scores for each treatment arm suggest that, on average, the standard treatment arm has
the highest utility values at discharge. At 90 days, the PTX-only arm has the highest average utility score
but at 1 year, PTX only has the lowest average utility score. At 1 year, the standard treatment arm again
has the highest average utility score (see Table 35). When interpreting Table 35 caution needs to be taken
as the results are presented only for survivors who completed the EQ-5D-3L; this is because this table is
also used as a data source for the model-based economic evaluation. The numbers with utility data in each
treatment arm decrease by approximately 30% from discharge to the 90-day visit, with a further 40%
TABLE 32 Follow-up resource use at 90 days: non-liver related
Follow-up resource
use – day 90
OO AO OB AB
na Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
A&E 106 0.77 (5.706) 104 0.19 (1.080) 94 0.14 (0.521) 107 0.28 (0.799)
Inpatient 106 2.72 (11.600) 104 3.01 (14.390) 94 1.20 (9.387) 107 0.86 (3.583)
Day case 106 0.04 (0.191) 104 0.02 (0.138) 94 0.00 (0.000) 107 0.04 (0.191)
Outpatient 106 1.10 (8.753) 104 0.59 (1.568) 94 0.14 (0.499) 107 0.33 (1.106)
GP practice 106 0.38 (0.990) 104 0.81 (1.817) 94 0.23 (0.663) 107 0.66 (1.447)
GP home 106 0.06 (0.361) 104 0.05 (0.256) 94 0.00 (0.000) 107 0.04 (0.305)
Practice nurse 106 0.98 (8.746) 104 0.65 (3.547) 94 0.39 (2.515) 107 0.37 (2.365)
District nurse 106 0.35 (2.143) 104 0.10 (0.704) 94 0.11 (0.695) 107 0.05 (0.319)
Social worker: home 106 0.08 (0.686) 104 0.08 (0.534) 94 0.03 (0.230) 107 0.01 (0.097)
Social worker: office 106 0.14 (1.199) 104 0.05 (0.490) 94 0.03 (0.309) 107 0.00 (0.000)
Care worker: home 106 0.08 (0.329) 104 1.05 (8.891) 94 0.20 (1.380) 107 0.45 (2.819)
Care worker: office 106 0.15 (0.903) 104 0.08 (0.534) 94 0.01 (0.103) 107 0.06 (0.408)
Prescription 106 3.40 (15.077) 104 1.04 (3.424) 94 0.43 (1.092) 107 0.56 (1.319)
A, prednisolone; A&E, accident and emergency; B, PTX; O, placebo; SD, standard deviation.
a n is the number of participants in each arm who responded to the questionnaire.
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TABLE 33 Follow-up resource use at 1 year: liver related
Follow-up resource
use – 1 year
OO AO OB AB
na Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
A&E 52 0.83 (1.593)b 51 1.16 (2.838) 44 1.07 (2.688) 45 0.53 (1.392)
Inpatient 52 12.69 (23.772) 51 7.63 (16.949) 44 8.36 (26.049) 45 5.04 (13.588)
Day case 52 0.46 (1.540) 51 0.75 (2.719) 44 0.95 (4.529) 45 0.24 (0.679)
Outpatient 52 2.71 (2.637) 51 2.53 (3.331) 44 2.48 (2.724) 45 2.51 (2.873)
GP practice 52 1.77 (2.784) 51 2.61 (4.336) 44 2.45 (4.196) 45 3.40 (6.257)
GP home 52 0.83 (4.993) 51 0.12 (0.711) 44 0.52 (2.140) 45 0.13 (0.457)
Practice nurse 52 0.98 (5.020) 51 0.88 (2.414) 44 1.09 (2.400) 45 0.42 (1.288)
District nurse 52 0.02 (0.139) 51 0.37 (1.777) 44 0.45 (2.107) 45 0.02 (0.149)
Social worker: home 52 0.19 (1.253) 51 0.73 (5.040) 44 1.98 (10.866) 45 0.04 (0.208)
Social worker: office 52 0.12 (0.832) 51 0.00 (0.000) 44 0.00 (0.000) 45 0.00 (0.000)
Care worker: home 52 0.12 (0.583) 51 0.02 (0.140) 44 2.00 (10.920) 45 0.31 (2.087)
Care worker: office 52 0.83 (5.044) 51 0.47 (2.845) 44 0.20 (1.357) 45 4.62 (27.062)
Prescription 52 9.38 (37.795) 51 4.35 (10.451) 44 3.66 (6.463) 45 3.98 (7.617)
A, prednisolone; A&E, accident and emergency; B, PTX; O, placebo; SD, standard deviation.
a n is the number of participants in each arm who responded to the questionnaire.
b How to interpret the table: the average A&E attendances from those in the placebo group who responded to the
questionnaire was 0.83 visits.
TABLE 34 Follow-up resource use at 1 year: non-liver related
Follow-up resource
use – 1 year
OO AO OB AB
na Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
A&E 52 0.33 (0.585) 51 0.31 (0.812) 44 0.30 (1.133) 45 0.27 (0.580)
Inpatient 52 4.04 (20.981) 51 1.41 (4.904) 44 2.52 (10.551) 45 1.18 (3.695)
Day case 52 0.10 (0.358) 51 0.18 (0.623) 44 0.05 (0.211) 45 0.04 (0.208)
Outpatient 52 0.90 (1.902) 51 1.14 (1.960) 44 0.86 (1.534) 45 0.78 (2.055)
GP practice 52 1.77 (3.246) 51 1.96 (3.013) 44 1.61 (2.879) 45 1.11 (2.102)
GP home 52 0.21 (1.391) 51 0.18 (0.888) 44 0.66 (2.167) 45 0.27 (1.372)
Practice nurse 52 0.73 (2.011) 51 0.31 (0.678) 44 2.23 (10.828) 45 0.24 (0.645)
District nurse 52 1.73 (8.047) 51 0.29 (1.501) 44 0.59 (2.182) 45 0.24 (1.495)
Social worker: home 52 0.08 (0.436) 51 0.00 (0.000) 44 0.45 (2.715) 45 0.02 (0.149)
Social worker: office 52 0.02 (0.139) 51 0.00 (0.000) 44 0.02 (0.151) 45 0.02 (0.149)
Care worker: home 52 0.00 (0.000) 51 0.18 (1.260) 44 0.09 (0.603) 45 0.89 (5.373)
Care worker: office 52 0.21 (1.177) 51 0.00 (0.000) 44 1.00 (6.633) 45 1.00 (5.502)
Prescription 52 8.04 (37.996) 51 1.02 (2.596) 44 0.77 (2.371) 45 0.89 (2.665)
A, prednisolone; A&E, accident and emergency; B, PTX; O, placebo; SD, standard deviation.
a n is the number of participants in each arm who responded to the questionnaire.
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decrease between the 90-day visit and 1-year visit. Imputations were made for missing data in the
economic analysis at 1 year but they are not represented in Table 35. The assumptions made in the
economic analysis at 1 year were explored in the sensitivity analysis and a multiple imputation method was
adopted. For participants who partially completed the questionnaire we used the ‘worst-case scenario’
method of imputation. This assumption was explored and had little to no effect on the average utility
scores for each treatment arms owing to the low number of participants it affected.
Primary analysis
The primary analysis conducted for the health economics focused on the costs and outcomes at the end of
the treatment phase (day 28). The costs included in the 28-day analysis were the intervention costs, length
of initial admission (including time spent in ICU), nutritional supplements, discharge procedures and
adverse event investigations. Discharge procedures were considered only if a participant was discharged
within the treatment phase. If a participant was discharged after the treatment phase, the length of their
initial admission was capped at 28 days.
For participants whose discharge form included some information, but for whom complete data were
not available, we assumed that what was recorded represented all procedures performed. If a participant
was in hospital on any of the days during the treatment phase but had no laboratory test information,
we assumed that the laboratory tests that were specified in the protocol were performed during and after
the treatment phase. These laboratory tests included LFTs (AST, ALT, albumin, ALP, bilirubin and total
protein), creatinine, urea, PT and FBC (haemoglobin, WBC, neutrophils and platelets). Other laboratory
tests (e.g. glucose) were available and performed on other participants during the 28-day treatment phase,
however, these additional tests were not specified in the trial protocol and hence not included in our
imputation. This assumption was explored in the sensitivity analysis in our model-based analysis. This could
result in a slight underestimation of laboratory costs for all treatment groups. The investigations performed
as part of an adverse event were recorded in the adverse event form. We identified the time at which the
investigation was performed based on each patient’s start date and the date of the investigation. Only
investigations that were performed during the 28-day treatment phase were included in this analysis.
On average, standard treatment was the most costly treatment over 28 days. This was because of the
longer initial admission and more frequent ICU admissions, on average, compared with the other
treatment arms. The total cost on average for standard care was just under £4900 over the 28-day
treatment phase. PTX alone was the only treatment to have a higher probability of death at 28 days than
standard care and was, hence, on average, more costly and less effective (i.e. dominated) by prednisolone
only and dual treatment. Both prednisolone only and dual treatment (prednisolone and PTX) dominated
standard care and PTX only. At 28 days, prednisolone had on average a 0.023 higher probability of
survival than standard care, while the dual treatment arm had an average 0.032 higher probability
of survival (Table 36).
TABLE 35 Utility values at discharge, 90 days and 1 year for survivors only
EQ-5D results during the trial na Discharge (SD) n 90 days (SD) n 1 year (SD)
OO 143 0.654 (0.316) 103 0.582 (0.371) 46 0.673 (0.306)
AO 147 0.615 (0.329) 100 0.545 (0.362) 48 0.566 (0.381)
OB 119 0.616 (0.347) 83 0.604 (0.326) 36 0.477 (0.376)
AB 128 0.635 (0.332) 91 0.561 (0.353) 40 0.604 (0.324)
A, prednisolone; B, PTX; O, placebo; SD, standard deviation.
a n is number of participants in each treatment arm.
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An incremental analysis was performed across all treatment arms. If one treatment was not dominated by
another treatment, then we calculated the ICER to compare these treatments. The least costly option was
prednisolone. Only dual treatment was more effective than prednisolone alone but this was more costly
and the incremental cost per additional survivor was over £26,125 (Table 37). This number is difficult to
interpret but with other things remaining equal, every additional survivor at 28 days would need to gain
almost 0.77 QALYs each over their remaining lifetime for the incremental cost per QALY to be £30,000
[note: PTX and prednisolone (dual treatment) has a 0.009 higher probability of an additional survivor at
day 28]. Assuming the difference in cost remains the same then assuming the maximum willingness to pay
per QALY is £30,000, then the QALY gain for each additional survivor would need to be 0.77 QALYs
(209/30,000/0.009= 0.77).
Figure 10 was produced by bootstrapping estimates of the mean costs and mean probability of dying
across the four treatment arms. It is an illustrative example of the changes in the probability of each
treatment being cost-effective at a range of willingness-to-pay values. It is analogous to a one-sided CI in
that if it is judged that society is willing to pay an upper limit for the cost per survivor, then society will
certainly pay a lower value.
TABLE 36 A 2×2 factorial design: within-the-table cost-effectiveness analysis
Parameter OO (n= 272) AO (n= 274) OB (n= 273) AB (n= 272)
Mean costs, £ (SD) 4869 (8131) 3618 (4052) 4194 (2810) 3827 (2711)
Incremental cost/patient
vs. OO, £
N/A –1251 –675 –1042
Patients in each arm who died
during the treatment phase,
n (%)
45 (16.7) 38 (14.3) 50 (19.4) 35 (13.5)
Probability of mortality at
28 days (95% CI)
0.167
(0.1287 to 0.2169)
0.143
(0.1058 to 0.1878)
0.194
(0.1355 to 0.2344)
0.135
(0.0882 to 0.1654)
Probability of survival at 28 days 0.833 0.856 0.806 0.865
Incremental survival vs. OO N/A 0.023 –0.027 0.032
Incremental cost/survival vs. OO N/A Dominant Dominated Dominant
A, prednisolone; B, PTX; N/A, not applicable; O, placebo.
Patients whose status at 28 days was ‘unknown’ were excluded from this analysis.
TABLE 37 Incremental cost per additional survivor at 28 days
Intervention Cost (£) Survival
Incremental cost per
additional survivor (£)
Probability that intervention is
cost-effective for different
threshold values for society’s
WTP for an additional survivor
£0 £5000 £10,000
AO 3618 0.857 – 0.79 0.79 0.60
AB 3827 0.865 26,125 0.20 0.13 0.08
OB 4194 0.806 Dominated by AO and AB 0.01 0.08 0.30
OO 4869 0.833 Dominated by AO and AB 0.00 0.00 0.02
A, prednisolone; B, PTX; O, placebo; SD, standard deviation; WTP, willingness to pay.
Assumes no interaction between PTX and prednisolone.
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At-the-margins analysis
The effects of both active treatments, prednisolone and PTX, were compared individually in two
subsequent analyses [(prednisolone and placebo plus prednisolone and PTX vs. placebo and PTX plus
placebo and placebo) and (prednisolone and PTX plus placebo and PTX vs. placebo and placebo
plus prednisolone and placebo)]. Since prednisolone appeared to be the most cost-effective treatment at
28 days when compared with the other three treatments, our first analysis determined the cost-effectiveness
of prednisolone vs. no prednisolone (see Table 38).
Table 38 shows the results of the at-the-margins analyses comparing prednisolone vs. no prednisolone.
These results support the findings in the four-arm comparison, as prednisolone dominates no prednisolone
(prednisolone and placebo plus prednisolone and PTX vs. placebo and PTX plus placebo and placebo). The
results of this analysis were bootstrapped to show that the statistical imprecision surrounding the estimates of
incremental cost and incremental survivors (see Figure 11) and probability of prednisolone being cost-effective
compared with no prednisolone (see Figure 12). In Figure 11, caution needs to be taken when interpreting
our results because we are looking at the incremental difference in mortality between both treatment arms.
The majority of iterations produced from the bootstrapping analysis are in the south-west quadrant and this
clearly illustrates that prednisolone is dominant because it has a lower cost on average and a lower probability
of mortality compared with no prednisolone. Figure 12 highlights that as society’s willingness to pay for an
additional survivor increases, the likelihood that prednisolone compared with no prednisolone would be
considered cost-effective decreases, but it still remains the most likely to be considered cost-effective.
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FIGURE 10 Cost-effectiveness acceptability curve: placebo vs. prednisolone vs. PTX vs. prednisolone and PTX.
TABLE 38 Cost-effectiveness analysis: prednisolone vs. no prednisolone
Intervention Cost, £ (SD) Survival
Incremental cost per
additional survivor
Probability that intervention is
cost-effective for different
threshold values for society’s
WTP for an additional survivor
£0 £5000 £10,000
Prednisolone (n= 546) 3722 (3448) 0.861 – 1.00 0.98 0.81
No prednisolone (n= 545) 4531 (6082) 0.800 Dominated 0.00 0.02 0.19
A, prednisolone; B, PTX; O, placebo; SD, standard deviation; WTP, willingness to pay.
Assumes no interaction between PTX and prednisolone.
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FIGURE 11 Cost-effectiveness scatterplot: prednisolone vs. no prednisolone at 28 days.
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FIGURE 12 Cost-effectiveness acceptability curve: prednisolone vs. no prednisolone at 28 days.
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The next at-the-margins analysis we conducted looked at PTX vs. no PTX. The incremental and
bootstrapped results are presented in Table 39 and Figures 13 and 14.
The PTX arm was slightly less effective but less costly than the no PTX arm. The incremental cost per
additional survivor for no PTX compared with PTX was in excess of £25,000 (see Table 39). The plots of
bootstrapped mean costs and differences in survival are shown in Figure 13. This figure illustrates the
statistical imprecision surrounding estimates of survival but that it is highly likely that PTX is less costly than
no PTX. The situation of the average iterations in the south-east quadrant suggests that despite the cost
savings generated by PTX it has a very slightly higher probability of mortality compared with no PTX.
The cost-effectiveness acceptability curve is illustrated in Figure 14. This figure illustrates that there is
approximately a 75% chance that PTX would be considered cost-effective over the range of threshold
values for society’s willingness to pay for an additional survivor.
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FIGURE 13 Cost-effectiveness scatterplot: PTX vs. no PTX at 28 days.
TABLE 39 Cost-effectiveness analysis: PTX vs. no PTX
Intervention Cost, £ (SD) Survival
Incremental cost per
additional survivor, £
Probability that intervention is
cost-effective for different threshold values
for society’s WTP for an additional survivor
£0 £5000 £10,000
PTX (n= 545) 4012 (2765) 0.836 – 0.76 0.77 0.74
No PTX (n= 546) 4241 (6441) 0.845 25,444 0.24 0.23 0.26
A, prednisolone; B, PTX; O, placebo; SD, standard deviation; WTP, willingness to pay.
Assumes no interaction between PTX and prednisolone.
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Sensitivity analysis
In conjunction with our stochastic sensitivity analyses we also conducted other sensitivity analyses to
reduce uncertainty from our base-case analysis. In our initial analysis we could identify a small number
of patients in each treatment arm who were having a high impact on the total average cost in each
treatment arm. We removed the most costly 10% of patients in each treatment arm and reran our
base-case analysis. Unsurprisingly the average total cost across treatment arms was lower but overall
differences in costs remained similar across arms, as there was an even spread of high-cost patients. One
key difference to note is that 14% of high-cost patients who were removed from the analysis died during
the treatment phase. This resulted in prednisolone being the dominant treatment compared with every
other treatment option. Table 40 highlights the results from the sensitivity analysis.
In our probability of survival we excluded patients whose status at 28 days was unknown. If we assumed
that they were still alive at 28 days, prednisolone only is still the favourable treatment option. Dual
treatment has a slightly higher probability of survival in this case but the ICER comparing dual treatment to
prednisolone alone suggests that the cost per additional survivor is in excess of £100,000 [355/(0.1463 –
0.1434)= 355/0.003= £11,8333].
Our sensitivity analyses were conducted for the within-the-table analysis described above. We have
previously discussed how we estimated discharge procedures and adverse event investigations. Some of
the unit costs generated did not appear reflective of the procedure performed (e.g. chest drain).
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FIGURE 14 Cost-effectiveness acceptability curve: PTX vs. no PTX at 28 days.
TABLE 40 Cost-effectiveness sensitivity analysis with the most costly 10% of patients removed from each arm
Parameter AO (n= 246) AB (n= 244) OB (n= 245) OO (n= 245)
Mean costs, £ (SD) 2898 (1789) 3253 (2049) 3624 (2265) 3924 (2299)
Incremental cost/patient vs. AO N/A 355 726 1026
Probability of survival at 28 daysa 0.890 0.849 0.818 0.791
Incremental survival vs. AO N/A –0.041 –0.072 –0.099
Incremental cost/survival vs. AO Dominant Dominated Dominated Dominated
A, prednisolone; B, PTX; N/A, not applicable; O, placebo; SD, standard deviation.
a Patients whose status at 28 days was ‘unknown’ were excluded from this analysis.
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We conducted extreme sensitivity analyses around the costs of most concern. We initially removed these
costs completely from our analysis and then we doubled the cost of these procedures in our analysis. Both
extreme analyses did not affect the overall results from our primary analysis; prednisolone was still the
most cost-effective treatment option.
Model-based analysis
Our model was used to estimate the cost-effectiveness of the treatment arms over a 1-year period and
over a patient’s lifetime. The following section presents details on the methods we adopted, our results
and our sensitivity analysis.
Methods
As previously mentioned (see Methods overview) we used a Markov model to estimate the relative
cost-effectiveness of each of the four treatment arms over 1 year and over the patient’s lifetime time
horizon. A daily cycle length was adopted as this patient group has a high mortality rate. The parameters
used in the model were: cost of the treatment medications as our initial cost for each treatment arm;
average total cost per day, if alive, of management; average utility per day if alive; and probability of
mortality per day. By definition, both daily cost and utility were taken as 0 if the individual was dead.
The daily management cost per treatment arm incorporated: initial admission, ICU admission, discharge
procedures, adverse events, liver biopsy, alcohol counselling, laboratory test, renal failure support, liver
transplant, nutritional support and resource use at 90 days. The methods to determine these costs are
described in Methods. After we estimated the total average resource use cost per treatment arm over
90 days we estimated the daily total average cost per treatment arm by dividing this figure by 90.
We then estimated the average utility per day by treatment arm for people alive on a given day. The utility score
for someone who had died was taken as 0. To calculate the utility score by treatment arm per day we used the
data reported in Table 35 and assumed that the baseline utility was –0.402. This value was chosen to represent
the health state of patients with AH when they are admitted to hospital and enter the study. However, if a
patient was discharged within 10 days we used the discharge utility score as the baseline score; this was to
prevent us overestimating the treatment effect. This assumption was explored in a sensitivity analysis.
To estimate the utility score assigned to each day we first estimated the quality-adjusted life-days (QALDs)
over the first 90 days of follow-up. This was accomplished using the trapezoid method.
QALDs = (EQ5Dbaseline × days to discharge) + f½(EQ5Ddischarge−EQ5Dbaseline)=2
×days to dischargeg + ½(EQ5Ddischarge × (90−days to discharge)
+f½(EQ5D90 day−EQ5Ddischarge)=2 × (90−days to discharge)g. (3)
To give an average utility score for the 90 days of follow-up, QALDs were then divided by 90. This value
was used in the economic model as the utility score assigned for each day spent alive.
A small number of participants (< 1%) had their discharge utility score collected after 90 days, which was
excluded from our analysis. This allowed us to maintain consistency with the assumptions made when
estimating costs over 90 days. If a participant had a later discharge (i.e. later than 90 days) we assumed
that this was ‘missing’ and used the multiple imputation method to estimate their utility score. We also
reduced their length of discharge to 89 days for our QALD calculation so there was a difference of 1 day
and preventing their utility score being multiplied by 0.
The probability of mortality on a daily cycle was estimated using the patients’ status at 1 year. We used
information only on the participants that we had information for at 1 year. If the participant’s status
was unknown (i.e. late randomisation or lost to follow-up), he/she was excluded from this calculation.
We estimated the probability of mortality at 1 year on those who died, divided by the total number of
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patients with their status available at 1 year. This probability was converted into a rate, and this rate was
converted into a daily probability of mortality for each treatment arm using the following method:
[(1+ rate) (1/365)+1]. We assumed the patients without a 1-year status would have the same probability of
dying. We also included the annual probability of all-cause mortality and this was converted into a daily
rate using the same methods as described above.
Figure 15 is an illustration of the model structure used to estimate 1-year results and extrapolate the trial
results, and Table 41 reports the parameters used in our model.
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FIGURE 15 Economic model.
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The initial cost for each treatment arm is the cost of the initial medications. The distributions for
incremental costs were estimated using a gamma distribution using the mean and variance to estimate the
variables needed to define the gamma distribution. The incremental utility distributions were estimated
using a beta distribution (again the mean and variance were used to estimate the parameters needed to
define the shape of the beta distribution). The distribution of the daily probability of death owing to AH
was estimated based on the number of people dying in each arm on a daily basis. Of note in this analysis
is that the choice of parameter values is conservative for prednisolone alone with respect to mortality
in particular.
Sensitivity analysis
For the model-based analysis, probabilistic sensitivity analysis (PSA) was conducted on our modelled results
using the Monte Carlo simulation. This allowed us to vary all of our parameters simultaneously to
determine what effect this had on the overprobability of one treatment being cost-effective relative to the
others. Distributions for each model parameter, along with the information to define those distributions,
TABLE 41 Parameters used in the economic model
Parameters OO AO OB AB
Daily probability of dying
from AH
0.00162 0.00171 0.00168 0.00162
Daily probability of dying
from all causesa
0.000007–0.000961 0.000007–0.000961 0.000007–0.000961 0.000007–0.000961
Initial cost (£) 0.00 10.48 18.10 28.58
Incremental cost per day
spent alive, £ (SD)
95 (133) 80 (91) 78 (67) 80 (91)
Initial utility score –0.402 –0.402 –0.402 –0.402
Incremental utility score for
each day alive (SD)
0.3476 (0.3089) 0.3551 (0.2980) 0.2700 (0.3235) 0.3477 (0.2969)
Distribution form for costs Gamma Gamma Gamma Gamma
Distributions for cost/day –
alpha
0.51020 0.77285 1.35531 1.46924
Distributions for cost/day –
lambda
0.00537 0.00966 0.01737 0.01836
Distribution form for utilities Beta Beta Beta Beta
Distributions for utilities –
alpha
0.47851 0.56062 0.23851 0.54692
Distributions for utilities –
beta
0.89810 1.01814 0.64487 1.02604
Distribution form for daily
probability of dying
from AH
Beta Beta Beta Beta
Distribution for daily
probability of dying from
AH – alpha
0.44064 0.46854 0.45864 0.44064
Distribution for daily
probability of dying from
AH – beta
272 274 273 272
A, prednisolone; B, PTX; O, placebo.
a The range of the daily probability of all-cause mortality is estimated based on the assumption that the cohort has a
starting age of 48 years and the daily rate changes on an annual basis until the cohort reach the age of 100 years or die.
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are presented in Table 41. The results of this analysis are presented in a similar fashion to those from the
within-trial bootstrapped analysis. For the model-based analysis for up to 1-year follow-up, discounting
was not to be carried out.
Deterministic sensitivity analysis was carried out to test for the effect of our assumptions and variability,
such as an exploration of alternative unit costs applied to the different resources used and the number of
visits a participant had with a counsellor. We chose to conduct the deterministic sensitivity analysis as part
of our model-based analysis because, in addition to the assumptions made in our base-case analysis,
we also made assumptions with regard to costs estimated over the 90-day period. By conducting this
analysis as part of the model analysis we can capture all of these assumptions and make amendments in
one analysis.
Modelling results
The Markov model was run for 365 cycles in the first instance to present the results for the 1-year analysis.
In this analysis, QALDs, as predicted by the model, have been converted into QALYs by dividing by 365.
The least costly and least effective option is PTX alone (Table 42). The next least costly option is
prednisolone alone, which is associated with an incremental cost per QALY gained of £6924 compared
with PTX alone. No treatment and PTX treatment are, on average, less effective and more costly than
combination treatment (PTX and prednisolone) and unlikely to be cost-effectiveness compared with
prednisolone alone.
Table 43 reports the undiscounted incremental cost-effectiveness over a 10-year horizon (which, given
mortality rates, is equivalent to a lifetime time horizon). In this analysis, PTX alone is the least costly and
least effective intervention, which is consistent with the lower daily cost assumed for this intervention.
Dual treatment is dominated by prednisolone only as it is more costly on average and less effective.
Prednisolone only has an ICER of £2867 so would be considered cost-effective compared with PTX only.
No treatment is unlikely to be considered worthwhile. This analysis represents an extreme sensitivity
TABLE 42 Analysis at 1 year comparing the four possible treatment arms
Intervention Cost, £ Incremental cost, £ QALYs Incremental QALYs
Incremental cost per
QALY gained (ICER), £
OB 21,223 – 0.200 – –
AO 21,653 430 0.2621 0.0621 6924
AB 21,992 339 0.2604 –0.0017 Dominated by AO
OO 26,082 4429 0.2604 0.00 Dominated by AO
A, prednisolone; B, PTX; O, placebo.
TABLE 43 Lifetime (10-year) Markov results: undiscounted
Intervention Cost, £ Incremental cost, £ QALYs Incremental QALYs
Incremental cost per
QALY gained, £ (ICER)
OB 46,136 – 0.4375 – –
AO 46,503 367 0.5655 0.128 2867
OO 58,232 11729 0.5837 0.0182 644,451
1AB 46,644 –11588 0.5554 –0.0283 Dominated by AO
A, prednisolone; B, PTX; O, placebo.
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analysis representing a scenario when prednisolone alone might be cost-effective. Table 44 reports a
similar analysis but this time both costs and QALYs are discounted at the recommended 3.5% rate.
The findings of this analysis are similar. In this case, standard treatment is dominated by dual treatment.
This is because the standard treatment group have a marginally higher probability of survival but when
the additional QALYs gained over a longer period of time are discounted, the average QALY gain for that
treatment arm is lower than prednisolone only. Despite dual treatment not being dominated it would be
highly unlikely to be considered cost-effective when compared with prednisolone only. What these two
analyses illustrate is that relatively small differences in mortality, should they exist, could change conclusions
about cost-effectiveness when a lifetime time horizon has been taken. Overall, prednisolone only appears
to be the most favourable treatment option but caution needs to be taken interpreting these results.
Sensitivity analysis
As noted in the previous paragraph a PSA was conducted on our model parameters. The results of this
analysis at both 1 year and a lifetime were very similar in that the likelihood of any one treatment being
considered cost-effective was very similar (Figures 16 and 17). This reflects the considerable imprecision
surrounding estimates used within the model and again represents a cautious interpretation of the evidence
available. Taken together, the results of the deterministic and probabilistic economic evaluation would
suggest that treatment with prednisolone alone is a promising treatment but there is insufficient economic
evidence to be conclusive.
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FIGURE 16 One-year cycle PSA results.
TABLE 44 Lifetime (10-year) Markov results: discounted
Intervention Cost, £ Incremental cost, £ QALYs Incremental effect
Incremental cost per
QALY gained, £ (ICER)
OB 42,899 – 0.4068 – –
AO 43,275 376 0.5263 0.1195 3146
AB 45,517 2242 0.5420 0.0157 142,803
OO 54,052 8535 0.5418 –0.0002 Dominated by AB
A, prednisolone; B, PTX; O, placebo.
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We conducted a deterministic sensitivity analysis around some of the assumptions previously mentioned in
the chapter that were used to estimate the average daily cost for each treatment option. In this analysis we
assumed that all additional hospital admissions outside of the initial treatment phase (28 days) were in
ICU. We used multiple imputations to estimate all missing utility values at discharge and 90 days. Table 45
presents the updated parameters that were used in our model and the results at 1 year after these
changes were made. The key cost driver in this analysis was the cost of ICU admissions. This cost alone
undermined any of the cost savings made by changing all of our other assumptions. In this analysis,
despite producing similar results to our 1-year analysis, PTX alone would not be considered cost-effective
because of the higher ICER (£85,427) associated with it, owing to the increase in costs. If patients with AH
are treated in an ICU setting compared with a general ward, consideration needs to be taken on the effect
this will have on overall cost-effectiveness of prednisolone.
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FIGURE 17 Lifetime (10-year) cycle PSA results.
TABLE 45 Deterministic sensitivity analysis with 1-year Markov results
Parameter OB AO AB OO
Average daily cost, £ (SD) 349 (308) 360 (344) 373 (345) 407 (372)
Average daily utility score (SD) 0.2911 (0.2925) 0.3283 (0.2830) 0.3278 (0.2713) 0.3177 (0.2991)
Total average costs at 1 year, £ 94,897 97,400 102,435 111,741
Incremental cost difference at 1 year, £ N/A 2503 5034 9306
Total average QALY score at 1 year 0.2129 0.2422 0.2455 0.2379
Incremental QALY difference at 1 year N/A 0.0293 0.0033 –0.0077
Incremental cost/QALY at 1 year, £ – 85,427 1,525,455 Dominated by
AO and AB
A, prednisolone; B, PTX; N/A, not applicable; O, placebo.
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Summary
This chapter has reported both a preference elicitation exercise based on a SG experiment and an
economic evaluation. The aim was to estimate the QoL associated with the three Child–Pugh classifications
(A, B and C). Given the severity of the disease, relatively fewer people with Child–Pugh C were able to
complete the SG. The results of the analysis were in line with expectations in that higher utilities were
recorded for those in less severe health states compared with more severe states. Convergent validity was
tested by examining valuations of an individual’s own health today, as measured by the SG and EQ-5D.
These values were not significantly different, suggesting high levels of convergent validity between the two
measures values. These results hold for the full sample analysis and subsample analyses.
With respect to the economic evaluation, both within-trial and model-based economic evaluations were
conducted. The economic evaluation itself was complicated both by the nature and extent of the data that
needed to be considered, and more specifically the truncated follow-up of a substantial proportion of the
trial participants. The consequence of this truncated follow-up was that several of the pre-planned analyses
were not sensible to conduct given the very large quantities of missing data that existed. Nevertheless,
both a cost-effectiveness and a cost–utility analysis were conducted. The former was conducted as part of
a within-trial-based analysis and the latter as part of an economic model. It should be noted that because
of decisions made about the choice of parameter values used in the model, the model-based evaluation
is highly conservative against the prednisolone alone treatment strategy. Overall, the results of the
within-trial analysis suggest that prednisolone might be considered cost-effective compared with the other
treatment options. The deterministic model-based cost–utility analysis results at a 1-year time horizon
support this. However, under conservative assumptions these results did not hold over the estimated
lifetime of patients in the PSA. These and the results of an accompanying PSA suggest that there is
considerable uncertainty remaining over long-term cost-effectiveness and that, while apparently promising,
treatment conclusions about the use of prednisolone alone in the longer term remain inconclusive.
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Chapter 6 Discussion and conclusions
Summary of findings
Therapeutic effects
Although the trial results show that prednisolone at a dose of 40mg daily for 28 days reduces the mortality
at 1 month of severe AH by approximately 30% (odds ratio 0.72, 95% CI 0.52 to 1.01; p= 0.056), this fails
to reach the conventional threshold for statistical significance. In multivariate analyses, which allow small
variations in baseline variables to be taken into account, the beneficial effects of prednisolone are much
clearer (odds ratio 0.609, 95% CI 0.409 to 0.909; p= 0.015). Although the sample size is not powered for a
multivariate logistic regression analysis, the adjusted odds ratio provides a more precise estimate of the
treatment effect. Taken together with previous studies, summarised in Mathurin’s meta-analysis,17 it is
reasonable to conclude that prednisolone does have a therapeutic benefit up to 28 days. However, after
28 days the survival curves for prednisolone-treated and prednisolone-untreated patients converge, and at
90 days and 1 year there are no survival benefits to receiving steroids. Survival beyond 28 days may be
influenced by adverse events related to steroid use (see Adverse events) or, alternatively, may be influenced
by other factors and, in particular, recidivism. We were able to show a major effect of recidivism at 90 days
or mortality at 1 year, but do not have the data to demonstrate an effect at earlier time points.
Pentoxifylline has no impact on the mortality at 28 days, 90 days or 1 year. In previous studies,18 PTX has
conferred survival benefit through protection of renal function because of acute kidney injury. In this trial
the rate of acute kidney injury was low, so although there was numerically fewer acute kidney injuries
in the PTX-treated patients this failed to reach statistical significance. The combination of prednisolone with
PTX had no effect on patients’ survival at 28 days, 90 days or 1 year. Without being able to demonstrate
an effect on survival or acute kidney injury it is difficult to claim any therapeutic benefit for PTX.
Adverse events
Prednisolone, as expected, was associated with an increased risk of infection, with 13% of patients
experiencing an infection-related SAE in the prednisolone group compared with 7% in the control group.
Approximately 35% of infection-related SAEs resulted in mortality but this proportion did not differ
between treatment groups. The higher risk of an infection-related SAE continued in the prednisolone
group after the 28 days but by 90 days the risk was equivalent, irrespective of the treatment arm. Infection
is therefore likely to have accounted for the excess deaths after 28 days in the prednisolone-treated group
that caused the convergence of the mortality curves. However, it is difficult to be sure that infection is the
key cause of death in this group of patients, when mortality is usually associated with multiorgan failure.
Drawing on previous studies12 as well as results from the STOPAH trial, it is possible to conclude that
patients who fail to respond to steroids after 7 days, defined by a Lille score of > 0.45, may not benefit
from further treatment and, therefore, steroids should be stopped to avoid further risk of infection.
This is coherent with current European Association for Study of the Liver (EASL) guidelines.53
Although PTX has previously been reported to protect against hepatorenal syndrome or acute kidney injury
in patients with AH, this benefit could not be confirmed in the STOPAH trial as only 1.5% of patients in
the PTX-treated group and 2.5% in the controls experienced acute kidney injury.
Prognostic scores
The three prognostic scores based on baseline clinical and laboratory variables did not perform well for the
prediction of mortality at 28 days, with deteriorating performance for mortality at 90 days and 1 year.
None of the scores gave area under the ROC curve > 0.75. The scores do not inform physicians on the likely
response to prednisolone and, therefore, how to select patients who would benefit from the intervention.
At present, no scoring system assesses the risk of infection, which would be helpful in initial treatment selection.
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The 2011 trial of early liver transplantation for patients with AH relied on the Lille score to identify
prospective candidates.54 However, the data in the STOPAH trial suggest that patients with an adverse Lille
score (> 0.45) have an expected survival of around 50% compared with the 25% in the original study.
This rate of survival without transplantation does not justify the use of scarce donor organs, meaning that
a new system for selecting transplant candidates should be considered.
Health economics
The health economic component of this study comprised two elements: a preference elicitation exercise
using a SG experiment and an economic evaluation.
The preference elicitation component measured QoL directly using the SG, and indirectly using the
EQ-5D-3L. The aim was to collect information on the health state valuation of Child–Pugh classification A,
B and C. The results of the SG showed good face validity, with the Child–Pugh classification A health state
being preferred to Child–Pugh classification B health state, and the Child–Pugh classification B health
state being preferred the Child–Pugh classification C. The analysis also suggested high levels of convergent
validity with the EQ-5D-3L responses.
These data would be useful for future studies exploring the cost-effectiveness of other treatments for
alcoholic cirrhosis.
With respect to the economic evaluation, both prednisolone and PTX are very low-cost medications but the
costs of managing AH within the UK NHS are high. Furthermore, the trial addressed the possibility that one
or other, or indeed both, treatments may help alleviate some of the considerable morbidity and early
morbidity associated with the condition. Given the profile of the condition it was plausible, however, that a
more effective treatment might not be cost-saving simply because those who survive longer may need
considerable further costly care. The economic evaluation was expressly designed to explore these trade-offs.
At 28 days, the total average cost of treatment varied between £3618 per patient (prednisolone only) to
£4869 per patient (placebo patients). On average, in a within-the-table analysis, which compares all
four arms, prednisolone only was the least costly treatment and slightly less effective than dual treatment.
However, prednisolone was most likely to be considered cost-effective over the range of values considered
for society’s willingness to pay for an extra survivor. Much stronger results in favour of prednisolone were
found in the at-the-margins analysis, when prednisolone was compared with no prednisolone. PTX was
unlikely to be considered cost-effective, except in the at-the-margins analysis comparing PTX vs. no PTX,
when PTX was most likely to be considered cost-effective, primarily because the estimates of effects were
slightly in its favour (see Figure 14).
In terms of the incremental cost per QALY, the results tended again to favour the use of prednisolone.
However, in this case any conclusions would be tentative because the assumptions made in the model around
survival worked slightly against prednisolone and also there were very limited data available up to 1 year.
Strengths and weaknesses of the study
The STOPAH trial had a number of strengths; primarily the size of the study, which gave the trial adequate
power to detect even a relatively modest treatment effect. Furthermore, the speed at which the trial
recruited ensured that there were no significant changes in clinical practice during the study period, which
might have influenced background rates of mortality. Clinical practice guideline developers have a
preference for trials conducted at multiple sites rather than those focused on single centres. In this respect,
the STOPAH trial excelled, having recruited in 65 sites across the UK. This ensured that recruitment took
place in many district general hospitals as well as in liver units and teaching hospitals. In the UK, severe AH
is not routinely an indication for transfer to tertiary centres and it is, therefore, important to have assessed
the impact of treatment in the type of environment where the condition is usually treated.
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The STOPAH trial was deliberately designed as a pragmatic clinical trial with broad inclusion criteria. Other
trials in this field22,55 have required liver biopsy and histological confirmation of the diagnosis prior to
inclusion; however, in the UK, the USA and much of Europe, liver biopsy is rarely performed for diagnostic
confirmation and reserved only for diagnostic uncertainty. This strategy is vindicated by a number of
studies22,55–57 that show that clinicians can accurately judge the diagnosis by the recent use of alcohol and
also applying of strict criteria on the duration of jaundice. A trial requiring liver biopsy could not have
recruited this number of subjects, as many centres do not have access to the transjugular technique that
would be required in this group of patients or would have considered the procedure to be unethical.
Although the trial design allowed for the recruitment of patients with GI bleeding, sepsis and renal failure,
once these conditions had been stabilised, the number of patients with these conditions was relatively
small. Nevertheless, the results show no differences in the mortality rates or in the response to treatment in
these patients. This finding should be used to ensure these patients are not excluded from future studies.
Reporting on the rate at which patients completed at least 75% of prescribed medication was required in
order to define a ‘per-protocol’ population. Unfortunately, this issue was not reported well and was
probably impaired after patients were discharged from hospital. It is well recognised that this group of
patients is poorly adherent with follow-up procedures and reporting.
The SG exercise represents one of the very largest studies of its kind conducted in this area to date. It was
based on best practice methods and benefited from being conducted alongside the STOPAH trial. The
original aim of the SG was to estimate health-state valuations for those with cirrhosis owing to alcoholic
liver disease and cirrhosis owing to viral hepatitis. Unfortunately, only 50% of the targeted recruitment
was reached for viral hepatitis, thus limiting the applicability of findings to this group. Furthermore, the
majority of participants (58%) had the mildest form of liver cirrhosis and some of the participants with
Child–Pugh classification C found the SG difficult to complete or had limited ability to give informed
consent. Taken together, valuation of the Child–Pugh classification C health state is subject to some
uncertainty, as there were relatively few people with Child–Pugh classification C able to provide valuations.
The economic evaluation greatly benefited from being embedded in a rigorously conducted randomised
controlled trial in which considerable efforts were made to collect all relevant data. These data were
combined within an economic evaluation that followed explicit and rigorous methodology. Nevertheless,
the economic evaluation was not without its challenges. Among these was the decision to curtail patient
follow-up in order to maximise patient recruitment and sample size for the primary trial end point. This
decision required careful consideration of the relative importance of effectiveness, safety and economic to
all stakeholders. For the economic evaluation, the consequence of this decision was that not all the
pre-planned analyses were conducted. This is because longer-term data up to 1 year was not available.
This limitation was overcome in part by performing the economic evaluation on costs and survival at
28 days and attempting to model the incremental cost per QALY over 1 year and a patient’s lifetime. The
results of all these analyses are supportive of the use of prednisolone, but because of the limited long-term
data, from an economic perspective, conclusions can only be tentative. However, taking the totality of
evidence from the trial, of which the economics is only one part, the findings suggest the use of
prednisolone reduces short-term mortality and that a decision-maker needs to form a judgement whether
or not the suggested evidence on cost-effectiveness is sufficient.
Comparison with results of other studies
Mortality rates in AH have dropped since 1990. One can speculate that two factors have resulted in this
change: (1) patients with severe liver injury are being looked after more effectively now than when the
placebo-controlled trials were conducted 30 years ago, and (2) the patients with severe AH are not as
nutritionally compromised as those that were treated 30 years ago.
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The mortality rates in the STOPAH trial appear to be substantially lower than those reported in earlier
studies.14,15,17,58,59 It should be recalled that the placebo-controlled trials in severe AH were mainly conducted
between 1971 and 1990, and when the treatment of hepatic failure, renal failure and sepsis were
substantially less effective than they are today. The overall mortality in the STOPAH trial was 16% at
28 days, with 17% mortality in the placebo group and 14% mortality in the prednisolone only group. This is
entirely in keeping with other studies. Similar mortality at 28–30 days in steroid-treated patients were found
in other studies. Park et al.27 found a 12% mortality rate, Mathurin et al.23 found around a 12% rate and
Nguyen-Khac et al.31 found a 15% rate. In recent times there have been few placebo-controlled studies.
However, mortality in the Akriviadis et al.18 study was around 20% and in Boetticher et al.60 was 22%.
The mortality is clearly different from some older studies such as Ramond et al.,14 who found 38% mortality.
The power calculation for the STOPAH trial was based on an average mortality rate of 35% in placebo-treated
control subjects, whereas the observed mortality rate in placebo-treated subjects was actually 16.7%.
Inevitably this will mean that future studies should use STOPAH trial mortality figures for power calculations.
In Mathurin’s meta-analysis of placebo-controlled trials in patients with a DF ≥ 32, the hazard ratio for
survival in the prednisolone-treated group was 0.43 (95% CI 0.27 to 0.7) compared with controls.17
However, in these studies the mortality rate in the placebo arms was 34.3% compared with the 16.7%
in the STOPAH trial. Nevertheless it should be noted that when patients with outlying (absolute
standardised residual > 2) laboratory values are filtered out from the STOPAH data set, the odds ratio for
mortality in the prednisolone-treated group was 0.427 (95% CI 0.253 to 0.721; p= 0.001). It is therefore
likely that the magnitude of the steroid effect is highly comparable.
In view of the lower mortality figures, we compared the highly objective laboratory results with those
reported in previous trials. In the STOPAH trial, the levels of creatinine were slightly lower than those seen
in the Nguyen-Khac et al.31 study but PTs, bilirubin, MELD and DF scores were highly comparable.
The Lille score, which includes a component based on response to treatment, also performed poorly even
when the analysis was restricted to those patients who had received prednisolone treatment. A Lille score
of > 0.45 has been used to select patients who might be candidates for early liver transplantation.54
However, in this study approximately 50% of patients with this adverse Lille score survived to 1 year,
indicating that it would be a poor criterion for transplant selection.
The incidence of renal failure and infection observed in the STOPAH patients appeared to be lower than
that reported in other studies.61 This may be partially accounted for through a lack of comprehensive
reporting. No other systematic issue has been identified to explain the lower incidence of these
complications. However, it should be noted that the STOPAH trial was conducted in all types of hospital
and therefore did not suffer from the potential bias of a tertiary referral centre population.
Implications for services and future research
Prednisolone is already indicated for the treatment of severe AH in the guidelines published by the American
Association for the Study of Liver Diseases and EASL.62 Based on the STOPAH trial results, prednisolone may
now be considered as the standard of care in patients with AH and a DF ≥ 32; however, the temporary
nature of the benefit needs to be emphasised and steps taken to minimise the risk of infection.
As one of the major drawbacks to steroids, highlighted in this study as well as previous trials,63 is the
increased susceptibility to potentially fatal sepsis, future research should focus on strategies to reduce this risk.
In patients who do not respond to prednisolone (no fall in bilirubin after 1 week of treatment) steroids should
be stopped as indicated currently in the EASL guidelines. However, the optimal duration of steroid treatment
has not been adequately explored and consideration should be given to shorter courses such as 14 days.
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A second strategy to reduce infection would be to use N-acetylcysteine (NAC) alongside steroids. This is
based on the observation of lower rates of sepsis in the Nguyen-Khac et al. trial,31 which compared
steroids alone against steroids plus NAC. In the Nguyen-Khac et al. trial,31 mortality at 28 days was 24% in
the steroid only group compared with 8% in the steroid plus NAC-treated group and infection rates were
25% versus 12%, respectively. NAC appears to have a therapeutic benefit on immune function, which has
not yet been explained.31 An alternative strategy is to combine the use of steroids with granulocyte colony
stimulating factor, which has previously been evaluated in a small recently published trial.64
The STOPAH trial results do not demonstrate any benefit from the use of PTX in severe AH. The low
incidence of acute kidney injury in the STOPAH trial prevents a definitive conclusion being drawn on the
ability of PTX to prevent hepatorenal syndrome. Nevertheless, any renal benefit must be considered as a
secondary outcome compared with reduction of mortality.
Despite improvements in short-term (28-day) mortality in patients treated for severe AH, there is still a
relentless loss of patients after the initial admission, owing to alcoholic liver disease. The majority of
patients admitted with AH already have underlying liver cirrhosis and the observed mortality appears to
relate to complications arising from this condition. It is already well recognised that abstinence from
alcohol has a major impact on survival in patients with alcohol-related cirrhosis59 and the data in the
STOPAH trial confirm that abstinence at 90 days strongly influences survival at 1 year. Nevertheless, the
rates of complete abstinence in this cohort are relatively low. Future studies should concentrate on
strategies to promote abstinence post admission. Linking patients into consultant-led addiction services
while in hospital has been recommended in the National Confidential Enquiry into Patient Outcomes and
Death report on ALD but has not been widely implemented.63 Research is required to evaluate whether or
not a full implementation of the National Confidential Enquiry into Patient Outcomes and Death
recommendations would improve the outcomes of patients with AH or other ALD.
The use of anticraving medication to promote abstinence is sparse, despite clinical trial evidence of
benefit.65 Increased commissioning of alcohol addiction services in acute hospitals providing care for
patients with ALD will be required to maximise the opportunity for patients to maintain abstinence after an
admission for severe AH. In addition, we recommend a trial of anticraving medication to evaluate the
impact on mortality and hospital readmission rates.
The STOPAH trial results found that the existing prognostic scoring systems are weak. Clinical management
including the selection of patients for liver transplantation require more informative prognostic systems.
The use of metabonomic, genomic and cytokine profiling methods needs to be evaluated in this
population of patients.
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Appendix 1 Prognostic score formula
Discriminant function
DF = 4:6 × (prothrombin time (PTPATIENT  PTCONTROL) + serum bilirubin (µmol=l)=17:1: (4)
(PTCONTROL is defined as the mean value at each centre; this mean value may be updated on a weekly or
monthly basis.)
TABLE 46 Glasgow Alcoholic Hepatitis Score
Parameter 1 2 3
Age (years) < 50 ≥ 50 –
WBC (× 109) < 15 ≥ 15 –
Urea (mmol) < 5 ≥ 5 –
Prothrombin ratio < 1.5 1.5–2.0 > 2.0
Bilirubin (µmol) < 125 125–250 > 250
Lille score
Lille score = 3:19 − 0:101 × (age in years) + 0:147 × (albumin day 0 in g=l) + 0:0165
×(evolution in bilirubin level in µmol) −0:206 × (renal insufficiency) −0:0065
×(bilirubin day 0 in µm) − 0:0096 × (prothrombin time in seconds): (5)
Model for end-stage liver disease score
MELD = 9:57 × Ln (creatinine) + 3:78 × Ln(bilirubin) + 11:2 × Ln(INR) + 6:43: (6)
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Appendix 2 Substudies
Central pathology review
In patients with AH, liver biopsy is rarely performed in routine clinical practice as strict application of clinical
criteria accurately define the condition in the majority of cases. Nevertheless, some units routinely practice
liver biopsy for confirmation and a number of biopsies are performed owing to diagnostic uncertainty
when an alternative diagnosis may be implicated. In many clinical trials, liver biopsy confirmed diagnosis of
AH has been an inclusion criterion. The STOPAH trial used a clinical (rather than histological) diagnosis as
an inclusion criterion. We therefore sought to validate the clinical criterion by auditing the histology
diagnoses on those cases for which routine liver biopsy had been performed.
Two experienced pathologists (Professor Robert Goldin and Professor Alberto Quaglia) sent liver histology
sections for central review. In total, 200 liver biopsies were received, including 120 that had been
performed as part of routine clinical practice and 80 that had been performed for diagnostic uncertainty.
All biopsies were scored for the following characteristics:
l quality of biopsy
l fibrosis
l steatosis
l inflammation
l hepatocyte damage
l bilirubinostasis
l megamitochondria
l miscellaneous findings, for example iron, dysplasia, malignancy
l advanced/not advanced cirrhosis
l active/not very active
l consistent/not consistent with alcohol
l biopsy diagnostic of alcoholic steatohepatitis.
Among biopsies performed as routine clinical practice, the diagnosis of AH was confirmed in 95% of
cases. Other diagnoses included advanced cirrhosis without hepatitis, drug-induced liver injury and a case
of hepatocellular carcinoma.
This review confirmed that a clinical diagnosis of AH is accurate in the majority of cases. A publication
describing these findings and evaluating the ability of histological characteristics to predict the outcome
and prognosis will be submitted for publication in December 2014.66
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Serum samples
Serum samples were collected from all patients enrolled in the STOPAH trial. The serum was processed
from clotted venous blood samples at each centre and stored at –80 °C and transferred to the Health
Technology Assessment (HTA)-licensed biobank at Imperial College. The TMG gave approval for the serum
to be used in two studies:
1. An analysis of metabolomic biomarkers using 1H-magnetic resonance spectroscopy and ultra
high-performance liquid chromatography coupled to mass spectrometry. These analyses will seek
metabolite or metabolic profiles that correlate with prognosis and outcome of treatment. In addition,
serum samples from a group of patients with decompensated cirrhosis will be used as comparators to
identify novel biomarkers for use in distinguishing AH from decompensated cirrhosis.
2. Serum samples taken from patients who underwent liver biopsy during the trial will be used to identify
serum markers of liver fibrosis in the Nottingham University Hospitals NHS Trust and National Institute
for Health Research Biomedical Research Unit.
Genetic susceptibility in alcoholic hepatitis
Investigators were asked to collect 5ml of ethylenediaminetetraacetic acid whole blood from all consenting
STOPAH patients. These samples were transported to Imperial College and stored in the HTA-licensed
biobank. Genomic deoxyribonucleic acid (DNA) was extracted from 325 samples and sent for whole exome
single nucleotide polymorphism genotyping at the Sanger Centre in Cambridge. The same number of DNA
samples from a control group of patients with alcohol use disorders who did not have any history or
laboratory evidence of liver disease were also sent for genotyping and a genome-wide association study
was conducted after quality control procedures. Evidence of genetic association at a threshold of p< 10–5
has been identified at a number of loci. DNA from the remaining patients and an additional cohort of
controls is now being used in genotyping assays focused on candidate loci to replicate the associations.
Monocyte analysis
As demonstrated in the STOPAH study, as well as previous trials in AH,63 patients with this condition are
highly susceptible to infection, which is associated with higher rates of mortality. Previous work by
Dr Antoniades and Professor Thursz67–69 has demonstrated a defect in the function of circulating
monocytes in acute liver failure, suggesting that a similar problem may explain infection susceptibility
among patients with AH. Peripheral blood samples collected from patients in the STOPAH trial were used
to phenotype and functionally characterise the circulating monocyte population. To date, it has been
discovered that monocytes in AH are capable of phagocytosing bacteria, but they are unable to produce
the respiratory burst in the lysosomal compartments that are necessary to kill ingested organisms. The
oxidative burst defect was most pronounced in those patients who went on to develop infection. Further
investigations are under way to identify the molecular basis of the oxidative burst defect and to find
therapeutic interventions to improve monocyte function.
Past medication analysis
It is not known what triggers AH in heavy drinkers. One supposition is that specific drugs may either
precipitate or be protective of acute injury. Thirteen STOPAH sites were open to enter patients into the
STOPAH trial and the GP substudy; however, participation in this substudy was not compulsory. It involved
gaining an electronic download of all medications prescribed in the last year from the patient’s GP. Owing
to a poor response, it was decided by the TMG on 4 February 2013 that the substudy should not continue.
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Appendix 3 Sensitivity analysis of the primary
outcome
TABLE 47 Observed 28-day mortality (sensitivity analysis)a
PTX
No Yes Total
Prednisolone
No 16.0% (39/244) (placebo/placebo) 19.6% (45/230) (placebo/PTX) 17.7% (84/474)
Yes 14.3% (34/237) (prednisolone/placebo) 12.7% (29/228) (prednisolone/PTX) 13.5% (63/465)
Total 15.2% (73/481) 16.2% (74/458) 15.7% (147/939)
a Includes all randomised patients who have at least 28 days of data or died prior to or on day 28 excluding any patients
who were randomised and followed up but were later found to be ineligible.
TABLE 48 Logistic regression analysis for 28-day mortality (sensitivity analysis)a
Prednisolone
(n= 465)
No prednisolone
(n= 474) PTX (n= 458) No PTX (n= 481)
28-day mortality,% (n/N) 13.5% (63/465) 17.7% (84/474) 16.2% (74/458) 15.2% (73/481)
Adjusted odds ratiob (95% CI) 0.71 (0.50 to 1.02) 1.08 (0.76 to 1.54)
p-value 0.065 0.666
a Includes all randomised patients who have at least 28 days of data or died prior to or on Day 28 excluding any patients
who were randomised and followed up but were later found to be ineligible.
b Adjusted for true risk at baseline and factorial design.
Notes
Odds ratios of < 1 represent a favourable outcome for the corresponding intervention.
The interaction between the interventions was investigated as a secondary analysis and was found to be non-significant at
the 5% significance level (interaction coefficient= –0.403, (95% CI –1.120 to 0.313; p-value= 0.270).
Logistic regression model: 28-day mortality= intercept+ prednisolone indicator+ PTX indicator+ risk.
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Appendix 4 Unit cost: intervention, initial
admission and adverse events costs
TABLE 49 Unit cost: intervention, initial admission and adverse events costs
Unit Cost, £ Source
Drug costs: intervention
Prednisolone 40mg× 1 daily (× 28) 10.48 CRF/BNF
PTX 400mg× 3 daily (× 28) 18.10 CRF/BNF
Inpatient costs
General ward Per night: non-elective inpatient (long stay)
excess bed-days
265 Discharge visit form/NHS tariffs
HDU Per night: critical care, one organ
supported
981 Discharge visit form/NHS tariffs
ICU Per night: critical care, three organs
supported
1617 Discharge visit form/NHS tariffs
Nutritional supplements
(1.5 kcal per ml)
Per bottle 2.06 Discharge visit form/BNF
Lab tests
Creatinine Per test 2.96 Treatment-day forms/discharge
form/visit forms/lab tests
AST Per test 2.96 Treatment-day forms/discharge
form/visit forms/lab tests
ALT Per test 2.96 Treatment-day forms/discharge
form/visit forms/lab tests
Sodium Per test 2.96 Treatment-day forms/discharge
form/visit forms/lab tests
Phosphate Per test 2.96 Treatment-day forms/discharge
form/visit forms/lab tests
Glucose Per test 2.96 Treatment-day forms/discharge
form/visit forms/lab tests
Albumin Per test 2.96 Treatment-day forms/discharge
form/visit forms/lab tests
Urea Per test 2.96 Treatment-day forms/discharge
form/visit forms/lab tests
ALP Per test 2.96 Treatment-day forms/discharge
form/visit forms/lab tests
Bilirubin Per test 2.96 Treatment-day forms/discharge
form/visit forms/lab tests
Potassium Per test 2.96 Treatment-day forms/discharge
form/visit forms/lab tests
Calcium Per test 2.96 Treatment-day forms/discharge
form/visit forms/lab tests
Total protein Per test 2.96 Treatment-day forms/discharge
form/visit forms/lab tests
continued
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TABLE 49 Unit cost: intervention, initial admission and adverse events costs (continued )
Unit Cost, £ Source
INR Per test 7.49 Treatment-day forms/discharge
form/visit forms/lab tests
FBC Per test 4.94 Treatment-day forms/discharge
form/visit forms/lab tests
PT Per test 5.34 Treatment-day forms/discharge
form/visit forms/lab tests
Discharge procedures
CT scan – one area One area no contrast 92 Discharge visit form/NHS tariffs
CT scan – two areas Two areas no contrast 111
MRI scan Discharge visit form/NHS tariffs
Endoscopy Diagnostic endoscopic upper GI tract
procedures
184.20 Discharge visit form/NHS tariffs
Colonoscopy Discharge visit form/NHS tariffs
Renal replacement Hospital haemofiltration, with access via
haemodialysis catheter
147 Discharge visit form/NHS tariffs
Other discharge procedures and adverse event procedures
Ultrasound One site (assumed less than 20 minutes) 61 Discharge visit form/adverse
event form/NHS tariffs
Ultrasound Two sites (assume greater than
20 minutes)
64 Discharge visit form/adverse
event form/NHS tariffs
Ultrasound Doppler/portal
system
Two sites (assume greater than
20 minutes)
64 Discharge visit form/adverse
event form/NHS tariffs
Echocardiogram 72 Discharge visit form/adverse
event form/NHS tariffs
Chest drain 331.80 Discharge visit form/adverse
event form/NHS tariffs
Chest X-ray Skeletal X-ray as it includes chest X-ray 31 Discharge visit form/adverse
event form/UCL provider to
provider tariffs
Spinal X-ray 43 Discharge visit Form/adverse
event form/UCL provider to
provider tariffs
Other X-ray Skeletal X-ray 31 Discharge visit form/adverse
event form/UCL provider to
provider tariffs
Sigmoidoscopy Diagnostic sigmoidoscopy 520.05 Discharge visit form/adverse
event form/NHS tariffs
MRI scan One area no contrast 165 Discharge visit form/adverse
event form/NHS tariffs
Colonoscopy Diagnostic colonoscopy 238.95 Discharge visit form/adverse
event form/NHS tariffs
Draining ascites Minor therapeutic/diagnostic general
abdominal procedures
416.35 Discharge visit form/adverse
event form/NHS tariffs
Gastroscopy Diagnostic endoscopic upper GI tract
procedures
184.20 Discharge visit form/adverse
event form/NHS tariffs
MRCP MRI scan, one area, no contrast 169 Discharge visit form/adverse
event form/NHS tariffs
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TABLE 49 Unit cost: intervention, initial admission and adverse events costs (continued )
Unit Cost, £ Source
Liver biopsy Minor endoscopic or percutaneous
hepatobiliary or pancreatic procedures
351.40 Discharge visit form/adverse
event form/NHS tariffs
TIPS procedure Intermediate endoscopic or percutaneous
hepatobiliary or pancreatic procedures
w/CC score 0–1
747.70 Discharge visit form/adverse
event form/NHS tariffs
ERCP Minor diagnostic ERCP 699.90 Discharge visit form/adverse
event form/NHS tariffs
Hepatic wedge pressure Intermediate endoscopic or percutaneous
hepatobiliary or pancreatic procedures
w/CC score 0–1
164 Discharge visit form/adverse
event form/NHS tariffs
ECG ECG monitoring and stress testing 122 Discharge visit form/adverse
event form/NHS tariffs
PICC line Liver failure disorders, with single
intervention
622.90 Discharge visit form/adverse
event form/NHS tariffs
Central line Liver failure disorders, with single
intervention
622.90 Discharge visit form/adverse
event form/NHS tariffs
Pleural tap Minor thoracic procedures 751.96 Discharge visit form/adverse
event form/NHS tariffs
Urinary tract infections Kidney or urinary tract infections, without
interventions, with CC score 0–1
329.40 Discharge visit form/adverse
event form/NHS tariffs
Blood transfusion 123 Discharge visit form/adverse
event form/www.nhsbt.nhs.uk70
Ultrasound guided aspiration 124 Discharge visit form/adverse
event form/UCL provider to
provider tariffs
Endoscopic ultrasound cost Minor therapeutic or diagnostic general
abdominal procedures
416.35 Discharge visit form/adverse
event form/NHS tariffs
Blood test Blood culture 17 Discharge visit form/adverse
event form/lab costs
Stool test Faecal test microbiology 13.20 Discharge visit form/adverse
event form/lab costs
Urine test Urine culture 8.51 Discharge visit form/adverse
event form/lab costs
Hepatitis E test 35.98 Discharge visit form/adverse
event form/lab costs
HDU Critical care: one organ supported 981 Discharge visit form/adverse
event form/NHS tariffs
ICU Critical care: three organs supported 1617 Discharge visit form/NHS tariffs
IVU Dynamic studies of urinary tract 380 Discharge visit form/adverse
event form/NHS tariffs
NG tube Nutritional disorders, with interventions 127 Discharge visit form/adverse
event form/NHS tariffs
Counselling Alcohol health worker (A&E), 55-minute
consultation
48 Discharge visit form/adverse
event form/PSSRU50
Psychological consultation Consultant-led outpatient attendances –
non-admitted face-to-face first
appointment
264 Discharge visit form/adverse
event form/NHS tariffs
continued
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TABLE 49 Unit cost: intervention, initial admission and adverse events costs (continued )
Unit Cost, £ Source
Blood test Sodium, potassium, urea, creatinine,
glucose
14.80 Discharge visit form/adverse
event form/lab costs
LFT 6.80 Discharge visit form/adverse
event form/lab costs
Blood test FBC 4.94 Discharge visit form/adverse
event form/lab costs
Oesophageal surgery
(perforation)
Complex oesophageal, stomach or
duodenum procedures, 19+ years
3713 Discharge visit form/adverse
event form/NHS tariffs
Duplex scan Ultrasound mobile scan or intraoperative
procedures, 20–40 minutes
71 Discharge visit form/adverse
event form/NHS tariffs
Dietitian consultation 45-minute consultation (assumed first visit) 23.25 Discharge visit form/adverse
event form/PSSRU50
Renal blood test Urea 2.96 Discharge visit form/adverse
event form/lab costs
Removal of tooth Surgical removal of tooth, ≥ 19 years 1580 Discharge visit form/adverse
event form/NHS tariffs
Surgical consultation Consultant-led outpatient attendances –
non-admitted face-to-face first
appointment
153 Discharge visit form/adverse
event form/NHS tariffs
Ophthalmology attendance Outpatient appointment 86 Discharge visit form/adverse
event form/NHS tariffs
Septic screen FBC, urea and electrolytes, CRP, blood
cultures, urine sample and chest X-ray
70.25 Discharge visit form/adverse
event form/NHS tariffs/lab costs
Fluid swab (ascites fluid) Wound and fluid samples – microbiology 20.33 Discharge visit form/adverse
event form/lab costs
Sputum test Sputum culture – microbiology 25.74 Discharge visit form/adverse
event form/lab costs
Haematologist consultation Consultant-led outpatient attendances –
non-admitted face-to-face first
appointment
209 Discharge visit form/adverse
event form/NHS tariffs
Immunology test (blood) Immunology autoantibodies 20.71 Discharge visit form/adverse
event form/lab costs
Alcohol test (blood test) Alcohol – whole blood – biochemistry 7.78 Discharge visit form/adverse
event form/lab costs
Neurology consultation Consultant-led outpatient attendances –
non-admitted face-to-face first
appointment
209 Discharge visit form/adverse
event form/NHS tariffs
Dermatology consultation Consultant-led outpatient attendances –
non-admitted face-to-face first
appointment
110 Discharge visit form/adverse
event form/NHS tariffs
Cystoscopy Diagnostic flexible cystoscopy, ≥ 19 years 675.45 Discharge visit form/adverse
event form/NHS tariffs
Gynaecology exam 149 Discharge visit form/adverse
event form/NHS tariffs
Spinal tap 130 Discharge visit form/adverse
event form/NHS tariffs
Vascular consultation Consultant-led outpatient attendances –
non-admitted face-to-face first
appointment
133 Discharge visit form/adverse
event form/NHS tariffs
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TABLE 49 Unit cost: intervention, initial admission and adverse events costs (continued )
Unit Cost, £ Source
Bone marrow aspirate Biopsy of bone marrow – haematology 301.50 Discharge visit form/adverse
event form/NHS tariffs
Anal procedure Major anal procedures 1219.15 Discharge visit form/adverse
event form/NHS tariffs
Eye infirmary consultation Directly accessed diagnostic services.
Non-Surgical ophthalmology, without
interventions, with CC score 0–1
110 Discharge visit form/adverse
event form/NHS tariffs
Banding of varices GI with single intervention 522 Discharge visit form/adverse
event form/NHS tariffs
Bronchial lavage Fibre optic bronchoscopy, ≥ 19 years 299.40 Discharge visit form/adverse
event form/NHS tariffs
A&E, accident and emergency; CC, complications and comorbidities; CRP, C-reactive protein; CT, computerised
tomography; ECG, electrocardiogram; ERCP, endoscopic retrograde cholangiopancreatography; HDU, high-dependency
unit; IVP, intravenous pyelogram; IVU, intravenous urogram; MRCP magnetic resonance cholangiopancreatography;
MRI, magnetic resonance imaging; NG nasogastric; PICC, peripherally inserted central catheter; PSSRU, Personal Social
Services Research Unit; TIPS, transjugular intrahepatic portosystemic shunt; UCL, University College London; w/CC, with
complications and comorbidities.
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Appendix 5 Average adverse event investigations
per treatment arm
TABLE 50 Average adverse event investigations per treatment arm
Investigations
OO AO OB AB
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Stool testa 272 0.018 (0.160) 274 0.018 (0.134) 273 0.022 (0.147) 272 0.011 (0.135)
CT scan 272 0.007 (0.086) 274 0.022 (0.170) 273 0.007 (0.085) 272 0.011 (0.105)
MRI scan 272 0.007 (0.086) 274 0.004 (0.060) 273 0.004 (0.061) 272 0.000 (0.000)
Echocardiogram 272 0.007 (0.121) 274 0.004 (0.060) 273 0.007 (0.121) 272 0.000 (0.000)
Psychological consultation 272 0.000 (0.000) 274 0.004 (0.060) 273 0.000 (0.000) 272 0.000 (0.000)
Blood test 272 0.018 (0.135) 274 0.018 (0.159) 273 0.022 (0.147) 272 0.000 (0.000)
Other X-ray 272 0.015 (0.148) 274 0.004 (0.060) 273 0.004 (0.061) 272 0.004 (0.061)
Chest X-ray 272 0.052 (0.280) 274 0.058 (0.264) 273 0.055 (0.333) 272 0.052 (0.409)
Spinal X-ray 272 0.004 (0.061) 274 0.000 (0.000) 273 0.004 (0.061) 272 0.000 (0.000)
Doppler ultrasound 272 0.000 (0.000) 274 0.007 (0.85) 273 0.000 (0.000) 272 0.004 (0.061)
Gastroscopy 272 0.029 (0.190) 274 0.044 (0.293) 273 0.015 (0.120) 272 0.044 (0.254)
Urine test 272 0.011 (0.105) 274 0.007 (0.085) 273 0.007 (0.085) 272 0.007 (0.086)
Blood culture 272 0.037 (0.331) 274 0.029 (0.208) 273 0.018 (0.134) 272 0.029 (0.208)
Duplex scan 272 0.007 (0.121) 274 0.000 (0.000) 273 0.000 (0.000) 272 0.000 (0.000)
Endoscopy 272 0.004 (0.061) 274 0.007 (0.085) 273 0.015 (0.120) 272 0.004 (0.061)
Renal blood test 272 0.000 (0.000) 274 0.000 (0.000) 273 0.000 (0.000) 272 0.004 (0.061)
Ascites draining 272 0.040 (0.301) 274 0.033 (0.198) 273 0.018 (0.134) 272 0.033 (0.217)
Sigmoidoscopy 272 0.004 (0.301) 274 0.007 (0.085) 273 0.007 (0.085) 272 0.011 (0.105)
Septic screen 272 0.022 (0.226) 274 0.000 (0.000) 273 0.000 (0.000) 272 0.000 (0.000)
ECG 272 0.015 (0.121) 274 0.026 (0.180) 273 0.026 (0.314) 272 0.015 (0.120)
Fluid swab 272 0.011 (0.135) 274 0.000 (0.000) 273 0.004 (0.061) 272 0.000 (0.000)
Blood transfusion 272 0.000 (0.000) 274 0.000 (0.000) 273 0.004 (0.061) 272 0.000 (0.000)
Catheter 272 0.004 (0.061) 274 0.000 (0.000) 273 0.000 (0.000) 272 0.000 (0.000)
Immunology test 272 0.000 (0.000) 274 0.000 (0.000) 273 0.000 (0.000) 272 0.004 (0.060)
Alcohol test 272 0.000 (0.000) 274 0.000 (0.000) 273 0.004 (0.061) 272 0.000 (0.000)
Dermatology appointment 272 0.000 (0.000) 274 0.000 (0.000) 273 0.007 (0.085) 272 0.000 (0.000)
Cystoscopy 272 0.004 (0.061) 274 0.000 (0.000) 273 0.004 (0.061) 272 0.000 (0.000)
Gynaecology exam 272 0.004 (0.061) 274 0.000 (0.000) 273 0.000 (0.000) 272 0.000 (0.000)
Banding of varices 272 0.000 (0.000) 274 0.000 (0.000) 273 0.015 (0.120) 272 0.015 (0.171)
continued
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TABLE 50 Average adverse event investigations per treatment arm (continued )
Investigations
OO AO OB AB
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Ultrasound one site 272 0.044 (0.499) 274 0.007 (0.085) 273 0.029 (0.189) 272 0.007 (0.086)
TIPS procedure 272 0.004 (0.061) 274 0.000 (0.000) 273 0.000 (0.000) 272 0.000 (0.000)
Chest drain 272 0.004 (0.061) 274 0.000 (0.000) 273 0.000 (0.000) 272 0.000 (0.000)
A, prednisolone; B, PTX, CT, computerised tomography; ECG, electrocardiogram; MRI, magnetic resonance imaging;
SD, standard deviation; TIPS, transjugular intrahepatic portosystemic shunt.
a How to interpret the table: one person having a stool test would equal a probability between 0.018 (OO), 0.018 (AO),
0.022 (OB) and 0.011(AB), dependent on treatment arms.
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